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Abstract
Drug candidates that induce or promote cancer formation must be identified and elimi-
nated during the preclinical phase of drug development to minimize the risk of adverse,
carcinogenic effects in patients. Genotoxic carcinogens can be identified with short-term
assays. In contrast, the lifetime rodent cancer bioassay that is used to identify nongeno-
toxic carcinogenic substances, requires a high number of test animals and takes up to
five years for completion. In addition, the lifetime rodent cancer bioassay does not pro-
vide sufficient data to evaluate the human risk if carcinogenic effects are observed in
rodents. This can result in discontinuation of the development of the drug candidate or
a black label warning on the drug packaging. The application of high-throughput omics
methods such as transcriptomics or proteomics in toxicological studies is a promising
approach for the development of short-term alternatives to the lifetime rodent cancer
bioassay. However, these omics methods are difficult to use for life sciences researchers
and few specialized visualization tools exist for toxicogenomics data. Furthermore, most
existing studies used only a single omics platform to determine the molecular effects of
carcinogens.
This thesis introduces new approaches that integrate multiple omics platforms for the
identification of nongenotoxic carcinogens and presents analysis and visualization tools
that were specifically developed for toxicogenomics data. We performed a series of ex-
periments to demonstrate that our multi-omics approach improves the prediction perfor-
mance compared to single-omics approaches. To facilitate the access to our analysis and
visualization tools, we implemented two web platforms, the ZBIT Bioinformatics Tool-
box and MARCARviz. These web platforms enable toxicologists to gain new insights
into the mechanisms of nongenotoxic tumor promotion. Furthermore, we demonstrated
that our multi-omics approach can provide the basis of new short-term alternatives to the
lifetime rodent cancer bioassay.
iii

Kurzfassung
Arzneimittelkandidaten die die Entstehung und das Wachstum von Tumoren begünsti-
gen, müssen in der präklinischen Phase der Medikamentenentwicklung identifiziert und
aus der weiteren Entwicklung ausgeschlossen werden, um das Risiko von gefährlichen,
tumorfördernden Nebenwirkungen für Patienten zu minimieren. Während genotoxische
Substanzen mit Schnelltests identifiziert werden können, dauert das aktuelle Standard-
prüfverfahren zur Erkennung von nicht-genotoxischen, karzinogenen Substanzen bis zu
fünf Jahre und benötigt eine große Anzahl an Versuchstieren. Außerdem können aus dem
Ergebnis keine Hinweise auf den Mechanismus gezogen werden wenn bei der Prüfung
Tumore gefunden werden, was zur Einstellung der Entwicklung des Arzneimittelkandi-
daten oder zu einer Black-Box-Warnung auf der Verpackung führen kann. Die Anwen-
dung von modernen Hochdurchsatz-Technologien in toxikologische Studien, Toxikoge-
nomik genannt, ist ein vielversprechender Ansatz zur Entwicklung von Prüfverfahren,
die weniger Zeit und Versuchstiere benötigen. Allerdings sind die Methoden aus der
Toxikogenomik für Toxikologen oft schwierig anzuwenden. Außerdem berücksichtig-
ten die meisten existierenden Studien nur Daten einer einzelnen omics-Technologie und
es existieren nur wenige spezialisierte Visualisierungswerkzeuge für toxikogenomische
Daten.
Diese Arbeit stellt neue Analyse- und Visualisierungswerkzeuge vor, die spezifisch
für toxikogenomische Studien entwickelt wurden, sowie integrative Ansätze, die es er-
möglichen Daten von mehreren omics-Plattformen zu berücksichtigen, um die Identifi-
kation von nicht-genotoxischen Karzinogenen zu verbessern. Wir beschreiben eine Rei-
he von Experimenten mit einem neuen Toxikogenomikdatensatz, um zu demonstrieren,
dass unsere integrativen Ansätze die Vorhersage der Karzinogenität von Substanzen ver-
bessern. Die Weiterentwicklung der von uns beschriebenen integrativen Verfahren bietet
möglicherweise Alternativen zu dem aktuell verwendeten, zeitaufwändigen Verfahren
zur Feststellung der Karzinogenität. Außerdem beschreiben wir neue Webplattformen
zur Analyse und Visualisierung von Expressionsdaten aus der Toxikogenomik, die wir
entwickelt haben, um Toxikologen den Zugang zu bioinformatischen Werkzeugen zu
vereinfachen. Mit diesen neuen Webplattformen können Toxikologen neue Erkenntnisse
über die Wirkmechanismen der nicht-genotoxischen Krebsentstehung gewinnen.
v
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Chapter 1
Introduction
The discovery of drugs for common and rare diseases has improved the prognosis of
many diseases and greatly extended human life expectancy. The development and mar-
keting of pharmaceutical drugs is a multi-billion dollar industry. Based on the data of
106 randomly selected new drugs, DiMasi et al. (2016) report that pharmaceutical com-
panies invest over 10 years of research and $2.5 billion until a new drug is approved for
marketing. This estimate includes the cost of drug candidates that are discontinued dur-
ing the development or risk assessment process due to lack of efficacy or severe adverse
side effects. During the premarketing risk assessment, drug candidates are screened for
adverse side effects in a process that is divided into several phases. The preclinical phase
involves in silico, in vitro, and animal testing. Three subsequent clinical phases involve
increasing numbers of patients and healthy participants to evaluate the efficacy and side
effects of drug candidates in humans. Based on industry reports, DiMasi et al. (2016) cal-
culate a clinical success rate of 11.83%, which means that 88.17% of the compounds that
pass the preclinical phase fail during one of the three clinical phases. When drug candi-
dates pass clinical phase III, regulatory agencies approve them for marketing. Approved
and marketed drugs enter clinical phase IV, the postmarketing surveillance. Physicians
and regulatory agencies continue to monitor the effects of the drug in patients and ag-
gregate new results from further animal experiments. Onakpoya et al. (2016) report that
manufacturers and regulatory agencies withdrew 462 approved medicinal products due
to adverse drug reactions between 1953 and 2013. Hepatotoxicity (81 cases) was the
most common reason for withdrawals, and 114 of the 462 withdrawals were associated
with patient deaths. 61 drugs were withdrawn due to carcinogenicity. For example, the
antihistamine methapyrilene that was used in flu medicines was withdrawn after it was
found to be a potent liver carcinogen in animal carcinogenicity studies (Lijinsky et al.,
1980).
Animal studies are an integral part of toxicological research and the drug discovery
process. Mechanistic studies in animals establish biological pathways and determine
druggable targets for diseases. These druggable targets are the basis for modern drug de-
velopment. High-throughput chemical screenings identify small molecules (called leads)
that show a binding affinity for the druggable target. Molecular optimization increases
the binding affinities through modifications of the structure and composition of the lead.
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Further in vitro and in vivo animal studies establish the efficacy, toxicity, and pharma-
cokinetics of successful leads and act as a filter for the initial drug candidates. Estimates
by Bolten and DeGregorio (2002) indicate that only 1 in 1,000 compounds that pass the
early stages of drug discovery enter the clinical phase. Due to the high number of com-
pounds that fail before entering the clinical phase, pharmaceutical companies perform
the most expensive and time-consuming animal tests late in the development process,
long after clinical trials have started (Kramer et al., 2004). One of these tests is the life-
time rodent cancer bioassay (LRB). It requires more than 800 mice and rats, substantial
amounts of the drug candidate, and the histopathological examination of more than 40
tissues (Waters et al., 2010). Regulatory agencies demand the LRB for drug candidates
that are to be administered to patients chronically for more than six months. Tumor find-
ings in the LRB may cause significant delays in the approval of drug candidates or even
result in the withdrawal of approved drugs, as was the case for methapyrilene (Lijinsky
et al., 1980).
Because most compounds that cause DNA damage are potent carcinogens, pharma-
ceutical companies eliminate genotoxic compounds early in the development. However,
some carcinogens, such as methapyrilene, initiate or promote tumors but do not cause
DNA damage. These compounds are called nongenotoxic carcinogens (NGCs). In con-
sequence, the in vitro genotoxicity assays that are performed in early stages of drug de-
velopment fail to detect their carcinogenic potential. NGCs are the main reason for tumor
findings in the LRB. The relevance of these positive findings to humans is a controversial
issue, and the LRB does not provide mechanistic information to determine the mode of
action (MOA) through which a compound induces cancer (Ames and Gold, 1990). For
these reasons, as well as the high cost in time and money and more recent political initia-
tives to reduce the number of animal tests in risk assessment, pharmaceutical companies
and regulatory agencies are working towards alternative approaches for assessing the car-
cinogenic potential of new drugs. The innovative medicines initiative (IMI) MARCAR
project, which encompasses several European universities and pharmaceutical compa-
nies, is a combined effort to identify molecular biomarkers and tumor classifications for
nongenotoxic carcinogenesis. The MARCAR Consortium (2010) formulates four major
objectives: (i) Find early biomarkers that can reliably identify compounds with potential
for later cancer development, (ii) advance the scientific basis for the assessment of the
carcinogenic potential of nongenotoxic drugs, (iii) identify the molecular responses to
the exposure to NGCs to support the development of early biomarkers, and (iv) improve
the efficiency of risk assessment in drug development by progressing the development
of alternative research methods. The MARCAR consortium expects that early cancer
biomarkers improve the safety of participants in clinical trials and reduces the need for
animals in accordance with the proposed concept of reduction, refinement, and replace-
ment of animal experimentation (MARCAR Consortium, 2010).
The inclusion of bioinformatics and high-throughput technologies is a central compo-
nent of most proposed alternatives to the LRB. These so-called omics methods contribute
a rich source of molecular data, which toxicologists use to perform mechanistic analy-
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ses. Machine learning models extract biomarker signatures from this high-dimensional
data and predict the carcinogenicity of compounds. The field that combines toxicolog-
ical questions with omics methods has been coined toxicogenomics. The maturation
of microarray technologies and next-generation sequencing simplified the collection of
molecular data for many compounds. This led to the creation of two large standardized
databases of the effects of NGCs on gene expression in rodent tissues: the Toxicoge-
nomics Project-Genome Assisted Toxicity Evaluation System (TG-GATEs) by Uehara
et al. (2010) and DrugMatrix by Ganter et al. (2006). Prompted by the need for al-
ternative strategies for assessing the carcinogenic potential and the advances of omics
technologies, the MARCAR project explores the application of multi-omics and epige-
netic profiling in preclinical risk assessment. To this end, the MARCAR consortium
profiled gene expression, protein abundance, microRNA (miRNA) expression, and DNA
methylation in the same samples to generate an integrated model of the effects of NGCs
on all levels of gene regulation (see, for example, Thomson et al. (2014) and Unterberger
et al. (2014)). To efficiently analyze this data, new integrative bioinformatics methods
and specialized visualization tools are necessary.
1.1 Contributions of this thesis
This thesis presents the research that we conducted in cooperation with members of
the chair of Cognitive Systems and the MARCAR consortium. The presented research
focuses on the visualization and predictive analysis of the toxicogenomics data gener-
ated during the MARCAR project. Due to the integrative approach of the MARCAR
project and the high-dimensional nature of omics data, the analysis requires automated
processing pipelines, efficient data storage infrastructure, robust statistics, and advanced
machine learning methods. To facilitate data analysis and access to the data for the
whole MARCAR consortium, we developed web platforms which provide visualiza-
tions and analysis tools for the MARCAR data. In addition, we developed new toxi-
cogenomics approaches that were designed specifically for the integrative data collected
by the MARCAR project. The following paragraphs shortly summarize the four main
contributions of this thesis.
The ZBIT Bioinformatics Toolbox for computational biology
Due to the advance of high-throughput technologies in the life sciences, computational
data analysis is an integral part of modern research. However, the computational re-
sources and the technical knowledge of many wet lab researchers are limited, whereas
the requirements in both regards are rising with each new generation of omics technolo-
gies. For example, the installation of academic bioinformatics software often depends
on specific operating systems or third-party libraries. Also, many tools do not provide
graphical user interfaces or detailed documentation. In addition, the processing omics
3
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data can require large amounts of RAM and computational power, which are not avail-
able on standard desktop computers. For these reasons, we set up the ZBIT Bioinformat-
ics Toolbox, which provides web-based access to a collection of bioinformatics software
and pipelines. By porting bioinformatics software into the web, we enable researchers
to use our tools on our computation cluster, such that they do not need to install any
dependencies or worry about hardware restrictions. Currently, the software collection
in the ZBIT Bioinformatics Toolbox encompasses tools for systems biology, expression
data analysis, and transcription factor annotation. We use a customized version of the
Galaxy framework to host the tools and distribute the tool execution among the nodes
of our internal computation cluster. A workflow system allows the combination of tools
into automated pipelines and the ZBIT Bioinformatics Toolbox stores all results and pa-
rameters in accordance with scientific needs for persistence and reproducibility. As a
consequence, the user requires only a browser to access the tools, perform analysis, and
view results in standardized formats. We provided extensive documentation for all tools,
together with tutorials, use cases, and example data. The ZBIT Bioinformatics Toolbox
is freely available at https://webservices.cs.uni-tuebingen.de/ and was pub-
lished in PLoS ONE in 2016 (Römer et al., 2016b).
Similarity screening for characterization of drug candidates
ToxDBScan is a tool for evaluating the hepatocarcinogenic potential of drug candidates
or other compounds in rodents. Users can upload gene expression signatures, which
ToxDBScan uses to identify substances that induce similar changes. Based on the known
properties and mechanisms of these similar substances, users can extrapolate informa-
tion on hepatocarcinogenicity and potential modes of action. ToxDBScan uses a novel
similarity screening method, which requires only the up- and downregulated genes as
input. The ranking based on the new similarity scoring achieved a sensitivity of 88%
and a predictive analysis correctly predicted the carcinogenicity of 15 external validation
compounds. Furthermore, ToxDBScan visualizes the most similar expression patterns in
heat maps and performs a pathway enrichment analysis for the gene expression signa-
ture to provide the user with additional mechanistic information. ToxDBScan is freely
available from the ZBIT Bioinformatics Toolbox and was published in the International
Journal of Molecular Sciences in 2014 (Römer et al., 2014b).
Multi-omics approaches for prediction of nongenotoxic carcinogenicity
Traditionally, predictive toxicogenomics studies use mRNA microarrays to determine
molecular signatures for the early assessment of the carcinogenic potential of new com-
pounds. While some studies explore the use of other omics platforms such as miRNA
microarrays or proteomics arrays, most existing models are based on data from a single
omics platform. Here, we explored the integration of data from multiple omics plat-
forms to build predictive models for compound carcinogenicity. To this end, mRNA,
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miRNA, and protein expression profiles were collected from the livers of rats, which
were exposed to NGCs, genotoxic carcinogens (GCs), and noncarcinogens (NCs). We
developed new integrative feature representations which provide an abstraction from the
molecular perspective of traditional toxicogenomics models to a systematic, pathway-
and interaction-based perspective. These feature representations are calculated based on
the observed expression values and incorporate existing knowledge that is available from
molecular interaction databases and pathway databases, such as KEGG, BioCarta, or Re-
actome. We evaluated the performance of models for hepatocarcinogenicity prediction,
which were built with five different machine learning methods and several combinations
of the multi-omics features. With a repeated cross-validation procedure, we found that
the integration of data from multiple omics platforms increases the prediction accuracy in
hepatocarcinogenicity classification. We also demonstrated that the classification perfor-
mance increases further when the proposed integrative feature representations are avail-
able for classifier training. In consequence, we were able to demonstrate that the early
identification of NGCs can be improved by profiling and integrating data from multiple
omics platforms. This study was published in PLoS ONE in 2014 (Römer et al., 2014a).
Web-based interactive visualization of gene regulation data
The effective mining of high-dimensional toxicogenomics datasets is a non-trivial task
that usually requires bioinformatics support to extract relevant mechanistic patterns and
confirm toxicological hypotheses. MARCARviz is a web platform that enables biologists
to quickly address the most common questions associated with the MARCAR microar-
ray data, to identify relevant patterns in the data, and to generate or confirm mechanistic
hypotheses about nongenotoxic effects leading to cancer formation. The major advan-
tage of MARCARviz is that there is no software or advanced technical knowledge re-
quired to perform powerful analyses and generate visualizations of the MARCAR data.
MARCARviz greatly facilitates the confirmation of published MARCAR results and
generation of new insights from the collected data without the requirement for com-
plex preprocessing steps. MARCARviz is publicly available from https://tea.cs.
uni-tuebingen.de/ and was presented at the German Conference for Bioinformatics
2016 (Römer et al., 2016a).
1.2 Thesis structure
The following two chapters provide the biological and statistical background for the re-
search that is presented in this thesis. The first half of Chapter 2 describes the levels
of gene regulation that are relevant for nongenotoxic carcinogenicity and have been tar-
geted by molecular profiling in the MARCAR project, followed by a description of the
high-throughput technologies that were used to collect the data used in this thesis. The
second half summarizes the current knowledge of the mechanisms of chemical-induced
5
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carcinogenesis with particular focus on NGCs. Chapter 3 provides an overview of the
preprocessing and statistical analysis of gene regulatory omics data. Chapter 3 also in-
troduces the machine learning algorithms that have been used in the studies presented in
Chapters 5 and 6 and the validation strategies that are used to assess the classification
performance. The last section of Chapter 3 reviews the current state of predictive toxi-
cogenomics, its anticipated impact on preclinical risk assessment, and the limitations of
recent toxicogenomics studies.
Chapters 4 to 7 are based on the bioinformatics tools and toxicogenomics studies that
were published in collaboration with other researchers in the MARCAR consortium.
Chapter 4 describes the ZBIT Bioinformatics Toolbox, a web-based collection of bioin-
formatics tools for systems biology, expression data analysis, and transcription factor
analysis. The chapter provides an overview of the included tools and describes the user
interface, the technical setup, and the architecture of the web platform, along with use
cases for each major category of the ZBIT Bioinformatics Toolbox. Chapter 5 presents
ToxDBScan, a web tool for hepatocarcinogenicity assessment, and provides a detailed
mathematical background for the proposed similarity scoring index. In addition, Chap-
ter 5 includes the evaluation of ToxDBScan with data from the MARCAR project, ex-
amples of the MOA detection with ToxDBScan, and a proof of concept for a possible
extension of the tool with predictive analyses. Chapter 6 introduces two integrative fea-
ture types for multiplatform omics data, reports a predictive toxicogenomics study which
compares single-omics, multi-omics, and integrated features for hepatocarcinogenicity
classification, and discusses the observed results and their implications for the develop-
ment of alternative testing strategies. Chapter 7 presents MARCARviz, a web platform
for interactive visualization of the transcriptomics data that the MARCAR project has
generated. The chapter provides a detailed description of the platform architecture and
the user interface, as well as a use case for the application of MARCARviz for mecha-
nistic analyses.
To conclude, Chapter 8 discusses the presented results and tools in the context of the
MARCAR project and summarizes the conducted research and its potential contributions
to preclinical drug and compound development.
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Gene regulation and nongenotoxic
carcinogenesis
The regulation of gene expression is a complex, multistage process, which begins with
the structural and chemical properties of the DNA molecule and ends with biomolecules
that influence and control the life and activity of biological cells. Adverse perturbations
of the gene regulation in a single cell can have consequences for the whole organism. The
principal example for these errors in gene regulation are tumors, abnormal tissue growths
that originate from cells with a defective regulation of the cell’s life cycle. Malignant
tumors, also called cancer, can spread across the whole organism and are a leading cause
of death worldwide. Anand et al. (2008) estimate that environmental factors, such as
smoking, diet, sun exposure, and environmental pollutants, cause 90-95% of all cancer
cases. The formation of tumors can be attributed to three major external factors: physical
(e.g., ultraviolet and ionizing radiation), chemical (e.g., tobacco smoke), and biological
(e.g., virus infections) carcinogens (IARC, 2014)).
Chemical-induced carcinogenesis is often driven by DNA damaging effects, which
cause mutations in genes that regulate the cell life cycle. Genotoxic carcinogens (GCs)
are known to induce DNA damage , which initiates tumor formation through DNA mu-
tations. In contrast, nongenotoxic carcinogens (NGCs) promote tumor formation but
exhibit no genotoxic effects. While the mechanism of GCs is defined by their DNA
damaging properties, NGCs act through a wide range of mechanisms which disturb the
regulation of genes that control the proliferation, growth, and death of cells. The char-
acterization and identification of these nongenotoxic effects are the major goals of the
research presented in this thesis.
The first section of this chapter illustrates the molecular mechanisms of gene regula-
tion with regard to mRNAs, miRNAs, and proteins. The second section of this chapter
describes the omics technologies that are used to assess gene regulation in cells. The last
section of this chapter illustrates the differences between genotoxic and nongenotoxic
carcinogenesis and provides an overview of the mechanisms of NGCs.
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2.1 Molecular regulation of gene expression
Gene expression is the process of translating the genetic information that is stored within
the chemical structure of the DNA into biologically active proteins. This process is di-
vided into two major steps: (i) the transcription of the genetic code from the stable,
two-stranded DNA into a single-stranded mRNA molecule and (ii) the translation of the
mRNA molecule into a functioning protein (Twyman, 2001). These two steps can be
further dissembled into smaller steps, e.g., the uncoiling of the DNA for transcription,
RNA transport, or post-transcriptional modifications of mRNAs. From gene transcrip-
tion initiation to protein degradation each step is regulated by molecular and biochemical
mechanisms. The following sections describe the steps that are relevant for this the-
sis: the transcription of DNA to mRNA, the post-transcriptional silencing of mRNA by
miRNAs, the translation of mRNAs into proteins, and the post-translational modification
of proteins. Figure 2.1 shows a overview of these steps of gene regulation. The following
sections are based on literature and the book Developmental Biology by Twyman (2001).
Figure 2.1: Molecular regulation of gene expression. The genetic code of the DNA is
transcribed into mRNAs, which are the templates for the protein amino acid sequence.
The DNA also encodes non-coding RNAs that regulate DNA transcription and mRNA
translation. Non-coding miRNAs inhibit mRNA translation by binding to complimen-
tary regions on mRNAs and forming RNA-induced silencing complexes. Protein-coding
mRNAs are translated into peptide chains that are cleaved and folded to form the final
protein product. Post-translation modifications such as phosphorylation and methylation
regulate the activity of proteins.
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2.1.1 Transcription of DNA to mRNA
Transcription is the synthesis of RNA molecules based on the DNA template. Transcrip-
tion is the first and most crucial step of gene expression, as all subsequent steps depend
on the transcribed RNA molecules. In eukaryotes, the DNA is transcribed by three RNA
polymerases, but only RNA polymerase II produces mRNA for protein synthesis. RNA
polymerases I and III transcribe ribosomal and transfer RNAs, which are required to
build the ribosome and synthesize proteins. The RNA polymerase II binds to an up-
stream region of the gene, the promotor. The DNA sequence of the promotor determines
the binding affinity of the RNA polymerase II and can vary greatly between genes, which
leads to different expression profiles.
In prokaryotes, the ground state of gene expression, i.e., the expression without any
transcription altering molecules, is nonrestrictive. In consequence, gene regulation is
mainly a question of gene repression. In contrast, the ground state of gene expression
in eukaryotes is restrictive. This is the result of the tightly packaged chromatin struc-
ture, which prevents the binding of RNA poymerase II to the promotor in the absence of
transcription factors that catalyze the binding. The presence or absence of transcription
factors is the major driver of differentiation and cell- or tissue-specific gene expression.
Transcription factors bind to the promotor to initiate RNA polymerase II activity or in-
teract with enhancer sites on the DNA to increase the speed and stability of the RNA
transcription complex. Many transcription factors also influence the chromatin structure
to facilitate or impede the access to gene promotors.
Promotor binding and transcription initiation are the dominant regulatory factors of
transcription. However, after the transcription has started, the RNA synthesis can be
accelerated, slowed, or terminated. For example, RNA elongation (the addition of RNA
bases to the already synthesized RNA strand) is regulated by proteins and transcription
factors that bind to the RNA transcription complex.
2.1.2 Silencing of mRNA by miRNA
After transcription, the mRNA is subject to post-transcriptional processing. This pro-
cess of mRNA modification involves capping to improve stability, transport to specific
translation locations, and alternative splicing of introns. In addition to these mRNA mod-
ifications, mRNAs are also silenced and degraded to maintain steady levels of mRNA for
protein synthesis. The abundance of mRNAs in the cell and the translation of mRNAs
into proteins is regulated by many factors, such as degradation by non-coding RNAs and
enzymes and silencing by miRNAs. These miRNAs form a family of small RNAs of
21-25 nucleotides (nt), which bind to specific target mRNAs and inhibit their translation
into proteins (He and Hannon, 2004). The transcriptional regulation of miRNAs is still
subject of research (Lee, 2002). Some miRNAs have been found in the introns of both
protein-coding and non-coding host genes, which suggests that they are co-regulated
with other RNAs (Lagos-Quintana et al., 2003).
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By binding at 7 or 8 nt complementary base pair matches in the 3’ untranslated region
(3’-UTR) of the target mRNA, miRNAs form RNA-induced silencing complexes, which
inhibit translation during protein elongation or the release of the protein product (Olsen
and Ambros, 1999; He and Hannon, 2004). The post-transcriptional silencing of mRNAs
by miRNAs is also shown in Fig. 2.2. The discovery of the imperfect complementarity at
the mRNA-miRNA binding sites is the main access point for miRNA target prediction,
for which a variety of tools exist (Bartel, 2009). According to Bartel (2009), a simple
miRNA target recognition can be performed by a three-step procedure: first, identify the
miRNAs seed, which are the nucleotides 2-8 of the 5’ region of the miRNA, second,
use genome-wide alignments to compile orthologous 3’-UTRs, and third, search these
orthologous UTRs for conserved occurrences of the miRNA seed (Bartel, 2009).
The prediction of miRNA targets has revealed that miRNAs regulate a large number of
functionally diverse genes (Lim, 2003). In addition, miRNA expression has been found
to be stage-specific in development and tissue-specific in different organs (Bartel, 2004).
Bartel and Chen (2004) propose that miRNAs act as micromanagement modulator of
gene expression by (i) suppressing genes that should not be expressed in a specific cell
type and by (ii) adjusting the expression of genes to allow for a tissue-specific gene ex-
pression pattern. Lu and Clark (2012) report that genes which are regulated by miRNAs
Figure 2.2: Post-transcriptional silencing of mRNAs by miRNAs. (a) The miRNA
(red) binds to the 3’ untranslated region (3’-UTR) of the target mRNA at 7 or 8 nt com-
plementary base pair matches. (b) RNA-induced silencing complexes (RISC) inhibit the
elongation at the ribosome and the release of the translated protein.
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show a greater variation in expression at the population level compared to genes that are
not regulated by miRNAs. Lu and Clark (2012) conclude that post-transcriptional silenc-
ing has two major roles in gene regulation: (i) fine-tuning or canalizing the expression
levels of a subset of target genes and (ii) promote expression variation of other target
genes.
The dysregulation of miRNAs can lead to serious malfunctions of the gene expression
regulation. For example, the loss of tumor-suppressive miRNAs leads to an increased
expression of cancer-related genes (called oncogenes), whereas the increased expression
of cancer-related miRNAs (called oncomirs) can repress tumor repressor genes (Kasinski
and Slack, 2011). Targeting these miRNAs has been proposed as a potential cancer
therapy and a synthetic mimic of a tumor suppressor miRNA is currently in clinical
phase I trials for the treatment of liver cancers (Hayes et al., 2014). The deregulation
of miRNAs is also associated with other diseases and the Human microRNA Disease
Database lists 572 miRNAs that are involved in 378 diseases (Li et al., 2014).
2.1.3 Translation of mRNA to proteins
Translation is the synthesis of proteins based on the mRNA template and is the second
major step in gene expression. The synthesis of proteins is performed by ribosomes,
molecular complexes that are formed by ribosomal RNA (rRNA) and proteins. Ribo-
somes are assembled at the 5’ cap of an mRNA and start the protein synthesis when en-
countering an AUG codon. The protein is elongated with amino acids carried by transport
RNAs (tRNAs), which match the codon at the current position of the ribosome. When a
stop codon is detected, release factors cause the ribosome to disassemble and release the
synthesized protein.
Like all stages of gene expression, translation is regulated by multiple molecular and
structural mechanisms. In eukaryotes, translation initiation is controlled by enzymatic
factors that catalyze ribosome binding (Kozak, 1999). In addition, mRNA binding factors
affect the translational regulation, e.g., miRNAs, which repress protein elongation and
release. The number of ribosomes is also a limiting factor for the amount of proteins
produced by a cell.
The translation is one of the main targets of antibiotics due to the evolutionary dif-
ferences between prokaryotic and eukaryotic ribosomes. Most antibiotics that are used
clinically inhibit either the binding of tRNAs to the ribosome or the translocation of the
ribosome along the mRNA (Wilson, 2013). The disruption of translational control has
also been linked to cancer formation, e.g., by selective translation of oncogenes, and has
been found to be specific for various types of cancer or disease stages (Silvera et al.,
2010).
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2.1.4 Post-translational modification of proteins
After the release from the ribosomal complex, most proteins undergo post-translational
modifications (PTMs) that alter the protein structure, the amino acid composition, or
properties of the amino acid side chains. The most relevant PTMs for this thesis are
chemical modifications of the amino acid residues, such as phosphorylation, acetylation,
and methylation.
The reversible phosphorylation of serine, tyrosine, and threonine residues in proteins is
a major regulatory mechanism of protein activity (Johnson and Lewis, 2001). In humans,
approximately 86.4% of serine, 11.8% of threonine, and 1.8% of tyrosine residues are
phosphorylated (Olsen et al., 2006). Although tyrosine phosphorylation is less common,
it is critical for many cell signaling processes. Several oncoproteins, growth factors, and
hormones show tyrosine phosphorylating activity (Johnson, 2009b). Phosphorylation
can change the function of proteins through multiple mechanisms. The negative charge
of the phosphoryl group can lead to the formation of bonds with arginine residues, which
results in conformational changes of the protein (Mandell et al., 2007). In other cases, en-
zyme activity is inhibited without conformational changes, e.g., by the phosphate group
acting as a steric blocking agent (Russo et al., 1996) or impeding substrate recognition
(Hurley et al., 1990). The transfer of phosphate groups to amino acid residues is cat-
alyzed by proteins that are called kinases. The identification of the human kinome, i.e.,
the set of all kinases, led to the discovery of seven major groups of kinases (Manning
et al., 2002). Due to their prominent role in the regulation of cellular signaling, protein
kinases have been studied extensively and were linked to many types of cancers and dis-
eases. In 2008, ten kinase inhibitors had been approved as drugs for the treatment of
several cancer types, and several more are currently in clinical trials (Johnson, 2009a).
The acetylation of proteins usually occurs at lysine residues and neutralizes the pos-
itive charge of the lysine, which changes the protein function (Choudhary et al., 2009).
Histone acetylation plays an important role in the regulation of gene expression and has
long been known to increase transcription (Allfrey et al., 1964). More recently, lysine
acetylation has been shown to influence p53 function and interactions (Yang and Seto,
2008), which suggests a broader role of protein acetylation in gene regulation and protein
function. Acetylation and deacetylation are catalyzed by acetyltransferases and deacety-
lases, both for histones and lysine residues in general (Shahbazian and Grunstein, 2007).
Acetyltransferases and deacetylases have been identified as potential targets of drugs for
cancer or neurodegenerative diseases and are currently tested in clinical trials (Choud-
hary et al., 2009). However, despite the recent increase in interest, the knowledge of in
vivo acetylation sites is still sparse.
Protein methylation has long been associated mainly with histones and chromatin
modification, where they are a major part of the “histone code”, which regulates gene
transcription (Biggar and Li, 2014). Methylation occurs predominantly at lysine and
arginine residues, which can be methylated up to two (arginine) or three (lysine) times.
Recently, the methylation of non-histone proteins has been found to have a regulatory
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role in many cellular processes (Paik et al., 2007). Similar to the role of kinases for phos-
phorylation, methyltransferases that are specific for arginine or lysine act as an activator
by transferring methyl groups to the amino acid residues, which leads to the binding
of methyl-binding proteins or alters protein structure and activity. After the activating
stimulus is withdrawn, demethylases erase the methyl group and restore the previous
protein state. Methylation has long been considered to be a stable modification, but the
discovery of non-histone protein methylation has also shown that methylation can be as
dynamic as phosphorylation events (Dhami et al., 2013) and is linked to several crucial
cell signaling pathways, e.g., the mitogen-activated protein kinase (MAPK) signaling
cascade (Mazur et al., 2014). The SMYD3 gene in the MAPK signaling cascade also
links lysine methylation to cancer (Mazur et al., 2014), which indicates that methylation
also regulates oncogene expression.
2.2 Measuring gene regulation with omics technologies
Gene expression profiling is of great use for toxicological studies because changes in
the mRNA abundance are among the first detectable responses to compound adminis-
tration. The earliest methods for mRNA transcript profiling such as the Northern blot
by Alwine et al. (1977) performed one assay for each transcript. Meanwhile, these tra-
ditional methods have been replaced by techniques that can quantify the expression of
thousands of genes simultaneously. Among the most used technology in larger projects
are mRNA microarrays, which are commercially available since the 2000’s (Bumgarner,
2013). Despite the recent advent of next-generation sequencing for transcript profiling
(RNA-seq), microarrays remain an important technology for gene expression profiling
because they are cheaper, require less data storage, and provide well-established analysis
pipelines (Zhao et al., 2014). Besides mRNA arrays, manufacturers provide microarrays
for a wide range of other biomolecules such as non-coding RNAs, DNA methylation,
and proteins. This section describes the three types of array-based technologies that we
used to generate the data for the research presented in this thesis: Affymetrix mRNA
microarrays, Agilent miRNA microarrays, and reverse phase protein arrays (RPPAs).
2.2.1 Gene expression microarrays
Gene expression microarrays, also called DNA or mRNA microarrays, have been applied
in many fields of biology, such as pharmacogenomics (Debouck and Goodfellow, 1999),
cancer research (Khan et al., 1999), and pathology (Becich, 2000). The application of
microarrays involves multiple steps: array fabrication and probe spotting, hybridiza-
tion of probes and sample material, hybridization signal detection, and data analysis.
Microarrays are fabricated on glass, silicon, or plastic surfaces and spotted with DNA
probes, i.e., synthetic oligonucleotides, by in situ synthesis. The extracted DNA material
is labeled with reporters (fluorescent dyes) and a whole array scanner measures the signal
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of the bound reporter probes. Thus, an image of the microarray contains the complete
hybridization pattern and can be used for the hybridization analysis. The high-density
arrays manufactured by Affymetrix utilize a massively parallel approach for DNA hy-
bridization, with hundreds of thousands of test sites (probes) in less than 2 cm2 (Lockhart
et al., 1996).
To profile mRNA abundance in samples, the RNA is extracted, isolated, and purified
with RNA preparation kits and RNA quality is assessed. The extracted RNA is labeled
with a fluorescent dye that can be detected by the scanner and hybridized to the microar-
ray probes. Affymetrix provides reagent kits to perform the necessary hybridization
procedure, which includes hybridization, washing and staining. After hybridization, the
scanner captures a fluorescence image and calculates a signal intensity for each probe.
The probe signal intensity is a function of the amount of sample RNA that has hybridized
to a probe. These intensities are the raw data input for the bioinformatics analysis, which
is described in Chapter 3.
2.2.2 MiRNA microarrays
Perturbed miRNA expression can lead to dysfunctional cell regulation and is specific
for different tissues, diseases, and cancers. For this reason, miRNA profiling is of great
interest and microarray manufacturers have adapted the mRNA microarray technology
to miRNAs during the last decade. The main challenge in miRNA profiling is the small
size of miRNAs (∼ 22 nt) and the high degree of homology between different miRNAs
(D’Andrade and Fulmer-Smentek, 2012). Commercially available mRNA arrays typi-
cally use probes of 25 nt (Affymetrix) or 60 nt (Agilent), which necessitates a different
probe design for miRNA microarrays. The presence of unspliced precursor miRNAs
must also be considered in the probe design (D’Andrade and Fulmer-Smentek, 2012).
The miRNA data in this thesis was generated with Agilent miRNA microarrays, which
use a labeling method and probe design that is optimized for miRNAs (Wang et al.,
2006). Agilent also provides labeling and hybridization kits for the miRNA microarrays
to standardize sample processing. Subsequently, the miRNA microarrays are measured
with commercial scanners and images and signal intensities are analyzed with bioinfor-
matics methods.
2.2.3 Reverse phase protein arrays
Proteins are biologically active molecules that perform most cellular functions such as
catalyzing chemical reactions, transporting other molecules, or replicating the DNA.
Measuring protein expression and activation states is the most direct assessment of the
biological state of a cell. Traditional methods (e.g., two-dimensional gel electrophoresis
in combination with mass spectrometry) identify mostly high abundance proteins (Gygi
et al., 2000). However, up to 90% of the proteins in a cell are present in low copy num-
bers (Miklos and Maleszka, 2001) and there is no protein amplification method available.
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In addition, protein immobilization and binding is difficult due to the large differences in
function and structure. Proteins show high diversity, including anti-bodies, water-soluble
enzymes, and water-insoluble membrane proteins.
RPPAs utilize microarray technology to profile protein expression with specific anti-
bodies, which function as protein-binding probes. In contrast to most microarray tech-
nologies, in RPPAs the samples are immobilized on the chip instead of the probes. The
chip is spotted with beads of the sample solution and nonspecific binding sites on the
array are blocked. Then, the chip is stained with a protein-specific antibody that is la-
beled with a fluorescence marker, incubated, and washed to remove unbound antibodies.
A fluorescence detection system takes an image of the chip and measures the fluores-
cence signal intensity for each spotted sample. Depending on the availability of specific
antibodies, RPPAs can also detected protein modifications, e.g., phosphorylation at func-
tionally relevant sites, which allows the profiling of the activity state of proteins.
RPPAs have been applied in a wide range of applications, e.g., to identify risk factors
for liver diseases (Morales-Ibanez et al., 2016). We have also combined RPPAs with
RNA microarrays for the integrated assessment of the effects of the NGC phenobarbital
in the mouse liver (Braeuning et al., 2016). To generate the data used in this thesis,
we used the ZeptoMARK system, which uses a specialized fluorescence reader called
ZeptoREADER (Pawlak et al., 2002).
2.3 Mechanisms of chemical-induced carcinogenesis
Carcinogenesis is the formation of cancer, i.e., malignant tumors, which are character-
ized by uncontrolled cell proliferation and the ability to spread throughout the organism.
DNA damage, either naturally occurring or through endogenous and exogenous factors,
is considered to be the leading cause of cancer formation (Bernstein et al., 2013). The
causes of DNA damage can be roughly categorized to be either physical, such as ultravi-
olet and ionizing radiation, biological, e.g., infections with viruses, or chemical (IARC,
2014). However, long-term rodent carcinogenicity studies have repeatedly demonstrated
that chemicals that show no genotoxic activity can also induce carcinogenesis. A study
of approved pharmaceuticals found that 50% of the pharmaceuticals were rodent car-
cinogens but only six were found to be genotoxic (Van Oosterhout et al., 1997). This
demonstrates that many approved pharmaceuticals are NGCs, which are carcinogenic in
rodents but show no DNA damaging potential. NGCs act through a range of different
mechanisms, in contrast to GCs, for which the carcinogenic profile is determined by di-
rect DNA damage (Fig. 2.3). The following section describes genotoxic carcinogenesis
and illustrates proposed mechanisms of NGCs.
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2.3.1 Genotoxic carcinogenesis
Genotoxic carcinogens induce cancer formation by causing DNA damage through direct
interactions with the DNA. For this reason, they are also known as DNA-reactive carcino-
gens. The DNA reactivity can occur either by the carcinogen itself or by DNA-reactive
metabolites of the carcinogen. In contrast, NGCs act through secondary mechanisms
without directly damaging the DNA. However, the distinction between GCs and NGCs
is not absolute, as many GCs can also act through mechanisms other than DNA dam-
age and NGCs may indirectly lead to DNA damage (Benigni et al., 2013). Substances
that change the DNA sequence are only a subset of genotoxins, as genotoxins can also
cause DNA lesions, i.e., sites where the structure or the base-pairing of the DNA are
disrupted. Types of DNA lesions include sites where one base is missing (abasic sites),
single- and double-strand breaks, and covalent links between the two DNA strands (in-
terstrand crosslinks). DNA lesions can have strong effects on cells by inhibiting DNA
replication and transcription and require DNA repair, which is error-prone and can lead
to mutations.
Most GCs or their metabolites are strong electrophilic reactants, which bind to nu-
cleophilic sites in the DNA, RNAs, and proteins. The formation of carcinogen-DNA
adducts is linked to the occurrence of mutations. Altered bases are fixated by erroneous
Figure 2.3: Genotoxic and nongenotoxic tumorigenesis. Genotoxic carcinogens can
bind to the DNA to form DNA adducts and cause DNA mutations. Mutated tumor sup-
pressor genes or oncogenes can lead to tumor formation. In contrast, nongenotoxic car-
cinogens perturb the regulation of oncogenes and tumor suppressor genes by altering the
function of regulatory genes, which promotes tumor growth. Red arrows indicate direct
effects of the carcinogen, black arrows indicate indirect effects.
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base-pairing during DNA replication to form potentially initiated cells (Miller and Miller,
1981). Some GCs require metabolic activation to form electrophilic metabolites that can
bind to the DNA and form DNA adducts. For example, most N-nitroso compounds, such
as N-nitrosomethylurea or dimethylnitrosamine, require metabolic activation (Magee,
1969). The oxidative removal of one N-alkyl group produces a monoalkylnitrosamine,
which is unstable and rearranges to form electrophilic ions. Well-known GCs include
aflatoxin B1, a food contaminant that is a major risk factor for liver carcinomas (Kew,
2003), components of tobacco smoke (e.g., nitrosamines and polycyclic aromatic hy-
drocarbons, Hecht (1999)), and ethanol, which is metabolized to several DNA damag-
ing metabolites, e.g., acetaldehyde and reactive oxygen species (Boffetta and Hashibe,
2006).
Most GCs are not species-specific because DNA mutations are a general initiating
factor in carcinogenesis. For this reason, a battery of bacterial and in vitro assays has
been developed for the identification of substances with genotoxic effects. One regularly
used genotoxicity assay is the Ames test, a bacterial reverse mutation assay (Ames et al.,
1975). The Ames test detects genotoxins which cause point mutations and frameshifts.
As the Ames test requires only a few days, it is a standard assay for the risk assessment
of new chemicals. The Ames test has also been shown to identify a high percentage of
known carcinogens (McCann et al., 1975).
The majority of known chemical carcinogens is genotoxic, and the two largest risk
factors for lifestyle associated cancer are tobacco smoking and alcohol, which both act
as GCs (Anand et al., 2008; Hernández et al., 2009). The accumulation of activating
mutations in tumor-promoting oncogenes and silencing mutations in tumor suppressor
genes is a critical feature of carcinogenesis. However, Hernández et al. (2009) report
that 45 of the 371 chemicals (12%) considered to be carcinogenic to humans (IARC
Group 1) or likely to be carcinogenic to humans (IARC Groups 2A and 2B) are not
genotoxic and thus qualify as human NGCs. In consequence, a risk assessment driven
purely by genotoxicity findings is not sufficient, and nongenotoxic carcinogenesis has to
be considered in the development of new chemicals and drugs
2.3.2 Nongenotoxic carcinogenesis
NGCs are capable of promoting cancer formation without direct interaction with the
DNA. In contrast to the MOA of GCs, where the induced DNA damage leads to muta-
tions in tumor suppressor or oncogenes, the knowledge of the mechanisms of tumor in-
duction and promotion of NGCs is sparse. NGCs show a wide range of tumor-inducing
and tumor-promoting modes of action, such as peroxisome proliferation, immunosup-
pression, endocrine modification, or cytotoxicity (Williams, 2001).
Melnick et al. (1996) argued that limiting the evaluation of NGCs to their nongeno-
toxic effects is not sufficient, as some NGCs have been found to form DNA adducts and
induce DNA mutations although they are Ames-negative. For example, tamoxifen, a drug
used in the treatment of breast cancer, was long thought to be a rat-specific, nongeno-
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toxic liver carcinogen due to negative in vitro tests for mutagenicity and an assumed
hormonal perturbation mechanism (Tucker et al., 1984). However, it was later shown
that tamoxifen is activated by rat and human liver microsomes to form DNA adducts
(Pathak and Bodell, 1994), which provided evidence for a human relevance of tamoxifen
induced liver cancers. In 2012, tamoxifen has been reevaluated by the IARC and was
classified as a Group 1 carcinogen with sufficient evidence that tamoxifen is a carcino-
gen in humans (IARC, 2012). The argument by Melnick et al. (1996) demonstrates that
the classification into GCs and NGCs is not a clear distinction, as NGCs may initiate tu-
mors through weak genotoxicity and GCs may promote initiated cells to form tumors by
nongenotoxic mechanisms (Benigni et al., 2013). Mostly, the term nongenotoxic is used
to mean Ames negative because the Ames test is the most common assay to determine
the genotoxic potential in chemical development. Accordingly, the term nongenotoxic is
used to mean Ames negative in this thesis.
Genotoxic substances can be identified by a range of short-term bacterial and in vitro
tests and are excluded from further development. In contrast, NGCs are negative in
these genotoxicity assays and are only detected in the lifetime rodent bioassays (LRB,
Hernández et al. (2009)). However, the LRB is time-consuming, expensive, and no
longer in line with new policies for the reduction of animal testing. For this reason,
several projects and consortia have investigated NGCs in the last decade, among them
the MARCAR project. These projects try to expand the knowledge of the mechanisms
of nongenotoxic carcinogenesis to provide cancer assays that require fewer animals and
less time than the LRB. For human cancer risk assessment, the LRB is complemented
with data from 90-day toxicity studies and toxicological studies of chemical kinetics
and disposition in rodents (Hernández et al., 2009). Human epidemiological data is
also integrated into risk assessment when available. As NGCs act through a variety of
mechanisms, the following sections provide an overview of some of the most prevalent
mechanisms of human nongenotoxic carcinogenesis based on the reviews by Hernández
et al. (2009) and Silva Lima and Van der Laan (2000).
Endocrine modifiers
The glands that secrete hormones into the blood constitute the endocrine system. En-
docrine modifiers induce or promote cancer mainly by modifying the levels of hormones
or binding to hormone receptors. For example, 17β -estradiol and its metabolites can
bind to the estrogen receptor, which induces strong mitogenic effects by altering path-
ways mediated by the estrogen receptor. Estrogen is assumed to be a major factor in
cancer induction because it modulates transcription factors that regulate proliferation,
differentiation, and apoptosis (Chen et al., 2008). Hormones that bind to the estrogen
receptor are considered human NGCs (IARC, 1987). Other hormone receptors that are
targets for human NGCs are the progesterone receptor, the aryl hydrocarbon receptor,
and the thyroid hormone receptor. Some nongenotoxic substances can bind to multi-
ple receptors, for example, the pesticide dichlorodiphenyltrichloroethane (DDT). DDT
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promotes hormone-dependent pathology, induces several cytochrome P450 genes, and is
associated with increased incidences of lymphoma and lung cancers in workers exposed
to the pesticide (Sierra-Santoyo et al., 2000). These multi-receptor binding substances
can further complicate the human risk assessment of compounds. Ultimately, the im-
balance of the hormonal control by estrogen, progesterone, or other hormones, coupled
with cytotoxicity and other effects of NGCs is thought to be a major driver of tumor
promotion.
Goitrogens, i.e., substances that interfere with iodine uptake and thus disturb the pro-
duction of thyroid hormones in the thyroid gland, are the largest group of non-receptor
mediated endocrine modifiers. This class includes anti-thyroid drugs as well as cen-
tral nervous system-acting drugs (e.g., phenobarbital), chlorinated hydrocarbons (e.g.,
chlordane), and others (Hernández et al., 2009). These substances increase the periph-
eral production of thyroid hormones and the secretion of thyroid-stimulating hormone,
which have been linked to the induction of cell hypertrophy and hyperplasia and thyroid
tumors in the LRB.
Cytotoxicity and chronic cell injury
In tissues where tumor incidences are found in LRBs, cytotoxicity and regenerative hy-
perplasia are often observed after the administration of NGCs (Dietrich and Swenberg,
1991). The regenerative proliferation response to chronic cell injury leads to enhanced
cell replication, which is associated with cancer initiation and promotion. Melnick et al.
(1996) suggested that this is due to the reduced time available for DNA repair mecha-
nisms during cell division, which increases the probability of the fixation of endogenous
or exogenous DNA damage. Examples for NGCs with a proposed cytotoxic MOA are
the arsenic compounds dimethylarsinic acid and monosodium methane arsenate. These
two also inhibit DNA repair and suppress p53, which supports the hypothesis that prema-
ture replication fixates DNA damage in exposed cells (Cohen et al., 2006; Salnikow and
Zhitkovich, 2008). In general, tumor promotion by inhibiting DNA repair and inducing
cell cycle progression is often observed for cytotoxic NGCs (Safe, 1989; IARC, 1999;
Stickney et al., 2003).
Inhibition of gap junction intercellular communications
The maintenance of homeostasis, i.e., a stable state of the internal cell conditions, re-
quires intercellular communication. Gap junctions, which are plasma membrane chan-
nels that are formed by proteins, link adjacent cells and enable the exchange of small
molecules (Kumar and Gilula, 1996). This communication between cells is important
for the control of cell differentiation and proliferation. The disturbance of intercellular
communication by the inhibition of gap junctions has been observed for many NGCs
such as chlordane, DDT, phenobarbital, arsenic compounds, and peroxisome prolifera-
tors (Hernández et al., 2009; Rivedal and Witz, 2005; Budunova and Williams, 1994;
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Cowles et al., 2007). The exact mechanisms of the inhibition of gap junction commu-
nications are not clearly established for most NGCs. Cowles et al. (2007) found that
gap junctions can be affected by both direct (by DDT or Wy-14,643) and indirect (by
tetrachloride) connexin inhibition, particularly connexin 32 in the liver of rats. This also
demonstrates that NGCs often act through multiple of the presented MOAss.
Other mechanisms
In addition to the presented mechanisms, there are several others that have been proposed
to contribute to carcinogenesis, e.g., peroxisome proliferation, immunosuppression, or
oxidative stress (Hernández et al., 2009). However, several nongenotoxic substances act
through unique and not fully understood mechanisms. For example, carbon tetrachloride
is activated by CYP genes to form trichloromethyl radicals, which form DNA adducts
and disrupt cellular processes by inducing tumor necrosis and promoting growth fac-
tors (Weber et al., 2003). Perchloroethylene (PCE) is a solvent that is used by the dry
cleaning industry and is a nongenotoxic rodent carcinogen which is suspected to be less
relevant to humans. PCE is metabolized to trichloroacetic acid, which induces hepato-
cellular peroxisomes in rodent livers (Wernke and Schell, 2004). In general, peroxisome
proliferators, such as Wy-14,643, are suspected to be rodent-specific, although the exact
mechanism of carcinogenesis is not entirely understood.
Overall, NGCs are known to act through a wide range of mechanisms and often multi-
ple mechanisms are involved. As NGCs cannot be detected by the Ames test and require
extensive mechanistic and toxicological investigation, they remain an important factor
in human risk assessment during the development of new chemicals and drugs. For this
reason, toxicogenomics has gained much momentum during the last decade, and several
large projects and consortia have started to investigate new methods for the early identi-
fication of NGCs. The next chapter provides an introduction to toxicogenomics and the
statistical and machine learning techniques that have been proposed as new short-term
alternatives to the LRB.
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Introduction to toxicogenomics and
machine learning
Toxicogenomics uses automated high-throughput techniques, statistical and machine
learning methods, and computational models to address toxicological research questions.
The maturation of mRNA microarray technology provided toxicologists with powerful
new instruments for measuring the effects of chemicals on living organisms. More re-
cently, the advent of next-generation sequencing such as RNA-seq further enhanced the
repertoire of tools for assessing adverse drug effects. These new technological oppor-
tunities for toxicologists and life science researchers initiated the development of new
bioinformatics methods that were needed to analyze the increasing amounts of data that
current experiments produce. Databases of microarray data are growing fast, but batch
effects due to different protocols in different groups interfere with a simple combination
of datasets, which necessitates normalization and methods to account for batch effects.
Also, researchers and manufacturers are adding more omics layers to the repository of
high-throughput technologies. Mass spectrometry and RPPAs measure protein abun-
dance, DNA methylation arrays generate epigenetic maps of DNA modification, and
new, global expression microarrays include non-coding RNAs with regulatory functions.
To make full use of multilayered omics data, researchers need methods that can integrate
these different types of molecular data and extract meaningful biological signals.
Whereas mechanistic toxicogenomics uses omics data to examine a single substance or
a particular metabolic pathway, predictive toxicogenomics attempts to construct compu-
tational models and signatures that recognize groups of compounds with similar adverse
effects. Pharmaceutical companies and regulatory agencies explore predictive toxicoge-
nomics as an economical alternative to long-term animal tests such as the LRB, which
are expensive and time-consuming.
The first section of this chapter describes the bioinformatics methods that we used to
process and analyze the omics data measured with microarray technologies. The second
section provides an overview of the machine learning methods and validation strategies
that we used in our predictive toxicogenomics studies. The last section reviews the cur-
rent state of toxicogenomics and presents several studies that are relevant to this thesis.
21
Chapter 3 Introduction to toxicogenomics and machine learning
3.1 Omics data processing and analysis
The readouts of the microarray systems presented in Chapter 2 are fluorescence signal
intensities. These raw signal intensities are subject to systematic, instrumental, and ran-
dom noise, which introduces a bias that needs to be removed before the signal intensities
can be used to perform quantitative analyses. Microarray data processing encompasses
quality control to detect microarrays that did not function correctly and raw data normal-
ization to eliminate systematic bias and make samples comparable. After the processing,
statistical and numerical methods are applied to identify affected biomolecules and de-
termine the effect strength. This section first provides an overview of quality control and
normalization methods, followed by an outline of the statistical and numerical methods
used for data analysis.
3.1.1 Microarray quality control
Quality control is an essential step for microarray data processing. Whereas system-
atic and instrumental bias or batch effects can be addressed by experimental design and
normalization, random noise in the spotting and hybridization process or experimental
errors cannot be removed automatically. For example, spatial bias due to contaminations
or sample handling mistakes that affect amplification and hybridization can confound
experiments and introduce effects that are not a result of drug administration. Schuch-
hardt et al. (2000) list fluctuations that can affect all steps of the probe, sample or array
preparation, hybridization, and signal detection. Examples of fluctuations that need to
be detected during quality control are failed PCR amplification, unequally distributed
sample solution, hybridization failure due to temperature, time, or buffering conditions,
and overshining of signals due to external factors.
Several software packages are available to detect these experimental artifacts and
remove affected arrays from further analyses. For the MARCAR data, we used the
arrayQualityMetrics package by Kauffmann et al. (2009), which is generic and can
be applied to many types of microarrays independent of manufacturer. Specialized soft-
ware for Affymetrix (Parman et al., 2016), Illumina (Dunning et al., 2007), or two-
color cDNA arrays (Buness et al., 2005) are also available. The arrayQualityMetrics
package provides several analyses for detecting potential outliers such as density plots,
principal component analysis (PCA), pairwise distance matrices, or false color plots.
Figure 3.1 shows examples of these common quality control plots that were generated
with arrayQualityMetrics. We used both visual inspection methods (e.g., false color
plots and PCA plots) and statistical cutoffs (e.g., pairwise distances and dynamic range)
to identify and remove microarrays of insufficient quality from the analysis.
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Figure 3.1: Microarray quality control and normalization. (a) Pairwise distance heat
maps. (b) PCA identifies arrays that show global deviations, possibly due to process-
ing errors. The asterisk marks the outlier. (c) Array density plots identify arrays with
perturbed overall intensity distributions. (d) Array density plot after normalization. In-
tensities are normalized to have similar distributions.
3.1.2 Normalization methods for microarrays
Normalization is the scaling of microarray readouts to make data from multiple arrays
comparable (see Fig. 3.1(d), Hill and Whitley (2003)). As stated before, microarray ex-
periments are influenced by systematic and stochastic fluctuations, which can introduce
noise into data and confound the analysis (Schuchhardt et al., 2000). Sources of these
variations between samples include varying sensitivity to RNA degradation, systematic
fluctuation of the labeling, small differences in hybridization parameters (e.g., tempera-
ture, time, or sample volume), nonspecific binding, and saturation effects (Schuchhardt
et al., 2000). For two-color microarrays, the two conditions that are compared can be
considered to be comparable because they were subject to the same preparation, hy-
bridization, and detection process. In contrast, for one-color microarrays the raw signal
intensities need to be normalized before they can be compared. To eliminate the noise in
the data, systematic fluctuations are measured by control probes or statistically estimated.
Quantile normalization
Amaratunga and Cabrera (2001) introduced quantile normalization for the analysis of
viral DNA microarrays, which achieves a robust readout standardization (Bolstad et al.,
2003). Quantile normalization standardizes the distribution of probe intensities for all
arrays in an experiment.
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The procedure for quantile normalization is described by Bolstad et al. (2003) as fol-
lows: (i) build a matrix X of dimension p× n, given n arrays of with p probes, (ii) sort
all n columns of X to get Xsort, (iii) assign the mean across rows in Xsort to each element
in a row to get X ′sort, and (iv) rearrange the values in each column to revert X ′sort to the
original order in X , which gives Xnormalized. Thus, quantile normalization represents the
transformation x′i = F−1(G(xi)), where xi is the readout of array i, G is the empirical
distribution of each array, and F is the empirical distribution of the averaged sample
quantiles (Bolstad et al., 2003). The distribution F can also be replaced by an arbi-
trary reference distribution, such as the normal distribution. Quantile normalization is a
complete data method, i.e., it combines information from all arrays in the normalization
transformation.
Quantile normalization is a generic normalization algorithm that can be applied inde-
pendent of the array manufacturer. We used quantile normalization to standardize RPPA
readouts. For commercially distributed microarrays, specialized normalization software
and methods are available that account for specific microarray designs.
Robust multi-array average normalization
Affymetrix microarrays include perfect match (PM) and mismatch (MM) probes to esti-
mate noise by nonspecific binding. The normalization provided by the Affymetrix Mi-
croarray Suite deducts the MM probe signals from the corresponding PM probe signals
to calculate the probe set signal (Hill and Whitley, 2003). However, Irizarry et al. (2003)
report that MM probes may be detecting both true signal and nonspecific binding. Thus,
estimating the true signal as the difference between PM and MM probe signal adds noise
without removing bias, whereas estimaing the true signal by dividing the PM signal by
the MM signal results in a biased signal. For this reason, Irizarry et al. (2003) propose
robust multi-array average (RMA) normalization, which discards all MM probe signals
and estimates the true signal with a linear additive model that is based on three major ob-
servations. First, PM probe signals grow approximately linear to concentration, second,
signal variance is roughly constant, and third, probe-specific affinity is approximately
additive. Irizarry et al. (2003) also adjust the model to account for nonspecific binding
and background noise. The log scale measure of expression µin for array i and probe set
n is estimated with a linear additive model:
Yi jn = µin+α jn+ εi jn, i ∈ {1, . . . , I}, j ∈ {1, . . . ,J},n ∈ {1, . . . ,N}
where I, J, and N are the numbers of arrays, probes, and probe sets, Yi jn is the log-
transformed, background-corrected, quantile-normalized PM probe signal, α jn is the
probe affinity effect, and εi jn is an independent, identically distributed error term with
mean 0 (Irizarry et al., 2003). The background correction uses an additive model,
where the observed intensity S is the sum of signal X and background noise Y . Irizarry
et al. (2003) assume that X follows an exponential distribution, and Y follows a normal
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distribution, with Y ≥ 0, which allows estimating the background-corrected signal by
E(X |S = s) (full details are available from Bolstad (2004)).
The RMA algorithm was originally motivated by observations of Affymetrix microar-
ray data but has been modified and applied to microarrays from other manufacturers. For
Agilent microarrays, López-Romero et al. (2010) show that RMA normalization without
background correction is equally precise as other methods that are designed specifically
for Agilent arrays. We used the RMA implementation in the affy package (Gautier
et al., 2004) to normalize Affymetrix microarray data and the modified RMA algorithm
in the AgiMicroRNA package (López-Romero, 2011) to normalize Agilent microarray
data.
3.1.3 Statistical analysis of microarray data
The analysis of data from high-throughput microarray experiments requires efficient and
robust statistical methods. This section focuses on experimental designs that include a
reference condition (called control) for each sample. The sample-control design is the
most common experimental design because it addresses some common issues of mi-
croarray data analysis. First, expression values are semi-quantitative, i.e., they represent
not the absolute transcript abundance in a sample but an experiment-specific relative
transcript abundance. Second, laboratory-, time-, or technician-specific batch effects
may confound the biological effects even after normalization (Leek et al., 2010). The
inclusion of controls allows the estimation of the effects of a specific treatment or con-
dition compared to a reference condition and also the assessment of batch effects. For
example, in the MARCAR toxicogenomics studies, the reference condition was treated
with the compound vehicle (i.e., the solvent used to dilute the compound) that was also
used for the compound-treated animals to eliminate confounding effects of the vehicle
substance. In consequence, several conditions, e.g., animals treated with different car-
cinogenic compounds, can be compared based on the changes in transcript abundance
relative to the respective reference. Batch effects can be removed either by using batch-
matched controls that are processed in the same batch (i.e., at the same laboratory, the
same time, and by the same person) or by randomly distributing conditions and controls
across all batches, which allows a statistical estimation of the batch effect (Chen et al.,
2011). All studies that are described in this thesis use batch-matched controls to avoid
batch effects and provide reference-based estimates of the condition-specific effects on
transcript abundance.
Experimental designs with replicates allow the assessment of both the power of an
effect and its significance. Effect power is measured by the fold change and the sig-
nificance is commonly expressed by p-values. The following paragraphs describe the
calculation of fold changes and p-values with the limma package for R/Bioconductor
Smyth (2005), which we used in this thesis.
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Fold change
The fold change is a semi-quantitative measure of transcript abundance and is calculated
as the ratio of average normalized signal intensities in samples and controls. The fold
change xg is calculated as
xg =
n
√
∏
i∈1,...,n
sig
m
√
∏
j∈1,...,m
c jg
where sig and c jg are the normalized signal intensity of gene g in sample si and control
c j. Because signal intensities are ratios of detected fluorescence, the geometric mean
must be used. However, most normalization methods, including the RMA algorithm,
use a log-transformation and thus report logarithmized expression values. Then, the fold
change is calculated as the difference between the arithmetic means of logarithmized
expression values in samples and controls:
xg =
∑
i∈1,...,n
log(sig)
n
−
∑
j∈1,...,m
log(c jg)
m
The MicroArray Quality Control (MAQC) project presents strong evidence that a gene
ranking by fold change is reproducible across microarray platforms (Guo et al., 2006;
Patterson et al., 2006; Shi et al., 2005). Shi et al. (2006) argue that a combination of
fold change ranking and non-stringent significance filtering produce more reproducible
gene lists than ranking and filtering genes based on t-test statistic alone. Also, Patterson
et al. (2006) demonstrated that the fold change ranking is less dependent on the used
background correction and scaling method.
Nevertheless, when only considering fold changes, weak but significant effects might
be overlooked. For example, if the expression is high in two conditions A and B, then
the ratio the expression A/B might be small although the difference A−B can be large.
In contrast, if the expression of A and B is very low, even a small difference A− B
might result in a large ratio A/B. Therefore, fold changes are usually complemented by
measures of effect significance.
Statistical tests for differential expression
The significance of an effect is a common criterion for ranking and filtering genes in
microarray experiments. Statistical tests calculate p-values, which represent the prob-
ability of seeing an equal or higher expression difference between a group of samples
and a group of controls under a null hypothesis. The choice of the null hypothesis de-
pends on the applied test and may differ for different software and algorithms. Measured
expression levels are often non-normally distributed, and their distributions may be de-
pendent and non-identical between genes (Smyth, 2004). Furthermore, the large number
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of genes on a typical microarray presents a multiple testing problem, which requires the
consideration and application of multiple testing correction methods.
To assess effect significance in microarray experiments, Smyth (2004) propose the
use of empirical Bayes methods, which can borrow information from the ensemble of
genes to infer the variance of measurements of individual genes. Smyth (2004) also
reformulate the posterior odds statistic that is used by the Bayes method into a moder-
ated t-statistic, which allows the use of posterior residual standard deviations instead of
ordinary standard deviations and requires less hyperparameters to be estimated. By com-
bining the Bayesian approach with the t-statistic and providing closed form equations to
estimate the hyperparameters, Smyth (2004) extend an approach that was first proposed
by Lönnstedt and Speed (2001) to arbitrary experimental designs and microarray types.
In short, Smyth (2004) assume a linear model E[y j] = Xα j, where y j is the expression
data for gene j, X is the design matrix, and α j is the vector of coefficients. The contrasts,
i.e., the sample groups that are compared, are defined by β j = CTα j, where C is the
matrix of contrasts. By fitting the linear model E[y j], the coefficients α j are estimated,
which, in turn, enables the estimation of β j. The full details of the p-value calculation
are provided by Smyth (2004).
In this thesis, we used the limma package for R/Bioconductor (Smyth, 2005) to calcu-
late p-values and corrected for multiple testing with the method proposed by Benjamini
and Hochberg (1995). As mentioned above, filtering genes based solely on significance
may lead to non-reproducible gene lists across experiments, whereas the fold change
ranking offers better reproducibility (Shi et al., 2006). For this reason, we used gene fold
changes as our primary criteria for selecting deregulated genes and incorporated p-values
where possible. In particular, for our predictive toxicogenomics studies, we rely mainly
on the fold change to build machine learning models that predict adverse effects. The
following section provides an overview of the machine learning methods that we em-
ployed for model building and the validation strategies with which we assessed model
performance.
3.2 Machine learning methods for classification
Machine learning is a branch of computer science which encompasses learning algo-
rithms and artificial intelligence. During the learning phase, mathematical and heuristic
approaches are used to extract rules and patterns from the training data to construct pre-
dictive, data-driven models. In contrast to static, programmed predictors, the prediction
is defined not only by the new data but depends on the training data that was used in
the model construction process. A large number of algorithms have been explored in
machine learning, inspired by optimization theory (support vector machines, Boser et al.
(1992)), data structures (decision trees), or biology (artificial neural networks, McCul-
loch and Pitts (1943)). Machine learning methods employ various techniques from many
other branches of computer science and statistics and have, vice versa, been applied to
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many tasks in other fields such as spam detection (Laskov and Šrndic´, 2011) or computer
vision (Jiang et al., 2016). A distinction is made between supervised and unsupervised
machine learning. In supervised learning, labels are provided for each training instance,
whereas the labels are unknown in unsupervised learning. Thus, supervised learning al-
gorithms are prediction or regression methods that provide an output for new instances of
data. In contrast, unsupervised learning, also called data mining, is used for exploratory
data analysis and searches for hidden structure in the data.
Predictive toxicogenomics employs both supervised and unsupervised learning for dif-
ferent types of studies. The studies presented in this thesis built predictive models with
different, supervised machine learning algorithms, which are described in the following
sections.
3.2.1 Support vector machines
Support vector machines (SVMs) are among the most popular machine learning algo-
rithms and have been applied in many application areas. For example, SVMs are used in
bioinformatics for protein structure prediction (Cai et al., 2002) or prediction of adverse
drug effects (Ellinger-Ziegelbauer et al., 2008). Vapnik and Lerner (1963) developed the
first version of an SVM and Cortes and Vapnik (1995) published the soft margin SVM,
which is most frequently used today. The following description is based on a review of
SVMs in computational biology by Ben-Hur et al. (2008).
SVMs are maximum-margin classifiers, i.e., they maximize the distance of all points
in each class to a hyperplane that separates the classes (Fig. 3.2). The hyperplane is the
decision boundary for classification and depends only on a subset of the training vectors,
which are called support vectors and lie on the margin. One major constraint on the hy-
perplane is linearity in the input feature space. For this reason, the hyperplane can only
separate classes if the underlying decision problem is linearly separable, which for many
relevant applications is not the case. To overcome this limitation, the input features can
be transformed into a higher-dimensional space in which the data becomes linearly sep-
arable (Boser et al., 1992). This transformation is often referred to as the “kernel trick”
and provides an elegant solution for applying SVMs to non-linear problems. However,
the transformation into higher-dimensional kernel spaces increases the generalization er-
ror and thus requires more training examples. Due to the limited number of training
samples that is available in toxicogenomics studies, the experiments in this thesis used
only linear SVMs.
Linear SVMs learn hyperplanes in the input feature space and use a linear discriminant
function f (x), which is defined as
f (x) = 〈w,x〉+b, (3.1)
where x are data vectors, w is the weight vector, b is the bias, and 〈·, ·〉 is the dot product.
The points x that satisfy 〈w,x〉+ b = 0 define the hyperplane. For each point x, the
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Figure 3.2: Linear support vector machine. Linear SVMs separate classes with a linear
hyperplane H that maximizes the margin m between classes. The hyperplane is defined
by the equation 〈w,x〉+ b = 0, where w are the learned weights. New observations
are classified based on their position to the hyperplane. The hard-margin SVM (a) can
only learn linearly separable problems. By introducing slack variables ξ , the soft-margin
SVM (b) can also learn problems that are not linearly separable.
corresponding label y is the sign of the discriminant function f (x). By convention the
labels y are 1 for the positive class and −1 for the negative class. The training problem
for an SVM is to find the weight vector w and bias b which maximize the margin and
minimize the training error given a set of n training instances xi with associated labels
yi for i ∈ {1, . . . ,n}. The margin is the smallest distance between any point xi and the
hyperplane defined by f (x) = 0, and the training error is the number of points for which
sign( f (xi)) 6= yi, i.e., which are located on the wrong side of the hyperplane.
A classification problem is called linearly separable if a hyperplane exists such that
sign( f (xi)) = yi for all instances xi. For linearly separable classification problems, the
hard-margin SVM solves the training problem by maximizing the margin, which pro-
vides the best generalization that is possible based on the training instances (Fig. 3.2(a)).
The optimization problem for the hard margin SVM can be solved with solvers based on
convex optimization theory and is given by
min
w,b
1
2
||w||2
s.t. yi (〈w,xi〉+b)≥ 1, for i = 1, . . . ,n
(3.2)
While the hard-margin SVM can be efficiently applied for linearly separable problems,
most real-world classification problems are not linearly separable. This can be due to
measurement noise, problem complexity, or other reasons. To overcome this limitation,
Cortes and Vapnik (1995) developed the soft-margin SVM, which allows classification
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errors during the training (Fig. 3.2(b)). The soft-margin SVM introduces slack variables
ξi, which leads to an optimization problem similar to the hard-margin SVM:
min
w,b,ξ
1
2
||w||2+C
n
∑
i=1
ξi
s.t. yi (〈w,xi〉+b)≥ 1−ξi, i = 1, . . . ,n
ξi ≥ 0, i = 1, . . . ,n
(3.3)
The introduction of the slack variables in the constraints relaxes the hard constraints of
the hard-margin SVM. To minimize the classification error, the term C
n
∑
i=1
ξi in the ob-
jective function penalizes classification errors. The sensitivity to training errors can be
adjusted by setting the parameter C, which represents the trade-off between fitting the
maximum-margin hyperplane and the generalization of the resulting discriminant func-
tion. The parameter C is problem-specific and is often selected by parameter optimiza-
tion.
To solve the optimization problem in Eq. (3.3), the problem is transformed into the
dual problem, which is a maximization problem:
max
α
n
∑
i=1
αi− 12
n
∑
i=1
n
∑
j=1
yiy jαiα j〈xi,x j〉
s.t.
n
∑
i=1
yiαi = 0, with 0≤ αi ≤C
(3.4)
This maximization problem can be solved efficiently with gradient descent methods.
With the optimal solution for α and the training instances, the weight vector w can be
calculated:
w =
n
∑
i=1
yiαixi (3.5)
In the solution of the dual problem, αi 6= 0 only for support vectors. The remaining
training instances can be omitted after the learning phase, which provides a sparse repre-
sentation of the dataset and enables a more efficient classification. Finally, new instances
x are classified by calculating sign( f (x)) as defined by Eq. (3.1).
3.2.2 Neural networks
Artificial neural networks are a group of machine learning algorithms that were ini-
tially inspired by the architecture of the human brain. We used multi-layer perceptrons
(MLPs), feed-forward neural networks that extend on the idea of a perceptron. This de-
scription of MLPs is based on the book Pattern Recognition and Neural Networks by
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Figure 3.3: Multilayer perceptron (MLP) with one hidden layer. An MLP consists
of several layers of neurons that are fully connected. The connection between neurons
i and j are weighted by a weight wi j. Each neuron sums over all inputs and applies a
function f j to calculate the output which is propagated to the next layer. The features x
are presented to the input layer and the predicted class y is observed at the output layer.
Ripley (1996). Feed-forward networks consist of numbered units, which are connected
with other units by one-way links such that each unit is connected only to units with
higher numbers. For these networks, the units can be arranged in layers such that only
connections between layers exist (see Fig. 3.3), which also provides the name MLP.
Each unit sums all inputs received from incoming connections into a value x j and ap-
plies a function f j to determine the output y j, which is fed to the following units. All
connections are weighted by a factor wi j. Traditionally, MLPs were often used with three
layers: the input layer that is determined by the feature representation, a single hidden
layer, and the output layer. MLPs can be trained with backpropagation, which uses the
difference between the observed output and the known, desired output to modify the con-
nection weights and minimize the training error. Recently, deep neural networks, which
use many hidden layers, achieved good results on many classification tasks. However,
deep neural networks require a large number of training examples. Due to the limited
number of samples in toxicogenomics studies, we used MLPs with only one hidden layer
as implemented in the nnet package for R (Venables and Ripley, 2002).
3.2.3 Random forests
Random forests (RFs) comprise a group of classification methods which use multiple
independent decision trees to make predictions. Classification methods such as RFs are
also called ensemble methods because they employ an ensemble of smaller classifiers
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that contribute to the classification. The name “random forest” was first used by Breiman
(2001), who provides the following definition for a RF: “A random forest is a classifier
consisting of a collection of tree-structured classifiers {h(x,Θk),k = 1, . . .} where the
{Θk} are independent identically distributed random vectors and each tree casts a unit
vote for the most popular class at input x”. Breiman (2001) demonstrates that the gen-
eralization error converges as the number of trees in the RF increases, which indicates
that RFs do not overfit as more trees are added. RFs are parametrized by the number of
decision trees ntree and the number of features mtry which are used at internal splits in the
decision trees. However, results by Breiman (2001) show that RFs are not very sensitive
to the parameter values and good, robust classification results are obtained with standard
parameter values. A general algorithm for building a RF is provided by Liaw and Wiener
(2002) as follows: First, draw ntree bootstrap samples from the original data. Then, for
each bootstrap sample, grow an unpruned tree, where at each node mtry of the features
are chosen to compute the best split. Finally, the new data is predicted by collecting the
votes on all ntree trees. For each bootstrap sample, a random subset of training instances
is chosen to ensure the independence of the trees in the forest. The out-of-bag samples,
i.e., the training instances that are not selected for the tree building, are used to provide
an estimate of the generalization error. Implementations of RFs vary in the method for
selecting the features at each internal node, the proportion of features and instances in the
bootstrap sample, and the underlying decision tree algorithm. Nevertheless, the results
on convergence and overfitting by Breiman (2001) and the general algorithm by Liaw
and Wiener (2002) are shared by most implementations.
3.2.4 Validation of classification models
The generalization error is the most important measure for the evaluation and comparison
of classification models. To estimate the generalization error, a classification model is
applied to problem instances that have not been used in the classifier training. These left-
out instances are referred to as test or validation samples. Test samples need to be drawn
from the same distribution as the training samples and must be labeled with the same
classes and criteria. For this reason, the training and validation samples are selected from
a single dataset in most cases. To ensure that the estimated classification error provides
an unbiased estimate, training and validation must be independent, and each sample must
only be used in either training or validation. If a dataset contains samples that are not
independent (e.g., technical or biological replicates), these need special consideration
and have to be grouped to ensure that all replicates are in either training or validation set.
The following sections describe and compare the three most frequently used validation
strategies: the holdout method, bootstrapping, and cross-validation (CV). All descrip-
tions are based on the analysis by Kohavi (1995).
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Holdout validation
Holdout validation divides the dataset into a training and a validation set. The classifica-
tion model is build using only the training set. After the training, the model is applied to
the validation set to obtain class predictions which are compared to the actual classes to
estimate the classification error. However, Cawley and Talbot (2010) show that sampling
a single partition of data can arbitrarily favor a particular classifier, which is called sam-
pling bias. Also, Kohavi (1995) argues that the holdout method is a pessimistic estimator
because classification power is expected to increase with the number of available training
samples. Both problems are particularly problematic for the small datasets that are used
in toxicogenomics studies. Also, the holdout method does not provide an estimate of
the variance of classifier performance, which is a critical factor for comparing classifiers
(Cawley and Talbot, 2010). For these reasons, resampling methods are used to estimate
the variance of the classification error and avoid sampling bias.
Bootstrapping and cross-validation
A bootstrap sample of a dataset with n samples is obtained by sampling n samples with
replacement. Assuming a uniform sampling, the expected number of distinct samples in
a bootstrap is 0.632n (Kohavi, 1995). The selected samples are used as the training set,
and the remaining samples are used as the test set. To estimate the average performance
and the variance, the bootstrapping procedure is repeated.
In k-fold CV, a dataset is divided into k equal sized, pair-wise distinct partitions (called
folds) Each fold is used as validation set while the classifier is trained on the remaining
k−1 folds. Thus, in a k-fold CV, k independent estimates of the classification error are
obtained, which provides an estimate of the performance and variance. Stratified CV is
an extension of regular CV that ensures that the class distribution is approximately the
same in all folds. A special case is n-fold CV or leave-one-out validation, where each
sample is held out once and the classifier is trained on all remaining samples. However,
Kohavi (1995) argues that replicated k-fold CV with different folds produces more robust
estimates of the variance. He also shows that the CV of the estimate is unbiased for a
stable learning algorithm. A learning algorithm is stable if the trained model produces
the same predictions independently of the permutation of the training data. Furthermore,
Kohavi (1995) observed that the variance of k-fold CV does not depend on k.
For a set of real-world datasets with different characteristics, Kohavi (1995) demon-
strates that k-fold CV with 10 ≤ k ≤ 20 reduces the variance but increases the bias,
whereas smaller k≤ 5 increase variance due to the instability of the training set. He also
concludes that stratified CV is superior to regular CV and recommends replication of the
CV evaluation. Bootstrapping has low variance but he observed a large bias in the per-
formance estimates for some of the problems. Based on these findings, he recommends
stratified 10-fold CV for model selection.
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3.3 Toxicogenomics for preclinical risk assessment
Several studies have evaluated the performance of in vivo short-term rodent bioassays
for prediction of carcinogenic potential. These studies used microarrays to measure
the transcriptional response to the chronic or acute administration of compounds with
well-defined carcinogenic potential. Figure 3.4 shows the standard workflow of toxi-
cogenomics studies. The time point of transcriptomic profiling varied among the studies,
ranging from 24 hours to 13 weeks. Most predictive toxicogenomics studies used male
rats as the model organism and the liver as the target organ for tumor induction. For this
reason, most available data was collected from the liver of male rats. Nevertheless, fe-
male rats and other organs have been explored in toxicogenomics studies, as well as the
mouse as a possible model organism. In vitro studies have also been performed by some
research groups. The following section reviews the currently available toxicogenomics
literature for rat, mouse, and in vitro studies.
3.3.1 In vivo rat studies
Nie et al. (2006) performed the first large predictive toxicogenomics study. They ad-
ministered a single dose of 138 compounds to male Sprague-Dawley rats. Of the 138
compounds, 24 NGCs and 28 NCs were selected for model building. Nie et al. (2006)
used statistical and heuristic feature selection followed by an exhaustive search to iden-
tify six gene markers. They estimated an accuracy (ACC) of 88.5% with 10-fold CV.
Fielden et al. (2007) treated male Sprague-Dawley rats with 147 compounds for up
to 7 days. They used 25 NGCs and 75 NCs to build a linear classification model with
31 marker genes. Validation with 20 random bootstraps (60/40 split) resulted in 84.5%
ACC, with 56% sensitivity and 94% specificity. The external validation with the remain-
ing 47 compounds resulted in 78.7% ACC (71.4% sensitivity and 84.6% specificity).
The studies by Nie et al. (2006) and Fielden et al. (2007) were subsequently externally
validated in a collaborative study by Fielden et al. (2008). The signature proposed by Nie
et al. (2006) achieved an ACC of 63.9% on the Fielden et al. (2007) dataset and 55.1%
on an additional proprietary database. The signature proposed by Fielden et al. (2007)
achieved an ACC of 71.9% on the Nie et al. (2006) dataset and 63% on the proprietary
database. Based on these findings, Fielden et al. (2008) argued that the performance was
insufficient to advocate routine use of the signatures.
Ellinger-Ziegelbauer et al. (2008) reported a toxicogenomics study with male Wistar
rats treated daily with 29 compounds (9 GCs, 11 NGCs, and 9 NCs) for up to 14 days.
They used 13 compounds (5 GCs, 5 NGCs, and 3 NCs) to extract signatures and build
SVM models. For the best signature, they reported an ACC of 88% for the classification
of the validation compounds.
Uehara et al. (2008, 2011) performed two predictive toxicogenomics studies with
data from the Toxicogenomics Project-Genomics Assisted Toxicity Evaluation system
database (TG-GATEs, Uehara et al. (2010)). TG-GATEs encompasses gene expression
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Figure 3.4: Workflow in toxicogenomics studies. (a) Expression profiling workflow.
Substances are subchronically administered to rats or mice. After the treatment phase,
animals are sacrificed and genetic material is extracted from the target tissue. Gene
expression is quantified with high-throughput expression profiling methods. The ex-
pression profiles in treated and untreated animals are compared and filtered statistically.
Relevant expression changes are used for mechanistic analysis. (b) Predictive toxicoge-
nomics workflow. A dataset of expression profiles is collected for carcinogenic and non-
carcinogenic substances. Next, the dataset is divided into training and validation set and
machine learning or statistical methods are used to extract a biomarker signature from
the training set. Then, the predictive performance is evaluated with the validation set.
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profiles from male Sprague-Dawley rats treated with 150 compounds. First, Uehara et al.
(2008) used two NGCs and six NCs for prediction analysis for microarrays (PAM). An
external validation of the model with 22 additional compounds (8 NGCs and 14 NCs)
resulted in 73.3% ACC (37.5% sensitivity, 95% specificity). In 2011, Uehara et al.
(2011) reported a new model that was built using a larger subset of the TG-GATEs data.
Using 60 compounds (6 NGCs and 54 NCs), they used statistical feature selection and
trained an SVM model. The external validation on the remaining TG-GATEs compounds
yielded an ACC of 78.9% (15.8% sensitivity and 100% specificity). Further, Uehara et al.
(2011) applied their model to 14 compounds from the NEDO project (Matsumoto et al.,
2009), which resulted in 50% ACC (30% sensitivity, and 100% specificity).
The NEDO project (Matsumoto et al., 2009) treated male F344 rats with 88 com-
pounds for up to 4 weeks. In 2011, Hiroshi Matsumoto (2011) reported an SVM-based
model trained on a subset of 41 compounds (17 Cs, 24 NCs). They performed external
validation on the 45 compounds not used for training, which resulted in an ACC of 28.8%
(11.8% sensitivity and 81.8% specificity). Following the initial study, Matsumoto et al.
(2014) reported a new SVM model, which extended the number of compounds used for
training to 68 (46 Cs and 22 NCs). The new model achieved an ACC of 68.8% on the
validation data (72.7% sensitivity and 60.0% specificity).
In 2010, Auerbach et al. (2010) argued that carcinogenesis is a transient process,
which may not be detected after few weeks of drug administration. Using male F344
rats, they sampled gene expression profiles after up to 90 days of daily exposure to 10
compounds (4 Cs and 6 NCs). They used SVMs and recursive feature elimination (RFE)
and reported 100% ACC after leave-one-out validation for most models. However, ex-
ternal validation on an independent dataset resulted in accuracies ranging from 74.1%-
83.8% when using all time points and 84.5% to 90% when using data obtained after 90
days.
Following a previous study with in vivo mouse data, Eichner et al. (2014a) evaluated
ensemble feature selection (EFS) on the 14-day data of the TG-GATEs dataset. They
used 20 compounds (9 NGCs and 11 NCs) for training and applied linear SVMs, PAM,
RFE, and Golub’s signal-to-noise ratio to extract signatures. With three-fold CV, they
estimated a mean area under the receiver operating characteristic (AUC) of 0.95 for their
signature. They also applied EFS to four additional datasets and demonstrated improved
prediction ACCs compared to published signatures.
Recently, Gusenleitner et al. (2014) used TG-GATEs and DrugMatrix data to build
RFs with 500 genes selected by a variance filter. Using a 70/30 bootstrap split approach
with 200 resamplings, they estimated an AUC of 0.77 on the DrugMatrix dataset and
0.83 on the TG-GATEs dataset. A prediction of the TG-GATEs data with the model built
on the DrugMatrix dataset yielded an AUC of 0.77, confirming the robustness of the
model and its estimated performance. Additionally, Gusenleitner et al. (2014) explored
the use of perturbed pathways as potential markers, which resulted in a slightly lower
AUC in the internal performance evaluation (AUCs of 0.73 for DrugMatrix and 0.81 for
TG-GATEs), but better performance in the cross-data-set evaluation (AUC of 0.79).
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3.3.2 In vivo mouse studies
Several toxicogenomics studies have also investigated the use of the mouse as a model
organism. Thomas et al. (2007) profiled lung tissue of female B6C3F1 mice exposed to
7 lung carcinogens and 6 noncarcinogens. They used 10-fold CV to estimate an ACC
of 93.9% (95.2% sensitivity and 91.8% specificity). However, these results are likely
positively biased due to the presence of biological replicates in both training and test
sets. In 2009, Thomas et al. (2009) reported another study with 15 lung carcinogens and
11 noncarcinogens. They built a total of 84 different models, with the best achieving
77.5% ACC, estimated by an unbiased five-fold CV.
In 2014, Melis et al. (2014) profiled the liver of male C57BL mice after 28 days of
repeated administration of seven GCs, nine NGCs, and eight NCs. They build a multi-
class prediction model from a subset of 16 compounds (4 GCs, 7 NGCs, and 5 NCs).
External validation of the model on the remaining 8 compounds resulted in 50% ACC
(80% sensitivity and 0% specificity).
Eichner et al. (2013a) treated male and female CD-1 mice with three GCs, three NGCs,
four NCs and used EFS to extract marker genes. Evaluation with a bootstrapping ap-
proach yielded a mean AUC of 0.92 for C vs. NC classification and 0.83 for GC vs.
NGC classification.
3.3.3 In vitro studies
In vitro bioassays have also been proposed to replace animal experiments entirely. How-
ever, in vivo models remain the preferred method for chronic exposure tests because the
metabolic processing of drugs is reduced in in vitro systems (Waters et al., 2010). Never-
theless, in vitro assays provide a rapid and resource-efficient strategy for risk assessment
and can be applied to human cells to reduce problems introduced by cross-species dif-
ferences. In vitro toxicogenomics studies have used both human and rodent cells.
Among the first to explore the use of in vitro assays for predictive toxicogenomics
were van Delft et al. (2005). They treated human HepG2 cells with nine genotoxins and
seven nongenotoxins for 24 hours and trained four classifiers. The ACC ranged from
33% to 83% for in the external validation with six compounds.
In 2011, Yildirimman et al. (2011) treated hepatocyte-like cells with 15 compounds
(5 GCs, 5 NGCs, and 5 NCs) and derived a 592-gene signature. Using leave-one-out,
Yildirimman et al. (2011) reported an ACC of 93.8% for their model. However, due to
the inclusion of up to four replicates for each compound, this result is likely positively
biased due to the presence of replicates in the training set.
In a follow-up study, Doktorova et al. (2013) used five different cell types: human
embryonic stem cells, HepG2 cells, HepaRG cells, and two rat hepatocyte cell types.
They observed good correspondence of gene expression changes with carcinogenicity
but an identification of NGCs was not possible.
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Magkoufopoulou et al. (2012) used human HepG2 cells to predict in vivo genotox-
icity. They treated HepG2 cells with 62 compounds for up to 48 hours and used 34
compounds for model training with PAM. When using only transcriptomics data, they
achieved ACCs of 79% (leave-one-out on training set) and 57% (external validation).
In a series of studies, Schaap et al. (2014, 2012) explored the use of in vitro mouse
models. They treated murine cells with 26 compounds (16 NGCs and 10 GCs/NCs) for
up to 72 hours. Schaap et al. (2014, 2012) focused on unsupervised analysis and MOA
detection by defining pairs of NGCs with similar MOAs and using T-statistics to recall
the matching partner for each compound but did not report performance measures.
3.3.4 Limitations of toxicogenomics studies
As described above, many studies have demonstrated that predictive toxicogenomics can
be used to assess the carcinogenic potential of compounds. Nevertheless, some limi-
tations have to be taken into account when interpreting the reported results and con-
sidering predictive toxicogenomics for integration into preclinical risk assessment. In
their review, Waters et al. (2010) highlighted several problems concerning the compound
annotation. Genotoxicity is commonly defined as Ames positive, whereas Ames nega-
tive compounds are considered nongenotoxic (Jackson et al., 1993). However, some
Ames negative compounds have been shown to induce mutations in mammalian cells
and chromosomal damage, cell transformation, or loss of alleles in other in vivo or in
vitro genotoxicity assays. Waters et al. (2010) refer to these compounds as Ames nega-
tive genotoxic carcinogens. Currently, it has not been concisely evaluated if this should
be considered in the labeling of compounds for training sets and might have caused con-
founding effects in previous studies that aimed at distinguishing genotoxic and nongeno-
toxic compounds.
Also, the relevance of the LRB for human risk assessment has been called into question
(Cohen, 2010; Ward, 2007). Knight et al. (2006a) performed an extensive evaluation of
160 compounds for which carcinogenicity testing had been conducted in animals. Mice
(92.4%) and rats (86.7%) were used in most long-term bioassays, and the liver (66.3%)
was the organ affected by chemicals most often. However, upon inspection of chemicals
found to be carcinogenic in rodents that have also been assessed in monkeys, only half
were found to be carcinogenic in monkeys. Monro and Mordenti (1995) list substantial
differences between humans and rodents such as mean lifespan, food consumption, basal
metabolic rate, anatomical differences, and DNA excision repair rate that might confound
the prediction of human risk from rodent tumor findings. An analysis of 61 chemicals
that are carcinogenic in rats or mice showed that only 13 chemicals were carcinogenic in
both species and Knight et al. (2006a) conclude that “the profound discordance of bioas-
say results between rodent species, strains, and genders, and further, between rodents
and human beings, means that it is profoundly difficult to make human carcinogenicity
assessments on the basis of rodent bioassay data.” (Knight et al., 2006a). Nevertheless,
the LRB is still used by pharmaceutical companies and required by regulatory agencies
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for drugs with prolonged or chronic administration. Knight et al. (2006b) also propose
alternatives for the LRB. Among others they also put forward toxicogenomics, which
offers more information on MOAs than raw tumor incidence in the bioassay. Neverthe-
less, the question of how to translate positive findings from future toxicogenomics based
assays to human risk assessment is still discussed by experts (Ellinger-Ziegelbauer et al.,
2009).
The previous limitations apply to toxicogenomics in general and are being assessed
by experts in the field. However, there are also problems that are specific to studies in
predictive toxicogenomics. These problems concern the evaluation of proposed models.
First, the sample size is very low in many studies due to the resources (e.g., money,
time, animals) necessary to generate the gene expression profiles for toxicogenomics
studies. The first toxicogenomics studies sampled data for as few as six (Iida et al.,
2005) or nine compounds (Kramer et al., 2004). Meanwhile, larger databases have been
released: TG-GATEs with 150 compounds (Uehara et al., 2010), DrugMatrix with 130
compounds (Ganter et al., 2005), the dataset by Nie et al. (2006) with 129 compounds,
and the NEDO dataset with 88 compounds (Matsumoto et al., 2009). However, many
recent studies still collect expression profiles for less than 30 compounds (e.g., Thomas
et al., 2011; Eichner et al., 2013a; Ellinger-Ziegelbauer et al., 2008; Melis et al., 2014) or
use only a small subset of larger databases for training (e.g., Uehara et al., 2011, 2008).
In addition, NGCs act through a wide range of mechanisms (Silva Lima and Van der
Laan, 2000). Thus, many models built with a low number of NGCs as positive training
compounds are likely to suffer from low sensitivity. Notable examples are the studies
by Uehara et al. (2008, 2011), which are performed with only two and six NGCs with
very similar MOAs as training compounds and consequently yield low sensitivities. To
improve the sensitivity, more NGCs must be included in model generation and biomarker
extraction. Also, the training compounds should cover a broad range of MOAs to ensure
generalization.
Second, many toxicogenomics studies focus on a single dataset and do not perform
extensive validation of biomarkers, although large toxicogenomics databases are avail-
able (Ellinger-Ziegelbauer et al., 2008; Hiroshi Matsumoto, 2011; Matsumoto et al.,
2014; Schaap et al., 2014). Possible reasons are the choice of different microarrays, time
points, doses, or animal strains. However, these problems can be addressed by mapping
probes between microarrays or choosing the most similar time points and doses. This
was demonstrated early in an extensive external validation study performed by Fielden
et al. (2008), who found that the reported model performances within the same dataset
were higher than those observed in the inter-laboratory evaluation. This early finding
should stimulate more caution when reporting and interpreting the performance of mod-
els and biomarkers that have only been evaluated internally.
Third, the reported model accuracies are biased in some predictive toxicogenomics
studies due to flaws in the evaluation scheme. We identified three main sources of bias:
(1) the presence of samples from the same compound in training and test set (e.g., at
different time points or doses) (e.g., Uehara et al., 2011, 2008; van Delft et al., 2005;
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Yildirimman et al., 2011), (2) feature selection based on the whole dataset and subse-
quent CV of the selected markers (e.g., Jonker et al., 2009; Yildirimman et al., 2011;
Hiroshi Matsumoto, 2011; Matsumoto et al., 2014), which introduces selection bias
(Cawley and Talbot, 2010), and (3) exclusion (e.g., Fielden et al., 2007; Uehara et al.,
2011; van Delft et al., 2005) and mislabeling (e.g., Uehara et al., 2011) of compounds.
The mentioned flaws do not necessarily lead to positive bias, but can inflate the esti-
mated performance, mask over-fitting, and reduce the usefulness of the model for risk
assessment of unseen compounds. For this reason, predictive toxicogenomics studies
that use internal validation should use CV or bootstrapping where the whole process
of model building (signature extraction and classifier training) is performed anew for
each data split (Cawley and Talbot, 2010). Also, if multiple time points, doses, or repli-
cates are available for a compound, all should be in either the training or the test set,
not both. Further consideration is necessary when evaluating the model performance in
small studies (less than 20 compounds), as the choice of the evaluation model (e.g., 10-
fold CV or leave-one-out) can significantly influence the estimated performance (Airola
et al., 2009).
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The ZBIT Bioinformatics Toolbox for
computational biology
During the last 20 years, bioinformatics has become ever more present in biology and
biomedical research. At first, bioinformatics was required most prominently in ge-
nomics, in particular for sequence analysis. In sequence analysis, bioinformatics not
only enabled the reconstruction of the human genome from shotgun sequencing, but also
enabled the computational analysis of proteins or proteomics, e.g., for transcription fac-
tor identification (Wasserman and Sandelin, 2004). However, as the processing power of
computers increased and new high-throughput methods were established, bioinformatics
gained access to many branches of biology. With the development of cDNA microarrays
in the 1990s, gene expression analysis (or transcriptomics) was added to the repertoire
of genomics studies (Schena et al., 1995). The genome-wide gene expression screen-
ing stimulated bioinformatics research in unsupervised and supervised pattern analysis
(Brazma and Vilo, 2000). More recently, reverse phase protein arrays (RPPAs) enabled
the profiling of protein abundance and post-translational modifications (PTMs) (Spurrier
et al., 2008). The improving methodology and accuracy along with decreasing prices
and ever more powerful computation clusters prompted research into the simulation of
life. Systems biology has emerged as the primary branch for developing models of liv-
ing organisms on various scales (Kitano, 2002). The ultimate goal of systems biology
is the development of predictive, in silico models of living organisms, which could be
used to identify causes of metabolic diseases, develop target-specific drugs, or assess the
potential side effects of drugs in silico. Recently, Karr et al. (2012) reported a whole-cell
computational model to prove the viability of this goal. These simulation experiments
usually involve measurements of hundreds of metabolites to determine the internal model
structure and constraints. Overall, the advent of omics technologies and big data led to
great breakthroughs but also created new challenges. As high-throughput technologies
provided data at unprecedented scale and detail, new methods for automated analysis and
dimensionality reduction were necessary. This led to the development of new analysis
methods and computational frameworks designed to process big data.
Whereas the technology made great leaps in these 20 years, bioinformatics software
has retained a high entry burden for interested life science researchers. Commercial
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bioinformatics software is available for many standard analysis tasks, particularly for
gene expression analysis or genomics. Nevertheless, most bioinformatics tools are aca-
demic software developed for very specific tasks and often have a clearly defined user
group: bioinformaticians. For this reason, advanced technical knowledge is often re-
quired to efficiently use bioinformatics tools. For example, many tools depend on par-
ticular operating systems or require third-party libraries that are not included with the
software and have to be installed separately. Some tools are only available as source
code and have to be compiled by the user. Many tools define custom file formats with
more or less strict specifications, which often means that a parser or converter must be
written to use a tool or its output. In addition, graphical user interfaces are often not pro-
vided, such that knowledge of how to use the command line is required. Documentation
and usage examples may also be missing or be reduced to a bare minimum. This also
translates to computational frameworks for big data, which require tailor-made software
that can use the framework, technical knowledge for setup and maintenance, and the
necessary infrastructure such as computation clusters and database servers.
Web platforms have been proposed to address the above-mentioned problems and en-
able life science researchers to use bioinformatics tools and provide bioinformaticians
with a simple way to distribute their software. These web platforms provide predefined
interfaces to command line tools, which eliminates a number of problems: the user does
not need to install the tool or any dependencies locally, he can access the tool through the
familiar interface of his web browser, and the actual analysis is performed remotely such
that no specific hardware infrastructure is required. This makes the tool execution inde-
pendent of the user’s hardware and allows running computationally expensive analyses
remotely from a mobile device in the lab. A prominent example for porting bioinfor-
matics software to an online platform is the public Galaxy server, which is an open,
web-based platform for computational biology (Goecks et al., 2010). The public Galaxy
server is an instance of the Galaxy framework, which can be used to set up customized
web platforms with a different sets of tools. While the framework was initially developed
for sequence analysis, it has spread into many other omics branches such as proteomics
and systems biology (Narang et al., 2014; Hildebrandt et al., 2015). The Galaxy frame-
work provides an established, user-friendly graphical interface for command line tools
through the user’s browser. For developers, it provides many functions out of the box,
e.g., user management, storage of results, and histories of analysis.
With the ZBIT Bioinformatics Toolbox, we have created a customized Galaxy instance
that provides a number of bioinformatics tools to life science researchers without strong
technical background. This chapter is based mainly on the publication “ZBIT Bioinfor-
matics Toolbox: A Web-Platform for Systems Biology and Expression Data Analysis”
in PLoS ONE (Römer et al., 2016b).
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4.1 Tools included in the ZBIT Bioinformatics Toolbox
The ZBIT Bioinformatics Toolbox provides eight bioinformatics tools, which we have
categorized into three major branches of biology: systems biology, transcription factor
annotation, and expression data analysis. The tools were originally developed at the
chair of Cognitive Systems at the University of Tuebingen for various projects and are
available either as Java applications, R scripts, or command line tools. With the ZBIT
Bioinformatics Toolbox, we provide a user-friendly interface to these tools for biologists
and other life science researchers without a strong technical background. The tools that
we included in the ZBIT Bioinformatics Toolbox are BioPAX2SBML, SBMLsqueezer,
SBML2LATEX, and ModelPolisher in systems biology, TFpredict and SABINE for tran-
scription factor analysis, and RPPApipe and ToxDBScan for expression data analysis
(see Fig. 4.1).
4.1.1 Systems biology
The Systems Biology Markup Language (SBML, (Hucka et al., 2003)) and the Bio-
logical Pathway Exchange format (BioPAX, Demir et al. (2010)) are two of the most
widely used community standards in systems biology (Dräger and Palsson, 2014). For
a long time, both formats were not compatible: while the SBML standard is designed
for quantitative analysis, BioPAX is optimized for the exchange of qualitative pathways
between databases (Büchel et al., 2012). Researchers proposed and developed many
tools to convert models stored in a specific format into another format to facilitate the
exchange of models between systems biology groups and databases. In addition, some
tools can add information from external databases to improve or extend existing models.
The following paragraphs provide short summaries of the systems biology tools that are
part of the ZBIT Bioinformatics Toolbox and discuss their capabilities and relevance for
researchers.
BioPAX2SBML was the first converter that was able to translate models from BioPAX
into SBML and properly conserve the qualitative relations which are defined by BioPAX
(Büchel et al., 2012). BioPAX describes the semantics of biological networks and is used
mainly for qualitative analysis (Demir et al., 2010). In contrast, SBML describes quan-
titative models and includes mathematical expressions which are necessary for dynamic
simulations (Hucka et al., 2003). Before the definition of the Qualitative Models exten-
sion for SBML (qual, (Chaouiya et al., 2013)), it was not possible to include qualitative
interactions in SBML models. BioPAX2SBML was the first converter that used qual to
conserve the qualitative information in BioPAX models when converting them to SBML.
Büchel et al. (2012) implemented the translation by defining a mapping that for each el-
ement of the BioPAX model adds the translated SBML element to the converted SBML
model. This conversion maintains exact reactions where possible and includes all other
interactions as qualitative transitions. By using the KEGG API, the resulting SBML
models are further augmented with additional information from external databases such
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as KEGG (Kanehisa et al., 2014) and Entrez Gene (Maglott, 2004). Thus, BioPAX2-
SBML makes the information in curated, qualitative pathway databases accessible for
automated processing. For example, the Path2Models project used BioPAX2SBML to
create mathematical models in SBML for biochemical pathway maps retrieved from mul-
tiple data sources that provide BioPAX models (Büchel et al., 2013).
SBMLsqueezer generates kinetic equations from the stoichiometry, the participating
species, and regulatory relations stored in an SBML model (Dräger et al., 2008). These
kinetic equations are necessary for the dynamic simulation of models created from qual-
itative networks with BioPAX2SBML or from graphical representations of models such
as the Systems Biology Graphical Notation (SBGN). While the manual creation of mod-
els in SBGN is feasible with editors like CellDesigner, the assignment of kinetic rate
laws is not straightforward and prone to human errors (Dräger et al., 2008). By automat-
ing this step, SBMLsqueezer greatly facilitates model generation. SBMLsqueezer uses
the annotations of reactants, products, and regulatory elements in each reaction to gen-
erate the correct rate law and supports numerous kinetics. In addition, SBMLsqueezer
retrieves experimentally determined rate laws from the SABIO-RK database (Wittig
et al., 2012) to extend the available information for simulations. The models augmented
with SBMLsqueezer can then be simulated using standard simulation software such as
CellDesigner. The Path2Models project used SBMLsqueezer to add kinetic equations to
the SBML models created with BioPAX2SBML (Büchel et al., 2013). Other groups have
used SBMLsqueezer for various dynamic simulations of biological networks, which can
be used to predict the behavior of cells in response to stress factors such as drug admin-
istration or heat shocks. Notable examples are Pathak et al. (2013), who modeled the
MAPK machinery activation in plants, and Gupta and Misra (2013), who simulated the
effects of drugs with systems biology approaches.
SBML2LATEX is an SBML converter that generates human-readable reports for SBML
models (Dräger et al., 2009). For this purpose, the XML-based SBML model is trans-
lated into a LATEX document, which can be compiled into either DVI or PDF format
for printing or HTML for web pages. SBML2LATEX facilitates the complicated model
development process by providing human-readable reports, which allow easier error-
checking than the machine-readable XML files, and facilitating model communication
between researchers. The model report can also be included in scientific writing, e.g.,
as supplemental material to ease model interpretation for external researchers in publi-
cations. To translate the SBML model into a PDF report, SBML2LATEX creates tables
of all included reactions, species, constraints, rules, and definitions. These are included
in separate sections of the report and linked to relating elements. For example, each
reaction is represented by a subsection of the “Reactions” section and lists the involved
reactants, the reaction equation, and relevant kinetic laws. The most prominent example
for the usage of SBML2LATEX is the BioModels Database (Li et al., 2010; Chelliah et al.,
2015), which uses SBML2LATEX to automatically generate human-readable PDF reports
for each model in the database.
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Figure 4.1: Analysis workflows available in the ZBIT Bioinformatics Toolbox. The
workflows presented in this figure represent fundamental use-case scenarios that combine
tools from all three basic classes of tools within the ZBIT Toolbox. (a) SBML model pro-
cessing with BioPAX2SBML, SBMLsqueezer, and SBML2LATEX. BioPAX2SBML con-
verts models from BioPAX to SBML and conserves qualitative models. SBMLsqueezer
generates kinetic rate laws for each reaction contained in an SBML file. SBML2LATEX
creates human-readable reports from SBML files. (b) Transcription factor analysis us-
ing TFpredict and SABINE. TFpredict is used to identify transcription factors and pre-
dict their superclass and DNA binding domains. SABINE uses this information to infer
the PFM that represents their DNA binding profile. (c) RPPA analysis with RPPApipe.
RPPApipe implements a customizable pipeline for RPPA data analysis. This includes
normalization and annotation of raw data, statistical methods for the detection of dereg-
ulated and differentially modified proteins, and their association with alterations on the
pathway level, and visualization of the results. Figure from Römer et al. (2016b).
BioPAX2SBML, SBMLsqueezer, and SBML2LATEX all use the SBML format and are
therefore fully compatible. They can be combined into pipelines that create and extend
SBML models and provide human-readable summaries for each model (Fig. 4.1a), either
from BioPAX models that are converted with BioPAX2SBML or with models that are
already available in SBML format.
ModelPolisher is a more recently developed tool that generates well-annotated SBML
models based on the BiGG Models knowledge base (King et al., 2016). ModelPolisher
enriches SBML models that use the conventions of the constraint-based modeling com-
munity with additional annotation by complementing their components with annotations
from the BiGG database. MIRIAM annotations and Systems Biology Ontology (SBO)
terms (Courtot et al., 2011) are added to individual elements of the model. To this end,
ModelPolisher matches the model components against the specification of their BiGG
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IDs (see King, 2015) and pulls the available metadata for the corresponding entries in
the BiGG database. The BiGG IDs are used to recognize specific reaction and metabo-
lite types for which new SBO terms have been defined, e.g., flux bounds and biomass
reactions (King et al., 2016). In addition, ModelPolisher confirms the validity of the
SBML syntax and the structural correctness of the SBML model to detect mass balance
deficiencies. ModelPolisher exports an updated SBML model that can be used as input
for following tools within the toolbox or external tools that support the SBML format.
4.1.2 Transcription factor annotation
Transcription factors (TFs) are proteins that bind the DNA at defined regions, so-called
DNA domains, and thereby regulate the transcription of genes. TFs have an important
role in gene regulation, and researchers identified TFs that are associated with many dis-
eases, for example, inflammatory lung diseases (Rahman and MacNee, 1998), rheumatic
diseases (Firestein and Manning, 1999), or cancer (Darnell, 2002). TFpredict uses ma-
chine learning to decide if a protein is a TF or non-TF based on the protein’s amino acid
sequence (Eichner et al., 2013b). For proteins that are predicted to be TFs, TFpredict
also attempts to predict the structural superclass and uses the InterProScan web service
to detect the TF’s DNA-binding domain (DBD) (Jones et al., 2014). The DBD of a TF
is the part of the amino acid sequence that is involved in the DNA binding event dur-
ing gene expression regulation. The structural superclass is a concept of classification
based on the tertiary structure of the DBD of a TF. Generally, four main superclasses are
used: Basic Domains, Zinc-coordinating DBDs, Helix-turn-helix, beta-Scaffold Factors
(Matys et al., 2006). A fifth superclass comprises TFs that belong in neither of these
four superclasses. TFpredict employs a sequence-based machine learning approach to
build a prediction model for these characteristics and trains the model on data from the
TF databases TRANSFAC (Cartharius et al., 2005) and MatBase (Matys, 2003). Eichner
et al. (2013b) defined BLAST score percentile features, which are based on a BLAST
search for the submitted sequence and a comparison of the results with results obtained
for TFs and non-TFs. These BLAST search results are used to build a feature vector for
the SVM model that predicts if the submitted amino acid sequence is a TF or not. A
similar approach in combination with a multi-class SVM is used to predict which of the
five superclasses a predicted TF belongs to. In their publication, Eichner et al. (2013b)
demonstrated that TFpredict performs better than previously published methods.
SABINE (Stand-Alone BINding specificity Estimator) builds on the results of TFpre-
dict to infer the DNA motif of a TF as a position frequency matrix (PFM) (Eichner et al.,
2013b). SABINE predicts the PFM based on the amino acid sequence, the DBDs that
were detected with InterProScan, the superclass that was predicted by TFpredict, and
the species. SABINE uses support vector regression models to identify other TFs from
the training set with well-defined PFMs, which were obtained from TF databases, e.g.,
TRANSFAC (Cartharius et al., 2005) and MatBase (Matys, 2003). Eichner et al. (2013b)
determined the similarity of TFs based on evolutionary, structural, and chemical similar-
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ities. The PFMs of the best matching TFs are then filtered based on the similarity of their
respective PFMs using a dynamic threshold value. The remaining PFMs are then merged
with a progressive alignment algorithm by the program STAMP, which constructs a con-
sensus DNA motif. As the last step, SABINE performs an error estimation to assess the
confidence of the PFM inference.
In combination, TFpredict and SABINE allow the structural and functional annotation
of TFs (see Fig. 4.1b). In wet-lab experiments, NR2C2 and PPARA have been confirmed
to be TFs in human hepatocytes, as TFpredict and SABINE had previously predicted
(Schröder et al., 2011). Currently, TFpredict and SABINE are limited to eukaryotes, but
an extension to prokaryotes is in development.
4.1.3 Expression data analysis
Since their advent in the mid-1990s, DNA microarrays have changed the field of genet-
ics, and high-throughput gene expression analysis is now an integral part of biological
research (Brazma and Vilo, 2000; Lenoir and Giannella, 2006). Microarray-like technol-
ogy is today applied in related areas, such as proteomics, where reverse phase protein
arrays (RPPAs) are used in individualized medicine or cancer biology (Gallagher and
Espina, 2014; Unterberger et al., 2014).
RPPApipe provides a set of tools for RPPA experiments, which allow preprocessing,
annotation, statistical analysis, clustering, pathway analysis, and visualization of RPPA
data (see Fig. 4.1c, (Eichner et al., 2014b)). Researchers can easily combine these tools
to build workflows that are tailored to their experiments. RPPApipe supports several
experimental designs: standard paired condition and control designs as well as more
specialized designs with multiple conditions or replicated time-series. The major advan-
tage of RPPApipe in comparison with generic array processing software is the support for
RPPA-specific analysis. RPPApipe provides specialized visualizations and analyses, e.g.,
volcano plots that show the differential modification of proteins or pathway profiles that
account for the lower number of analytes on RPPAs compared to transcriptomics studies.
RPPApipe offers full compatibility with InCroMAP (Wrzodek et al., 2013), a software
for integrated multi-omics visualization and pathway analysis. This allows the integra-
tion of RPPA data with additional omics layers, e.g. transcriptomics data (messenger- and
micro-RNAs), epigenetic modifications, or metabolomics data (Wrzodek et al., 2013).
In a recent review, Waters et al. (2010) have investigated the integration of transcrip-
tomics studies into the preclinical drug development process. The profiling of drug-
induced changes in gene expression might allow an earlier assessment of potential unde-
sired side effects in preclinical animal studies. The expression profiles that are obtained
in these studies can be compared to reference datasets of chemicals with known side ef-
fects. With TG-GATEs (Uehara et al., 2010) and DrugMatrix (Ganter et al., 2005), two
large datasets have been released to the public and are available for this purpose. Both
datasets encompass gene expression profiles of rats after subchronic administration of
carcinogenic and noncarcinogenic chemicals.
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ToxDBScan uses a similarity scoring approach to identify well-characterized chemi-
cals that induce gene expression changes similar to the observed gene expression pro-
file (Römer et al., 2014b). The effects of these most similar chemicals may provide
leads for mechanistic analysis of the MOA and the potential side effects of the new com-
pound. To this end, ToxDBScan calculates and reports a similarity score that is based
on significantly deregulated genes. This similarity score can be used to rank the refer-
ence compounds by the similarity of the induced effects on gene regulation. ToxDBScan
also performs a pathway enrichment analysis to aid the identification of possible MOAs.
In our publication of ToxDBScan, we have shown that our similarity scoring approach
is successful at identifying carcinogenic substances and have validated our results with
external data for compounds that are not included in either TG-GATEs or DrugMatrix
(Römer et al., 2014b). A detailed description of ToxDBScan is given in Chapter 5.
4.2 Setup of the web platform
The ZBIT Bioinformatics Toolbox is hosted on a dedicated server, which is running a
GNU/Linux server operating system. Users can access the ZBIT Bioinformatics Tool-
box under the address https://webservices.cs.uni-tuebingen.de through their
web browser. The server uses the Galaxy framework (Goecks et al., 2010) to provide a
user interface, serve static content, handle user requests (e.g., job submissions) and for
data storage and database management. Galaxy is an open framework that was devel-
oped to provide web platforms for data intensive research, particularly next-generation
sequencing projects in biomedical research. The Galaxy developers provide a public
server that hosts the tools that are included with the framework. We set up our own
Galaxy instance and use it to host the tools that were developed at our chair. The Galaxy
framework is implemented mainly in Python, along with a medley of other components
in JavaScript, HTML markup dialects, and others. Our own tools were implemented in
either Java™ or the R programming language for statistical computing. We installed
all requirements for Galaxy on the dedicated server. In addition, three nodes from our
internal computation cluster have been assigned to the ZBIT Bioinformatics Toolbox to
distribute the handling of web traffic and job execution. Each cluster node is running
a GNU/Linux operating system. On the server, Apache2 and Python 2.7.3 were pulled
from the main Ubuntu repository. We use the Oracle Grid Engine to handle the distri-
bution and management of jobs on the small computation cluster. The Java™Runtime
Environment (JRE, version 1.8.0) and R (version 3.2.3) (R Core Team, 2015) were in-
stalled on each cluster node to run the tools. All required third-party libraries were also
installed on the cluster nodes. We integrated our tools into the Galaxy framework with
a set of XML files that define the user interfaces and shell scripts that handle argument
and output processing. Where necessary, we extended the tools to include a command
line interface and respective argument handling. We enforce HTTPS and SSL encryption
to secure all connections between users and the ZBIT Bioinformatics Toolbox. HTTPS
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Figure 4.2: General architecture of the ZBIT Bioinformatics Toolbox. Clients access
the platform through their browser. All in- and outgoing traffic is handled by Apache.
On the server host, the Galaxy framework is used to provide the front end. Galaxy
also handles user management, workflows, and persistent data storage. The Oracle Grid
Engine distributes jobs to cluster nodes and manages the queue of running, waiting, and
finished jobs. After the execution finishes, results are passed back along this command
chain to Galaxy, which stores and displays results for clients. Figure from Römer et al.
(2016b).
protects users and their data against unauthorized access and guarantees that users are
communicating with the correct server. A schematic overview of the system is shown in
Fig. 4.2.
The ZBIT Bioinformatics Toolbox provides several example workflows that represent
use cases for each of the three branches of bioinformatics covered by the ZBIT Bioinfor-
matics Toolbox. Workflows are analysis pipelines that can be built by using the output
of one tool as the input of another tool. This is inspired by the UNIX philosophy: each
tool does one task and does it well, which ensures modularity and reusability of tools and
code, and by combining these simple tools, complex problems can be solved. Workflows
can consist of two or more tools, and outputs of one tool can be used as input for sev-
eral tools, e.g., for multiple visualization tools. The user can set the parameters that are
used for each tool individually. Users can save workflows to reuse them for later, similar
analysis or share them with other users who want to analyze similar problems. The pre-
set parameters can be adjusted when using predefined workflows. This enables users to
build a workflow that analyzes the data from their experiment and reuse the pipeline if
they perform similar experiments or replications. An example of a common workflow is
the combination of BioPAX2SBML and SBMLsqueezer in Path2Models project (Büchel
et al., 2013). An overview of the example workflows is given in Table A.1.
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4.3 Use cases for the ZBIT Bioinformatics Toolbox
This section demonstrates the usage of the ZBIT Bioinformatics Toolbox with exemplary
use cases for each of the three major categories: systems biology, transcription factor
annotation, and expression data analysis. For these use cases, we used the predefined
workflows to analyze real data obtained from public repositories. All data required for
these use cases has been deposited in the ZBIT Bioinformatics Toolbox for reproduction
and as an example for users.
4.3.1 Creation of full kinetic models from pathway maps
Curated pathway databases provide qualitative pathway maps that have been assembled
manually from literature and primary research, e.g., KEGG (Kanehisa et al., 2014), the
Pathway Interaction Database (PID) (Schaefer et al., 2009), or Reactome (Matthews
et al., 2009). The Path2Models project attempted to make these qualitative pathway
maps usable for systems biology by converting these qualitative pathways to quantitative
networks (Büchel et al., 2013). For the Path2Models, Büchel et al. (2012) and Dräger
et al. (2008) developed the tools BioPAX2SBML and SBMLsqueezer to allow the auto-
mated generation of SBML models that can be used for systems biology modeling from
the BioPAX models that are available from the major pathway resources. In this use
case, we demonstrate how to use the ZBIT Bioinformatics Toolbox to perform an ex-
tended version of the Path2Models approach. We use BioPAX2SBML, SBMLsqueezer,
and SBML2LATEX (which was not used in Path2Models) to convert a BioPAX model to
the SBML format, add kinetic equations, and generate a human-readable report that can
be used to inspect and verify the created SBML model.
For this example, we used the ceramide signaling pathway. Ceramides are sphin-
golipids from the family of waxy lipid molecules that are found in the cell membrane
in high concentrations. Several researchers have demonstrated that ceramide signaling
may be involved in differentiation, apoptosis, and programmed cell death (Haimovitz-
Friedman et al., 1997; Obeid et al., 1993).
We downloaded the ceramide signaling pathway from PID in BioPAX and created a
workflow that combines BioPAX2SBML, SBMLsqueezer, and SBML2LATEX with de-
fault parameters. This workflow automatically pipes the output files of the previous tool
to the next and generates a full kinetic model stored in the community standard SBML
format and a human readable PDF report (see also Table A.1 and Fig. 4.3 (a)). The
workflow performs three major steps: First, BioPAX2SBML converts the BioPAX file
to SBML without loss of information (see Fig. 4.3 (b)). Second, SBMLsqueezer gener-
ates and adds kinetic equations for all reactions in the model (see Fig. 4.3 (c)). Third,
SBML2LATEX generates a human readable report as PDF. We used this workflow without
changing the default options of the involved tools.
After the conversion of the qualitative model, the created SBML model contains 50
reactions with 93 involved molecules and 263 kinetic parameters. Any modeling soft-
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Figure 4.3: Creation of a full kinetic model for the ceramide signaling pathway.
(a) Predefined Galaxy workflow for the creation of kinetic models from BioPAX files.
BioPAX2SBML is used to convert the BioPAX encoded pathway to a draft SBML model.
SBMLsqueezer infers reaction equations and kinetic rate laws for the relations defined
in the resulting SBML model. SBML2LATEX creates a human-readable report for model
inspection to facilitate interpretation and curation. (b) This network represents a small
part of the full ceramide signaling pathway that is involved in creation and degradation
of ceramide. It contains four reversible reactions (dark gray squares) and 13 reactants.
The black arrows indicate the participation of reactants in reactions. Blue lines indicate
the enzymatic behavior of reactants. The reaction highlighted in red degrades ceramide
to sphingosine and fatty acid and is catalyzed by Platelet-derived growth factor subunit
A (PDGFA). We used CySBML (Konig et al., 2012) to visualize the draft SBML model
generated by SBMLsqueezer. (c) Reaction equation for ceramide degradation. SBML2-
LATEX creates reaction equations for all reactions in the PDF report. This reaction de-
grades ceramide to sphingosine and fatty acid and is catalyzed by the enzyme PDGFA.
The reaction is also part of the subnetwork shown in (b) and is highlighted in red. Figure
from Römer et al. (2016b).
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ware that supports the SBML community standard and the SBML Level 3 qual package
could then be used to perform further experiments with the ceramide signaling pathway.
Both SBMLsqueezer and SBML2LATEX provide options to further customize or improve
the model and the report.
4.3.2 Identification of transcription factors and DNA binding
domains
For this use case, we used NF-κB, which is a human TF that is present in almost all cell
types and involved in the cell’s response to stress induced by, for example, cytokines,
radiation, or bacterial and viral antigens (Gilmore, 2006). NF-κB participates in the
regulation of the immune response to infections and errors of its regulation have been
linked to several adverse conditions such as cancer, autoimmune diseases, or immune
system deficiencies.
We obtained the amino acid sequence of NF-κB from UniProt (ID: P19838) in the
FASTA format and created a two-step workflow for this analysis: First, we used TFpre-
dict to predict if NF-κB is a TF or not, along with its DBDs and structural superclass.
Second, we used the results of the prediction with TFpredict as input for SABINE to
infer the PFM of the DNA-binding site that is recognized by NF-κB. This workflow is
available from the ZBIT Bioinformatics Toolbox as an example for users, along with the
FASTA input file and additional sample sequences.
TFpredict correctly predicted NF-κB to be a TF (see Fig. 4.4a). TFpredict also pre-
dicted NF-κB to belong to the beta scaffold superclass and InterProScan identified four
potential DBDs. Based on the identified DBDs and the structural superclass, SABINE
was able to infer the putative PFM with medium confidence (see Fig. 4.4b and c). We
compared the predicted PFM to the accepted PFM from the literature and found a good
concordance. The PFM inferred by SABINE is 5'-GGRAANYCCC-3', the actual PFM
is 5'-GGGRNYYYCC-3', where R represents a purine, Y a pyrimidine, and N any nu-
cleotide (Wan and Lenardo, 2009).
4.3.3 Effects of drugs on protein expression
For this use case, we obtained a protein expression dataset that measured in the liver of
rats which have been exposed subchronically to 11 NGCs, 2GCs, and 2 NCs, which is
available from GEO under the accession number GSE53084 (Edgar et al., 2002; Römer
et al., 2014a)). In this experiment, each group of three rats was administered with one
substance or the corresponding vehicle for 14 days. Then, the rats were sacrificed, the
liver was extracted, and protein expression was measured.
We used RPPApipe to assess the effects of NGCs on the protein expression in rat liver
and compare it with the expression observed for GCs and NCs. To this end, we built
an analysis workflow for a two-class experimental design, where for each substance the
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(a)
(b)
GGGRNYYYCC
(c)
Predicted DNA binding profile
Experimental DNA binding profile
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Predict Transcription Factors
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sabine_infile (sab.in)
html_outfile (html)
Predict PFMs
SABINE input file
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Figure 4.4: Transcription factor prediction for human NF-κB with TFpredict and
SABINE workflow. (a) Predefined Galaxy workflow for transcription factor annotation.
The input FASTA sequence file contains the protein sequence. TFpredict uses the se-
quence to predict if the protein is a transcription factor, infer its superclass, and detect
DNA binding domains. SABINE uses the output of TFpredict to identify the DNA se-
quence that is bound by the transcription factor. (b) TFpredict output for NF-κB protein
sequence. NF-κB was correctly classified as a transcription factor. TFpredict predicted
the beta scaffold superclass and detected four DNA binding domains. (c) DNA binding
profile predicted by SABINE. SABINE predicted a PFM with medium confidence. The
predicted DNA binding profile shows good concordance with the consensus DNA bind-
ing profile established by Wan and Lenardo (Wan and Lenardo, 2009). In the consensus
sequence, R represents a purine, Y a pyrimidine, and N any nucleotide.
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group of rats receiving the vehicle is used as the control for the group of rats that received
the actual substance. The workflow has three phases with a total of 12 tools and requires
as input the observed protein expression in the animals (also referred to as samples) and a
class definition file, which defines the relations of treatments and controls (see Fig. 4.5a).
First, during the preprocessing, each sample is assigned to a treatment group according
to the defined relations. Here, we omitted scaling and log-transformation, as the data
was already quantile normalized. In the preprocessing, RPPApipe also fetches addi-
tional information from public databases, e.g., protein descriptions or alternative identi-
fiers. Second, RPPApipe calculates fold changes and p-values to determine which pro-
teins are differentially expressed between the treated samples and the controls. We used
limma (Smyth, 2005) to identify differentially regulated proteins and corrected p-values
for multiple testing with the Benjamini-Hochberg correction (Benjamini and Hochberg,
1995). Third, RPPApipe generates several plots to visualize the results of the experiment,
e.g., volcano plots for differential regulation and modification, and KEGG (Kanehisa and
Goto, 2000) pathway profiles (see Fig. 4.5b). These visualizations allow an easy inter-
pretation of the general effects that we observed in the experiment.
The clustering analysis shows that there is a distinct difference in the protein expres-
sion in rat liver after administration with the two NCs, Nifedipine and Cefuroxime, and
the carcinogenic substances, as can be seen in Fig. 4.5c. We also see a lesser distinction
between the NGCs and the two GCs, C.I Direct Black 38 and Dimethylnitrosamine. This
suggests that carcinogenic substances can be identified in short-term assays, e.g., by mea-
suring protein expression after subchronic exposure to the drug candidate (Römer et al.,
2014a).
4.4 Related web platforms
In the field of systems biology, the ZBIT Bioinformatics Toolbox includes the tools
BioPAX2SBML, SBMLsqueezer, SBML2LATEX, and ModelPolisher. The SBML com-
munity website1 provides the SBML Software Guide, which is actively maintained and
lists software and tools that use or support the SBML format. The SBML Software
Guide includes web platforms in several categories such as SBML editing (semantic-
SBML, (Krause et al., 2010)), visualization (PATIKAweb, (Dogrusoz et al., 2006)), and
annotation (MetaNetX, (Ganter et al., 2013)). However, of the tools listed, none provides
the functionality of the tools that we provide through the ZBIT Bioinformatics Toolbox.
In the category of BioPAX converters, BioPAX2SBML has only one alternative: SyBiL,
which is not available as a web platform and requires installation, along with manda-
tory third-party libraries. While there are other SBML converters that are also available
from web platforms, none is able to convert BioPAX models to SBML. For example, the
System Biology Format Converter Online2 supports BioPAX conversion only to GPML,
1http://sbml.org, accessed Feb. 22, 2016
2https://www.ebi.ac.uk/biomodels/tools/converters/, accessed Feb. 22, 2016
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Figure 4.5: Analysis of the effects of drugs on protein expression with RPPApipe.
(a) Predefined Galaxy workflow for RPPA data analysis. Two input files are required: a
CSV file containing the RPPA expression values and a class file, which defines the rela-
tions between samples. First, the data is normalized and annotated. Second, differential
expression of proteins is determined. Third, various plots are generated, and pathway en-
richment and clustering are performed. (b) Volcano plot and pathway profile for RPPA
data. These example plots were generated using a dataset for effects of drug exposure on
the protein expression in rat liver. Several proteins are differentially modified after treat-
ment with Wy-14643, a NGC (left). Differentially regulated proteins have been mapped
to KEGG pathways to identify potential deregulation on pathway level (right). (c) Clus-
tering of drugs by effects in rat liver. All 15 drugs in the dataset were clustered by their
protein expression profiles. The two NCs (Nif, CFX) formed a separate cluster from the
carcinogens. The two GCs (CIDB, DMN) formed a cluster within the carcinogens. The
NGCs formed several clusters. Figure from Römer et al. (2016b).
55
Chapter 4 The ZBIT Bioinformatics Toolbox for computational biology
not to SBML. Currently, none of the other three systems biology tools has a direct com-
petitor listed in the SBML Software Guide, neither as stand-alone software nor as a web
platform. With SBML2TikZ (Shen et al., 2010) there is a tool that provides additional
functionality that might be used together with SBML2LATEX, e.g., to render the SBML
model in addition to generating a human-readable summary. However, SBML2TikZ is
no longer available as a web tool and must be installed locally.
For transcription factor analysis, the ZBIT Bioinformatics Toolbox provides TFpre-
dict and SABINE. The experimental methods that researchers have traditionally used to
identify were time-consuming and expensive. This has stimulated the development of
a number of in silico methods in the last decade, which use computational models or
machine learning. Among the published methods for identification of DNA-binding pro-
teins are also web platforms. The two most notable examples are iDNA-Prot|dis by Liu
et al. (2014) and nDNA-Prot by Song et al. (2014), which are specifically designed for
the prediction of DNA binding based on the amino acid sequence. Both iDNA-Prot|dis
and nDNA-Prot are accessible through web interfaces that consist of a paste box for the
DNA sequence without further options or much documentation. Both tools only provide
the prediction, DNA-binding or not, without further information. In contrast, TFpredict
predicts if the protein is a TF or not and also infers the superclass and the DBDs with In-
terProScan. Both iDNA-Prot|dis and nDNA-Prot have been reported to outperform their
competitors, but have not been compared to each other, nor to TFpredict. An additional
advantage of TFpredict is the compatibility with SABINE, which allows further analy-
sis, whereas the other two web tools only provide raw prediction results. For the PFM
prediction with SABINE, we have not found any competing web platforms.
For analysis of expression data, the ZBIT Bioinformatics Toolbox provides RPPApipe
for protein expression data and ToxDBScan for gene expression data. Wachter et al.
(2015) have recently reviewed the tools which are available for the analysis of RPPA
data. In their list, they mention only two web platforms: RPPApipe and Miracle by List
et al. (2014). All other tools discussed by Wachter et al. (2015) are either Excel macros
or R packages. For this reason, we compared RPPApipe only to Miracle, which in theory
also provides a web platform. However, at the present, only the source code is available
on GitHub and no official Miracle web server exists. Users are required to set up a custom
server, which requires infrastructure for hosting a web server and advanced programming
and administration knowledge. Thus, RPPApipe is currently the only analysis pipeline
for RPPA data that is freely available as a web platform. In particular, RPPApipe provides
specific analysis methods and visualizations for RPPA data analysis, e.g., the analysis of
differential modification of proteins. For the more general case of finding patterns in the
RPPA expression data without addressing the RPPA specific questions, users could use
web platforms designed for gene expression analysis. For example, PaGeFinder (Pan
et al., 2012) provides pattern analysis for user submitted expression data and PaGenBase
provides a database of pattern genes in a number of model organisms (Pan et al., 2013).
These web platforms can be used to identify genes that are specifically expressed in
certain conditions, e.g., to identify spatiotemporal patterns in sequential gene expression
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experiments.
ToxDBScan is a similarity search engine for gene expression patterns which scans the
two largest databases for the effects of NGCs on gene expression: TG-GATEs and Drug-
Matrix. Currently, two other tools provide related functionality: Toxygates by Nystrom-
Persson et al. (2013) and LTMap by Xing et al. (2014). Toxygates is a data portal which
provides exploration tools for the TG-GATEs data, allows compound ranking by gene ex-
pression and links expression data with pathology reports (Nystrom-Persson et al., 2013).
However, Toxygates does not provide similarity search based on differentially regulated
genes provided by the user. LTMap performs similarity ranking based on user-submitted
probe lists in TG-GATEs data, but does not offer any additional analyses (Xing et al.,
2014). In contrast, ToxDBScan performs pathway enrichment analysis for the submit-
ted data and renders heat maps that enable researchers to visually inspect the similarity
of the gene expression profiles. Also, at the time of writing, the LTMap server was
not available and we received no response from the developers when we informed them
of this issue. A definitive advantage of ToxDBScan in comparison with Toxygates and
LTMap is the integration of the DrugMatrix data, which almost doubles the number of
compounds available for similarity search.
4.5 Summary and conclusions
In this chapter, we presented the ZBIT Bioinformatics Toolbox, which is a web platform
for bioinformatics tools. In total, the ZBIT Bioinformatics Toolbox encompasses eight
tools that have been developed at the chair of Cognitive Systems at the University of
Tuebingen. These tools solve problems in three branches of bioinformatics: systems bi-
ology, expression data analysis, and transcription factor analysis. In systems biology, the
focus of the ZBIT Bioinformatics Toolbox is on SBML conversion and model develop-
ment. BioPAX2SBML is a converter that translates biological networks from BioPAX to
SBML. SBMLsqueezer infers kinetic rate laws for dynamic simulation of SBML mod-
els. SBML2LATEX generates human-readable reports from the XML-based SBML mod-
els for error-checking and model presentation. ModelPolisher augments SBML models
with additional annotations and information from the BiGG models knowledge base.
For expression data analysis, the ZBIT Bioinformatics Toolbox focuses on protein ar-
ray data processing and gene expression database screening. RPPApipe offers a pipeline
for RPPA data processing, annotation, analysis, and visualization. ToxDBScan performs
large scale similarity screening for gene expression profiles in two large toxicological
databases. For transcription factor annotation, TFpredict predicts if a protein is a TF
or non-TF based on its amino acid sequence. SABINE uses the results of TFpredict to
infer the DNA motif that is recognized by the identified TFs. The tools in the ZBIT
Bioinformatics Toolbox have been used by researchers to gain new knowledge in sys-
tems biology (Pathak et al., 2013; Gupta and Misra, 2013; Schröder et al., 2011) and are
adopted in established databases (Li et al., 2010).
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The ZBIT Bioinformatics Toolbox is a free resource for life science researchers who
want to use our bioinformatics tools and will be maintained and extended if more tools
are developed. The most recent addition to the ZBIT Bioinformatics Toolbox was Model-
Polisher, which was added in early 2016. Because it is a web platform, it can be accessed
through the browser from any device without any hardware restrictions. The only re-
quirements for using the ZBIT Bioinformatics Toolbox is a browser and Internet access.
Therefore, in theory, biologists could use mobile devices to submit jobs while in the lab.
Another advantage of the ZBIT Bioinformatics Toolbox is that it requires no technical
knowledge for use, in contrast to the original tools, which would require the installation
of third-party software or knowledge of command line usage. We used the Galaxy frame-
work to implement our web platform. The Galaxy framework provides an established in-
terface that is familiar to many biologists who already used other bioinformatics tools on
other web platforms. The framework was developed for scientific software and provides
excellent support for storage of results, scalability, and reproducibility in concordance
with the requirements for scientific software. In addition, it allows the creation of anal-
ysis pipelines, so-called workflows, which combine multiple tools to perform complex
analysis without much effort. The ZBIT Bioinformatics Toolbox provides examples and
tutorials for all tools along with links to documentation. We have compared our web
platform with other web tools that were created to solve similar tasks and showed that
the ZBIT Bioinformatics Toolbox either provides added value for researchers or pro-
vides unique tools that are not available from other web platforms. We hope that the
ZBIT Bioinformatics Toolbox will facilitate the usage of our bioinformatics tools for life
science researchers and thus further their research and enable new insights.
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Similarity screening for
characterization of drug candidates
Chapter 1 introduced the MARCAR project, which is concerned with the identification
of early biomarkers for nongenotoxic carcinogenesis. While genotoxic drugs are elimi-
nated at the beginning of the development process by in vitro assays like the Ames test
(Ames et al., 1975), nongenotoxic carcinogens (NGCs) cannot yet be reliably detected
by in vitro assays (Jacobs, 2005). Drugs that are to be approved for chronic human ad-
ministration have to provide an estimation of carcinogenic risk. The carcinogenic risk
is commonly assessed using the LRB, a 2-year, in vivo, chronic administration assay
with rodents, typically rats or mice. If carcinogenic effects are observed after the com-
pletion of these long-term rodent bioassays, the market introduction of new, potentially
important medicines for patients may be delayed. Often, these long-term bioassays are
performed as one of the last steps in the safety assessment, after the first clinical phases
are already running or even completed, require 5 years until completion, and cost up
to 2 million US dollars (Johnson, 2012). However, due to a high rate of false positives
and background tumor incidences in control animals, these long-term rodent bioassays
have drawn a lot of criticism (e.g., Johnson, 2012; Cohen, 1995; Jacobs, 2005). Other
problems include appropriate selection of the administered dose and that the observed
endpoints do not provide mechanistic insight into the process of cancer formation.
To address these problems and provide more informative short-term assays, many re-
searchers have proposed toxicogenomics, which employs in silico, in vitro, and in vivo
methods. Currently, the most promising approach in toxicogenomics are short-term in
vitro or in vivo rodent assays that use microarrays or RNA-seq to profile global gene
expression, which is then analyzed with supervised or unsupervised machine learning
and pattern recognition methods (see Chapter 3 and the review by Waters et al. (2010)).
The studies which investigated these short-term rodent assays are often based on a small
number of drugs and use only the data collected in a single study and by a single group.
Frequently, competing groups also use costumized profiling technologies (e.g., different
microarray platforms) and only report chip-specific identifiers, which further compli-
cates the interpretation of the study and the comparison with external data. Due to the
heterogeneous modes of action of nongenotoxic substances, the small sample sizes may
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be particularly problematic. For this reason, two large databases have been established
through the cooperation of national institutes and companies: TG-GATEs (Uehara et al.,
2010) and DrugMatrix (Ganter et al., 2005), which also used the same profiling technol-
ogy. The large number of compounds that was used in comparison with previous studies
may allow an improved analysis of common MOAs and similarities of nongenotoxic
substances. Using the gene expression profiles in the two databases, toxicologists could
predict the carcinogenicity of new compounds and identify similar compounds to extrap-
olate information, e.g., potential side-effects. At the time of writing, to our knowledge,
only one study had assessed cross-prediction of TG-GATEs and DrugMatrix (Gusenleit-
ner et al., 2014) and no tools were available that made use of both databases.
This chapter presents ToxDBScan, a web application that searches TG-GATEs and
DrugMatrix for substances that induce gene expression patterns which are similar to the
patterns induced by new substances. We designed ToxDBScan to be accessible to all re-
searchers, independent of technical background or the profiling technique that they used
to profile gene expression patterns. ToxDBScan uses a newly developed similarity scor-
ing system based on a modified Tanimoto similarity index and provides the user with an
HTML report that can be viewed in most modern web browsers. The ToxDBScan web
application is part of the ZBIT Bioinformatics Toolbox, which was described in Chap-
ter 4. ToxDBScan only requires the up- and downregulated genes to identify similar
compounds and thus does not oblige the user to provide any potentially confidential data,
e.g., the chemical structure, the experimental setting, or microarray data. This allows a
quick and easy identification of potentially similar compounds for further mechanistic
analysis, assessment of their hepatocarcinogenic potential, or MOA discovery. The con-
tent of this chapter was published in the International Journal of Molecular Sciences
under the title “ToxDBScan: Large-scale similarity screening of toxicological databases
for drug candidates” (Römer et al., 2014b).
5.1 Data resources
We used data from three public databases in the development of ToxDBScan: the Car-
cinogenic Potency Database (CPDB), TG-GATEs, and DrugMatrix. The CPDB provides
information on the outcome of long-term rodent carcinogenicity assays for more than
1000 compounds. TG-GATEs and DrugMatrix provide profiles of the gene expression
in the liver of male rats after subchronic administration of hundreds of compounds. The
combination of results from long-term assays as a gold-standard carcinogenicity anno-
tation and gene expression changes after subchronic administration provides users with
a lot of additional information that can help in the characterization of compounds for
which they have obtained gene expression profiles. This section describes these three
major data resources for ToxDBScan and explains their relevance in toxicogenomics in
general.
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5.1.1 The Carcinogenic Potency Database
The CPDB was established by Gold et al. (1984) as a database for standardized results
of animal bioassays. Currently, the CPDB is hosted by the U.S. National Library of
Medicine as part of the TOXNET1, a resource for searching toxicology databases which
list hazardous substances, literature on their biochemical effects, and more (Fitzpatrick,
2008). Since 2011, the CPDD is no longer updated following the death of its direc-
tor Lois Swirsky Gold, who initially established the CPDB in 1984. Nevertheless, the
CPDB is an invaluable resource for toxicogenomics because it is currently the only pub-
lic machine-readable database for carcinogenicity and genotoxicity annotations.
The CPDB records results of chronic, long-term in vivo animal cancer tests that were
reported in the general literature and by the National Cancer Institute until 2004. As
of its last update in 2005, the CPDB encompasses both positive and negative results of
6540 bioassay experiments for 1547 chemicals performed in rats, mice, hamsters, dogs,
and nonhuman primates. It standardizes the variations in protocols, nomenclature, and
information provided by the authors of the original literature and provides an easy and
machine-readable format. Most importantly for the function of ToxDBScan, the CPDB
lists tumor occurrence by organism, sex, and target organ. This allows ToxDBScan to
provide site-specific information, e.g., only results which are found in the liver of male
rats. In addition, the CPDB provides the outcome of an auxotroph-based Ames test for
many chemicals.
We used the CPDB to assign hepatocarcinogenicity for compounds as follows: First, a
compound was classified as a carcinogen (C) if there was at least one positive experiment
which listed the liver as a target organ. Otherwise, the compound was classified as an
NC. Second, we assigned genotoxicity through the recorded result of the Ames test. If
a positive Ames test is recorded, the compound was classified as genotoxic, and if a
negative Ames test is recorded, it was classified as a nongenotoxic. Finally, we assigned
one of three classes, based on the genotoxicity and hepatocarcinogenicity: GC if the
compound is genotoxic and hepatocarcinogenic, NGC if the compound is not genotoxic,
but hepatocarcinogenic, or NC if the compound is not hepatocarcinogenic, regardless
of genotoxicity. Compounds are considered unclassified if no carcinogenicity tests is
recorded in the CPDB or if they are hepatocarcinogenic but have no recorded Ames test
results. To annotate unclassified compounds, we used the annotations by Uehara et al.
(2011), who provide classifications for the compounds included in TG-GATEs.
5.1.2 Open TG-GATEs
The TG-GATEs database was established by a consortium of the Japanese government
and several Japanese pharmaceutical companies (Takashima et al., 2006). In 2010, it was
released to the public under the name Toxicogenomics Project-Genome Assisted Toxicity
1http://toxnet.nlm.nih.gov/cpdb/, accessed March 8, 2016
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Evaluation System (TG-GATEs, Uehara et al., 2010). TG-GATEs was the first public
toxicogenomics project that established an extensive database of gene expression profiles
in the liver of male rats after subchronic administration of drugs and other compounds.
In total, TG-GATEs contains microarray data for 160 chemicals, which include car-
cinogenic substances as well as approved drugs. These 160 chemicals were administered
to male Sprague-Dawley rats for the subchronic in vivo assays and cultured human and
rat hepatocytes for in vitro assays. In the in vivo experiments, liver and kidney were
removed and profiled for gene expression after a defined exposure duration. Affymetrix
Rat Genome 230 2.0 microarrays were used to profile the gene expression for in vivo ex-
periments and in vitro rat hepatocyte experiments. Each compound was administered in
three dose levels: low, middle (3-fold low dose), and high dose (10-fold low dose). Each
dose level for each compound was further profiled at different time points: either 3, 6, 9,
and 24 hours after a single administration, or 4, 8, 15, or 29 days after repeated daily ad-
ministration of the compound. Each condition, i.e., each combination of chemical, dose
level, and duration, was performed in triplicates. In total, TG-GATEs contains data for
14,143 microarrays, which provide data for 3,528 different combinations of chemical,
dose level, and exposure duration and the corresponding, time-matched controls. The
raw data for these microarrays was deposited at ArrayExpress (Kolesnikov et al., 2015)
under the accession number E-MTAB-800.
For ToxDBScan, we used only data that was obtained by in vivo experiments through
the profiling of gene expression in the liver of male rats. Through CPDB and Uehara
et al. (2011), we were able to annotate 123 compounds, which account for 2,768 con-
ditions. We obtained the raw microarray data from the ArrayExpress FTP server and
preprocessed the data using RMA normalization implemented in the affy package for
R/Bioconductor (Gentleman et al., 2004; Gautier et al., 2004).
5.1.3 DrugMatrix
The DrugMatrix data is available from the Gene Expression Omnibus (GEO, Barrett
et al. (2004)) under the accession number GSE57822. In total, DrugMatrix contains
expression profiles for 612 compounds, of which in 2005, 460 were approved drugs,
25 were withdrawn drugs, and 127 were reference compounds or compounds of toxico-
logical interest (Ganter et al., 2005). The expression profiles were compiled from seven
different tissues, e.g., liver, kidney, and heart, taken from male Sprague-Dawley rats after
subchronic administration. Codelink microarrays were used for expression profiling in
the initial studies. Later, the tissue samples were profiled with the Affymetrix Rat Gen-
ome 230 2.0 Array, which was also used by TG-GATEs. DrugMatrix contains profiles
after both single (six hours and one day) and repeated (three and five days) administra-
tions, which leads to a total of 3,200 different drug-dose-time-tissue combinations, for
which time-matched controls are available.
Again, for ToxDBScan we used only the expression profiles that were obtained from
the liver of the male rats. Thus, 1,939 expression profiles are available for 200 of the 612
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compounds, which accounts for 654 of the 3,200 drug-dose-time-tissue combinations.
These were performed mostly in triplicates with time-matched controls, however, for
some conditions only one or two replicates were available. Through CPDB, we were
able to annotate 132 of the 200 compounds, which account for 440 of the 654 conditions.
If compounds with missing annotation were also included in the TG-GATEs database,
annotations from Uehara et al. (2011) were added where possible. We obtained the RMA
normalized data from the DrugMatrix FTP server2.
5.1.4 Comparison of Open TG-GATEs and DrugMatrix
TG-GATEs and DrugMatrix are the two biggest expression profile databases available for
toxicological research and are also among the largest resources in microarray research in
general. At the time of writing, ArrayExpress listed only one study, a comprehensive hu-
man expression map collected from multiple resources, which was larger in terms of the
number of microarrays used (16,241 for TG-GATEs and 10,899 for DrugMatrix3). Both
databases are publicly available and contain more than 100 compounds, far more than
most other toxicogenomics studies used. More importantly, both databases were profiled
using the same microarray platform (Affymetrix Rat Genome 230 2.0 Array), which
greatly simplifies the comparison of expression profiles, because no identifier mapping
is required. We used the CAS numbers to identify compounds that are contained in both
TG-GATEs and DrugMatrix and found an overlap of 51 compounds.
However, there are differences in the chosen exposure durations and dose levels be-
tween the two databases. For TG-GATEs, the highest dose was selected as the maximum
dosage that is considered acceptable for one month of repeated dosing (Uehara et al.,
2010). In DrugMatrix, the dose levels are based on estimates of the maximum toler-
ated dose or the fully effective dose, which were based on previous dose finding studies
and literature research (Giffin et al., 2008). As a consequence, the administered dosage
is higher in DrugMatrix for almost all of the 51 compounds that are present in both
databases. Also, the longest exposure duration in DrugMatrix, 5 days, is much shorter
than the 29 days used in TG-GATEs, which is most likely also a result of the different
strategies of dosage selection. According to Gusenleitner et al. (2014), the doses used
in TG-GATEs are considered suitable for the LRB and thus could be more useful for the
prediction of the bioassay result, whereas due to the high dosages used in DrugMatrix,
some chemicals which are not toxic in conventionally applied doses might show strong
toxic effects.
2ftp://anonftp.niehs.nih.gov/drugmatrix/, accessed March 10, 2016
3http://www.ebi.ac.uk/arrayexpress/browse.html, accessed March 10, 2016
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5.1.5 Validation dataset
In addition to TG-GATEs and DrugMatrix, we obtained a third dataset of gene expression
profiles after subchronic administration of pharmaceutical substances. This dataset is not
included in either TG-GATEs or DrugMatrix but was established by the Bayer AG and
published as part of the MARCAR project (Römer et al., 2014a). We use this dataset
as an external validation set for our new similarity coefficient and the prediction method
that we describe below. It is available from GEO under the accession number GSE53082.
The validation dataset contains 15 compounds, of which 11 are NGCs, 2 are GCs, and 2
are NCs.
Whereas the expression data is not included in either TG-GATEs or DrugMatrix, in-
dependent profiles for 10 of the substances in the validation dataset are encompassed by
one or both databases. The expression profiles in the validation dataset were generated
using a different microarray platform, the Affymetrix Rat Genome 230a Array, which
contains only a subset of the probes on the Affymetrix Rat Genome 230 2.0 Array used
for TG-GATEs and DrugMatrix. An overview of the 15 substances is provided in Ta-
ble A.2. We obtained the RMA normalized data from GEO and applied all additional
processing steps as described for TG-GATEs and DrugMatrix.
5.2 Similarity scoring for gene expression profiles
Finding similarities between gene expression profiles is a common problem for microar-
ray experiments. Several similarity measures have been proposed, Pearson or Spearman
rank correlation and the Euclidean distance are the most common, but others have also
been investigated (Yona et al., 2006). These measures share a common problem: they
require numerical values, such as fold changes or ranks, for the same entities (e.g., probe
sets or gene symbols). In microarray experiments, a systematic bias between different
laboratories may lead to varying dynamic ranges that could confound these similarity
measures.
The large number of different microarray platforms that are available also requires the
mapping of identifiers or restriction to a common set of identifiers. Furthermore, the
number of genes that are deregulated in a certain experiment is usually expected to be
small compared to the number of genes on the microarray chip. Thus, small, random
variations may prevent the detection of similar profiles if, for example, the Euclidean
distance is used. Because the number of differentially expressed genes (DEGs) is gen-
erally expected to be small, we propose to use sparse gene fingerprints and similarity
coefficients for sets to measure the similarity of these fingerprints.
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5.2.1 Gene expression fingerprints
So-called fingerprints are often used as feature representation of chemicals in chemoin-
formatics. A well-known example is the extended connectivity fingerprint, which rep-
resents a chemical compound as a set of its contained substructures (Rogers and Hahn,
2010). Here, we define a gene expression fingerprint as the set of genes (identified by
their official gene symbol) that is found differentially expressed in a specific condition. In
addition, we retain information on the gene’s direction of regulation, such that we know
whether the gene was up- or downregulated for each element of the set. The thresh-
olds used to select DEGs are dependent on specific experiments and are based mainly
on two criteria: intensity ratios and p-values. Intensity ratios are calculated by dividing
the observed average intensity in treated conditions by the observed average intensity in
control conditions. These intensity ratios are also called fold changes. Here, whenever
we refer to fold changes, we mean the base 2 logarithmized intensity ratio. The p-values
are obtained by statistical analysis of the intensity ratio and the observed variations in the
intensities. Several methods have been proposed to calculate p-values for microarrays,
e.g., simple t-tests or more sophisticated approaches using moderated t-statistics (Smyth,
2005). However, most methods require at least three replicates of both treated and con-
trol conditions to calculate p-values. In general, both approaches are combined such that
genes are considered to be differentially expressed if the observed intensity ratio is large
and the p-value is below a chosen false-discovery rate, e.g., less than 5%.
Here, we used only the fold changes to identify DEGs because for many conditions
in DrugMatrix only one or two replicates were available. We also mapped probe sets
to gene symbols using the biomaRt package (Durinck et al., 2009) and summarized all
probe sets that are assigned to the same gene symbol. Finally, we used two fold change
thresholds to select DEGs in TG-GATEs and DrugMatrix and extract the gene expression
fingerprints for each condition.
5.2.2 Tanimoto similarity coefficient and Jaccard index
Gene expression fingerprints are sets of DEGs identified from gene expression profiles.
For this reason, we need a similarity measure for sets to calculate the similarity be-
tween gene expression fingerprints. The Tanimoto coefficient is a well-established sim-
ilarity measure for sets and is used, for example, in chemoinformatics for substructure
and similarity searching. The Tanimoto coefficient was derived from the Jaccard index
(Levandowsky and Winter, 1971), which is also called Jaccard similarity coefficient and
uses the Jaccard distance, a metric for calculating the distance between two arbitrary sets.
It is defined as the ratio of the number of elements in the overlap of two sets A and B and
the number of elements in the union of the two sets and can be calculated as
J =
|A∩B|
|A∪B| (5.1)
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This is equivalent to calculating
J =
|A∩B|
|A|+ |B|− |A∩B| (5.2)
which does not require the union of the sets A and B. The Tanimoto coefficient T is the
equivalent of the Jaccard index defined on binary vectors X ,Y ∈ {0,1}n:
T =
n
∑
i=1
Xi∧Yi
n
∑
i=1
Xi∨Yi
(5.3)
By reformulating the sets A and B, the Tanimoto coefficient can be used to score arbitrary
sets. First, define a vector V that enumerates all entries of the sets A and B. Then, let X
and Y be vectors of the same length as V , where Xi and Yi are 1 if Vi is in the set A or B,
respectively, or 0 otherwise. The Tanimoto coefficient of X and Y will then be equal to
the Jaccard index of A and B.
5.2.3 Novel similarity coefficient for gene expression fingerprints
The gene expression fingerprints that we defined above contain information on the di-
rection of regulation of each gene. For this reason, our gene expression fingerprints are
not binary, but ternary, i.e., we have three states for each gene: “1” means the gene is
upregulated, “0” means the gene is not differentially regulated, and “-1” means the gene
is downregulated. We modified the Tanimoto coefficient to calculate the similarity of
ternary vectors as follows: For two gene fingerprints X ,Y ∈ {−1,0,1}n, where n is the
number of measured genes, the similarity score S is defined as:
S =
n
∑
g=1
δ (Xg,Yg)
n
∑
g=1
|Xg|+ |Yg|−δ (|Xg|, |Yg|)
(5.4)
where δ (x,y) is defined as:
δ (x,y) =
{
1, x = y 6= 0
0, else
(5.5)
With our modified score S, we can calculate the similarity of gene expression pro-
files by extracting their gene expression fingerprints and calculating the similarity of the
fingerprints. For binary vectors our modified Tanimoto coefficient S and the original
Tanimoto coefficient T are equal.
66
5.3 Evaluation of the new similarity coefficient
In previous experiments, we observed that the administration of pharmaceutical com-
pounds often induces an unspecific response, such that a number of genes are found to
be differentially regulated for many compounds, regardless of their toxicological prop-
erties. To account for this unspecific response, we introduced a weight factor w for each
gene, which is dependent on the observed frequency of deregulation. A higher frequency
of deregulation in the database implies that the gene is part of an unspecific response to
drug administration and may not be relevant for the assessment of potential drug effects
and thus means that the gene should get a lower weight. In contrast, genes that are only
found to be differentially regulated in few conditions are given a higher weight, as their
deregulation is considered to be more specific for certain drug effects. We calculate the
weight for each gene as
wg =−log10
∑
c∈C
|cg|
N
(5.6)
where N is the number of compounds in the database and C is the set of gene fingerprints
of the database compounds, i.e., cg is 1 if gene g is upregulated in compound c, −1 if
g is downregulated, and 0 if g is not deregulated. Thus, wg corresponds to the negative
decadic logarithm of the probability of observing deregulation of gene g when randomly
choosing a condition from the database. This approach is inspired by information theory,
where this concept of information content or self-information (Cover and Thomas, 2006)
is used to distinguish between relevant signals and noise. It should be noted that the
calculation of the information content of genes depends on the database and requires the
inclusion of reference compounds and compounds which are not toxic. By including the
weight, the modified coefficient is computed as
S =
n
∑
g=1
wgδ (Xg,Yg)
n
∑
g=1
wg (|Xg|+ |Yg|−δ (|Xg|, |Yg|))
(5.7)
5.3 Evaluation of the new similarity coefficient
The following section describes the validation of the gene expression fingerprints and
the proposed similarity coefficient. For the validation, we have used a dataset that is
not contained in either TG-GATEs or DrugMatrix and was generated by an independent
group in a different laboratory using a different microarray platform.
5.3.1 Gene expression fingerprint extraction
The first step of the evaluation was the extraction of gene expression fingerprints for
all conditions (compound-dose-time combinations) in TG-GATEs and DrugMatrix. We
extracted the fingerprints as described above by calculating intensity ratios (treated to
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control animals) using the RMA normalized data and subsequently filtering for genes
that are at least 1.5-fold (low threshold) or 2-fold (high threshold) up- or downregulated.
We selected these values because they are established as common intensity ratio thresh-
olds in gene expression analysis. We did not include a p-value threshold because many
conditions (and in some cases controls) in DrugMatrix were not performed in triplicates.
Using this procedure, we found at least one up- or downregulated gene in each condition
in both TG-GATEs and DrugMatrix. The distribution of fingerprint sizes (i.e., the num-
ber of up- or downregulated genes for a condition) is shown in the histograms in Fig. 5.1
for the low and high threshold.
The lower intensity ratio threshold lead to gene fingerprint sizes between 23 and 6,525
genes, with a median fingerprint size of 131 genes. On average, we observed smaller
fingerprints in TG-GATEs with a median size of 111 genes and larger fingerprints in
DrugMatrix with a median size of 603 genes. For the higher intensity ratio threshold,
the fingerprints are smaller, as would be expected. The fingerprint size ranges from 5 to
3,224 genes, and the median fingerprint size was 32 genes. Again, fingerprints in TG-
GATEs are on average smaller than in DrugMatrix, with a median fingerprint size of 27
genes in TG-GATEs compared to 152 in DrugMatrix. The higher compound doses that
were used in DrugMatrix are the most likely reason for the higher numbers of DEGs in
DrugMatrix samples. However, the shorter exposure time or inter-laboratory differences
could also lead to different dynamic ranges for the experiments.
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Figure 5.1: Gene expression fingerprint sizes for different intensity ratio thresholds.
Gene expression fingerprints were extracted by filtering genes by the ratio between the
observed normalized intensities in treated and control samples. These histograms show
the distribution of the size of the fingerprints for all conditions in TG-GATEs and Drug-
Matrix. Median fingerprint sizes are 131 genes for the lower threshold (a) and 32 genes
for the higher threshold (b).
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5.3.2 Identification of similar conditions
As the second step of our evaluation, we tested if we can use gene expression finger-
prints and our similarity score to identify TG-GATEs and DrugMatrix experiments that
use the same compound as experiments from an independent dataset. To this end, we
extracted gene expression fingerprints for each compound in the evaluation dataset (see
Section 5.1.5 and Table A.2). As the dynamic range of intensity ratios was very sim-
ilar to those observed for TG-GATEs and DrugMatrix, we used the method described
above to extract the fingerprints in the validation dataset. We collected genotoxicity
and carcinogenicity information for the evaluation compounds from the CPDB where
available. For the remaining compounds, we used annotations from the original publica-
tions (Ellinger-Ziegelbauer et al., 2008; Römer et al., 2014a). Then, we calculated the
similarity coefficient S for all fingerprints of the validation dataset and the TG-GATEs
and DrugMatrix fingerprints and ranked the TG-GATEs and DrugMatrix conditions by
similarity.
Ten of the 15 compounds in the validation dataset are also contained in either TG-
GATEs, DrugMatrix or both. Of these 10 substances, 8 are NGCs, one is an NC (nifedip-
ine, NIF), and one is a GC (nitrosodimethylamine, DMN). For five of the eight NGCs
(acetamide (AAA), ethionine (ET), methapyrilene (MP), phenobarbital (PB) and thioac-
etamide (TAA)) the condition that was most similar, i.e., had the highest similarity score
S, was a TG-GATEs or DrugMatrix experiment using the same substance. The remaining
three NGCs (cyproterone acetate (CPA), diethylstilbestrol (DES) and Wy-14643 (WY))
were only placed second in the respective rankings, but the most similar database condi-
tion was an experiment with a different NGC that has a very similar MOA. This indicates
that the combination of the gene expression fingerprints with our similarity score can re-
call experiments with the same or similar compounds from TG-GATEs and DrugMatrix.
We found that the ranking of database compounds can provide leads for the MOA
analysis for new compounds. For example, WY is an NGC that acts as a peroxisome
proliferator-activated receptor alpha (PPARa) agonist and is investigated as a potential
drug for treating cardiac dysfunction (Wölkart et al., 2012). The database conditions
that are most similar are experiments using fenofibrate, clofibric acid, and clofibrate
(see Fig. 5.2(a)). These three NGCs are also known to interact with PPARa (Peraza,
2005), which suggests a PPARa-related MOA for WY (as shown by Peraza, 2005). For
dehydroepiandrosterone (DHEA), an NGC that is not included in TG-GATEs and Drug-
Matrix, many known PPARa regulators are among the most similar database conditions:
fenofibrate, clofibric acid, WY, and clofibrate (see Fig. 5.2(b)). Again, this indicates a
PPARa-related MOA for DHEA, as was previously shown by Mastrocola et al. (2003).
For piperonyl butoxide (PBO), an NGC that is used as a component in pesticides,
the most similar database conditions are experiments with the NGCs omeprazole, hex-
achlorobenzene, carbamazepine, and spironolactone (see Fig. 5.2(c)). Of these chem-
icals, omeprazole, hexachlorobenzene, and carbamazepine are considered enzyme in-
ducers (Hayashi et al., 2012; Uehara et al., 2011), which suggests a similar, enzyme-
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(b) Dehydroepiandrosterone (NGC)
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(c) Piperonyl butoxide (NGC)
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(d) Direct Black 38 (GC)
Figure 5.2: Gene expression heat maps of similar compounds. For selected test chem-
icals, we extracted the most similar chemicals included in either TG-GATEs or Drug-
Matrix. Each column corresponds to a chemical that was identified as similar. The
chemicals are sorted from left to right by descending similarity score. The heat maps
show the log2 fold change of 20 selected genes from the gene fingerprints of the test
chemical. Genes above the black line are upregulated at least 1.5-fold in the test chemi-
cal, and genes below the line are downregulated. Genes were selected based on average
expression in the identified chemicals. The color bar above the chemical name indicates
the hepatocarcinogenicity annotation (legend is shown in (a)).
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inducing MOA for PBO, as was demonstrated by Goldstein et al. (1973). For other
enzyme inducers in the validation dataset, e.g., cyproterone acetate (CPR) and PB, we
observed similar effects. Omeprazole, spironolactone, and carbamazepine are among the
most similar compounds for CPR, suggesting enzyme induction as the major mechanism
of carcinogenicity, as Schulte-Hermann et al. (1980) have demonstrated. For PB, carba-
mazepine and hexachlorobenzene are among the most similar compounds, which again
suggests enzyme induction, as has been shown by Waxman et al. (1983). Sulfasalazine,
which is classified as an enzyme-inducing NGC by Uehara et al. (2011), is also among
the compounds most similar to PB, but because it has no positive test for hepatocarcino-
genicity in the CPDB, we here considered it to be an NC.
For the validation compounds TAA, MP, and ET (all NGCs) that are considered hep-
atotoxic oxidative stressors according to Uehara et al. (2011), we also observed that
compounds with similar MOA were found, although the evidence is weaker compared
to the compounds described above. For TAA, the most similar compound is MP, but
with a low similarity score S in comparison with the TAA experiments contained in TG-
GATEs, which suggests some differences in the observed gene expression. Among the
compounds most similar to MP are carbon tetrachloride and TAA, which supports the
hepatotoxic MOA, but also the PPARa-activator gemfibrozil, and the genotoxic com-
pound hydrazine. For ET, the most similar compounds include TAA and MP, as well as
carbon tetrachloride, which is also a hepatotoxic oxidative stressor (Uehara et al., 2011).
The genotoxic compound DMN was not recalled, which may also be due to the differ-
ent dose level and duration in the experiments (10 mg/kg/day for five days in DrugMatrix
vs. 4 mg/kg/day for seven days in the evaluation dataset). However, nitrosoethylamine
(DEN), which is very similar to DMN chemically, was identified as the most similar
compound for DMN, along with other GCs. Similarly, for Direct Black 38 (CIDB), the
second GC, the five most similar compounds are all GCs, the highest similarity score
was observed for acetamidofluorene (see Fig. 5.2(d)).
In summary, this evaluation demonstrates that database compounds with similar MOA
are found when using our fingerprint similarity scoring and compounds that are contained
in the validation dataset and one or both of the databases are recalled. This shows that the
proposed similarity scoring can be used for mechanistic analysis, e.g., to identify leads
for a MOA analysis or carcinogenicity evaluation.
5.3.3 Intensity ratio threshold evaluation
Next, we evaluated the thresholds that were used to extract the gene expression finger-
prints. These were selected in accordance with other publications that commonly use
1.5- or 2-fold up- or downregulation tresholds to select DEGs. To validate our choice,
we determined how the compounds that were found to be similar to a query substance
share it’s toxicological class. If a substance was present in the validation dataset and in
either of the databases, the database experiments with this compound were not consid-
ered to ensure an unbiased evaluation.
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We used the carcinogenicity and genotoxicity annotations from the CPDB to annotate
the TG-GATEs and DrugMatrix conditions as described above and also annotated the
validation dataset (see Table A.2). In detail, we counted the compounds that shared the
class of the query compound among the 5, 10, and 20 most similar compounds (see Ta-
ble 5.1). We observed that the lower threshold (1.5-fold deregulation) performed slightly
better than the higher threshold. For the lower threshold, on average 4.3 (4.1 for the
higher threshold) out of the 5, 8.0 (7.3) out of the 10, and 14.2 (14.0) out of the 20
compounds identified as the most similar shared same carcinogenicity class.
We also calculated relative similarity scores S˜ by dividing the observed similarity score
for each query compound with the highest observed similarity score. We determined the
percentage of conditions annotated with the same carcinogenicity class in the subset of
conditions with a relative similarity score higher than 0.8 and 0.7 (see Table 5.1). Again,
we observed a slightly better performance for the less conservative fold change cutoff.
On average, 88% and 80% of the identified conditions with a S˜ > 0.8 were of the same
class as the evaluation chemical, while only 80% and 78% conditions with matching
classes were found for S˜ > 0.7.
In conclusion, our evaluation shows that our similarity scoring approach can robustly
identify compounds with similar genotoxic and hepatocarcinogenic potential. The iden-
tification is possible for chemicals that are present in one or both databases as well as for
compounds that are not included in any of the two databases. Across all evaluations, the
1.5-fold deregulation threshold led to better results for the similarity search. One possi-
ble explanation may be the larger number of genes available for the similarity scoring.
For the lower threshold, the median fingerprint size is 269 genes, compared to 53 genes
for the higher threshold. We found that the number of differentially regulated genes was
particularly small for NGCs and NCs, which may lead to problems when distinguishing
these two substance classes. Based on the above evaluations, we found that the 1.5-fold
deregulation threshold performed better and consider conditions with a relative similarity
score S˜ > 0.8 as likely to share the same class.
Table 5.1: Percentage of correctly identified conditions. The most similar conditions
were extracted for each chemical in the evaluation set. The percentage of conditions
with the same carcinogenicity class in the 5, 10 and 20 most similar conditions and for
conditions with a relative similarity S˜ above 0.8 and 0.7 was calculated.
Neighborhood 1.5-Fold Deregulation 2-Fold Deregulation
Top 5 86 82
Top 10 80 73
Top 20 71 70
S˜≥ 0.8 88 80
S˜≥ 0.7 80 78
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5.3.4 Hepatocarcinogenicity prediction
Above, we demonstrated that gene expression fingerprints and our similarity score can
be used to find leads for mechanistic analysis and identify compounds with similar tox-
icological class. We proposed the use of a relative similarity S˜ above 0.8 as a threshold
for identifying compounds that are likely to have similar MOAs and toxicological prop-
erties. As the last step of our validation, we tested if we can use the extracted conditions
to predict the toxicological properties, here hepatocarcinogenicity and genotoxicity of
new compounds.
We used the lower threshold (1.5-fold up- or downregulation) because the number
of identified compounds with the same toxicological class was highest (see Table 5.1).
Again, we compared the gene expression fingerprints of the validation compounds with
all database conditions and calculated the relative similarity scores. We consider all con-
ditions with a relative similarity S˜≥ 0.8 to be similar, whereas conditions that do not meet
this threshold are considered different. Then, we calculated the percentage of GCs (RGC)
and NGCs (RNGC) in the conditions identified as similar and used an over-representation
test to assess if there are more GCs or NGCs in the set of similar conditions than would
be expected by chance. To estimate the probability of observing the actual or a higher
ratio by chance, we performed a random permutation test with n = 100,000 repetitions.
In each repetition, randomly drawn gene expression fingerprints were scored against the
database to estimate the distribution of the RGC and RNGC. This results in a p-value,
which is calculated as pGC = Nn , where N is the number of random gene fingerprints
that contained a higher ratio of GCs. Analogously, pNGC was computed. Using these
p-values and a false discovery rate threshold of 0.05, we classified a validation com-
pound as a GC if pGC < 0.05, or as an NGC if pNGC < 0.05, or as an NC if pGC > 0.05
and pNGC > 0.05. As the results in Table 5.2 show, the true class was predicted for all
15 validation chemicals. This shows that we can predict toxicological properties using
gene expression fingerprints, the relative similarity of these fingerprints, and a random
permutation-based over-representation test.
5.4 The ToxDBScan web application
We have implemented the similarity scoring of the TG-GATEs and DrugMatrix database
in ToxDBScan, a web application which provides a simple interface that life science
researchers can use to submit a query fingerprint. To perform a query, the researcher
submits only the list of up- and downregulated genes in separate input boxes and selects
the type of identifier that was used by the researcher. No confidential data needs to be
uploaded, such as the chemical structure, compound name, or experimental details. Cur-
rently, ToxDBScan supports official rat gene symbols (as provided by the Rat Genome
Database (Laulederkind et al., 2013)), Entrez IDs (Maglott, 2004), Ensembl IDs (Flicek
et al., 2014), and UniProt IDs (The UniProt Consortium, 2014). The user can also choose
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Table 5.2: Classification results. Similar conditions in TG-GATEs and DrugMatrix were
identified by computing the similarity score S and selecting conditions with a relative
similarity S˜ > 0.8. Ratios of genotoxic carcinogens (RGC) and nongenotoxic carcinogens
(RNGC) were calculated based on the annotation of the similar conditions. A permuta-
tion test (n = 100,000) was performed to assess the significance of over-representation
of GCs (pGC) and NGCs (pNGC). If the p-values were significant for α = 0.05, the cor-
responding class was predicted. If no significant enrichment was found for either of the
two classes, the test chemical was predicted to be an NC. Significant p-values are printed
in bold font.
Chemical RGC pGC RNGC pNGC Prediction
Genotoxic carcinogens
CIDB 1.00 0.001 0.00 1.000 GC
DMN 0.70 0.008 0.20 0.615 GC
Nongenotoxic carcinogens
MP 0.00 1.000 1.00 0.007 NGC
TAA 0.00 1.000 1.00 0.012 NGC
DES 0.00 1.000 1.00 < 0.001 NGC
WY 0.00 1.000 1.00 < 0.001 NGC
PBO 0.00 1.000 0.77 0.002 NGC
MCA 0.00 1.000 1.00 0.017 NGC
AAA 0.00 1.000 0.60 0.048 NGC
DHEA 0.00 1.000 0.88 < 0.001 NGC
ET 0.00 1.000 1.00 < 0.001 NGC
CPR 0.00 1.000 0.71 0.018 NGC
PB 0.00 1.000 1.00 0.019 NGC
Non-hepatocarcinogens
CFX 0.00 1.000 0.00 1.000 NC
NIF 0.25 0.132 0.25 0.399 NC
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between the lower and the higher threshold to account for the strictness that was used to
generate the query fingerprint. Additional options include the choice to use only one of
the two databases or exclude compounds without carcinogenicity annotation from the
database search. The web application ToxDBScan is publicly available from the ZBIT
Bioinformatics Toolbox (Römer et al., 2016b), which is described in detail in Chapter 4.
Similarity search report
ToxDBScan writes an HTML report that contains all information on the results of simi-
larity search in TG-GATEs and DrugMatrix (see Fig. 5.3). The HTML report is displayed
directly inside the ZBIT Bioinformatics Toolbox. Researchers can download the HTML
report as a compressed file and view the HTML file in any modern browser. This re-
port includes the results of the database scan for similar compounds and information on
the NGC-specificity and information content of the differentially regulated genes in the
Figure 5.3: HTML report of the compound similarity scan for PBO. This figure shows
the results of the similarity search against TG-GATEs and DrugMatrix. Additional in-
formation for each compound can be shown by clicking on the “plus” in the first col-
umn of the table. Additional information on the deregulated genes is available from the
“Gene analysis” tab at the head of the report. The results of the pathway enrichment
analysis against the KEGG database are available from the “Pathway analysis” tab. The
“Heatmaps” tab shows heat maps of the gene expression in the most similar compounds.
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query fingerprint. The results of the database scan include the similarity score and rela-
tive similarity score, the gene expression fingerprint for each condition, statistics on the
genes that are shared between fingerprints, and links to external information on genes and
compounds, e.g., CAS number, structure, or Entrez gene entries. For each condition, the
CPDB annotation for the administered compound is included. This information can be
used for a mechanistic analysis of the hepatocarcinogenic potential or MOA detection.
The report also includes heat maps that show the gene expression of the most similar
conditions. All tables can be downloaded as a PDF for printing and sharing or in tabular
format for further analysis.
Pathway enrichment report
In addition to the database similarity search, ToxDBScan performs a pathway enrichment
analysis with KEGG pathways (Kanehisa et al., 2014). To this end, gene symbols were
mapped to the corresponding Rattus norvegicus pathways, which we obtained from the
KEGG database. For each pathway in the KEGG database, a hypergeometric test was
performed to check for significant pathway perturbation. The enrichment p-value is
computed as:
P(X ≥ m) =
M
∑
i=m
(M
m
)(N−M
n−m
)(N
n
) (5.8)
where N is the number of all genes for which gene expression was measured, M is the
number of genes in the pathway of interest, n is the number of DEGs and m is the num-
ber of DEGs that are part of the pathway of interest. The resulting p-values were cor-
rected for multiple hypothesis testing with Benjamini–Hochberg correction (Benjamini
and Hochberg, 1995). The results of the pathway enrichment analysis are available from
a separate tab in the HTML report. For each pathway, this pathway enrichment tab pro-
vides the p-value, information on the genes that are part of the pathway, a pathway map
from the KEGG database, and links to external resources, e.g., the corresponding web
page in the KEGG database.
5.5 Summary and conclusions
In this chapter, we presented a similarity coefficient for gene expression fingerprints,
which can be used to assess the similarity of gene expression profiles that were col-
lected in transcriptomics studies. We applied our fingerprint extraction method to gene
expression data from TG-GATEs and DrugMatrix and evaluated our method for MOA
discovery, identification of compound with similar toxicological properties, and predic-
tive analysis of hepatocarcinogenicity. Using a dataset of microarray experiments that
are not part of either TG-GATEs and DrugMatrix, we demonstrated that our new method
can be used to robustly identify toxicologically similar compounds and predict hepa-
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tocarcinogenicity and genotoxicity. This evaluation dataset encompasses 15 chemicals,
which are either GCs, NGCs, or NCs.
The three major MOAs for the evaluation NGCs were oxidative stress-mediated hepa-
totoxicity (TAA, MP, ET), PPARa-regulation (WY, DHEA), and enzyme induction (PB,
PBO, CPR) (Peraza, 2005; Uehara et al., 2011; Schulte-Hermann et al., 1980; Goldstein
et al., 1973; Mastrocola et al., 2003). We demonstrated that the database conditions
that were identified to be the most similar induce toxicity through the same MOA. Fur-
thermore, GCs in the databases were identified as most similar to the genotoxic evalu-
ation chemicals (CIDB, DMN). This demonstrates that the proposed similarity scoring
approach using gene expression fingerprints provides a useful tool for researchers that
want to use TG-GATEs and DrugMatrix to investigate the MOA of new compounds or
drug candidates.
We explored several strategies to establish a neighborhood of similar compounds
based on the ranking that is produced by the database similarity search. The best results
were obtained with a low intensity ratio threshold (1.5-fold up- or downregulation) and a
relative similarity cutoff that only considers compounds as similar if they have a relative
similarity S˜ > 0.8. Using these parameters, we observed that 88% of the TG-GATEs and
DrugMatrix conditions that were found to be similar share the carcinogenicity class of
the evaluation compounds. Subsequently, we performed a predictive analysis in which
we determined the ratio of genotoxic and carcinogenic substances in the similarity neigh-
borhood and compared this ratio to a background ratio that was estimated using random
permutation sampling. We were able to correctly predict all 15 evaluation chemicals as
NGC, GC, or NC, respectively. This indicates that the proposed method can be used
to predict the hepatocarcinogenic potential of new compounds based on these two large
databases of compounds with known hepatocarcinogenic potential.
ToxDBScan is freely available as part of the ZBIT Bioinformatics Toolbox and was
developed to enable other researchers to use our similarity score for the identification
of similar compounds in TG-GATEs and DrugMatrix. ToxDBScan is independent of the
platform used to identify the deregulated genes, as only the list of up- and down-regulated
genes is required to run ToxDBScan. At the time of writing, we are not aware of other
web applications which offer a similarity search in both TG-GATEs and DrugMatrix.
With LTMap by Xing et al. (2014), a similar web application exists for scanning the TG-
GATEs database. However, LTMap does not scan DrugMatrix, nor provide the additional
analysis performed by ToxDBScan, e.g., pathway enrichment analysis or calculation of
the information content of genes.
In conclusion, our similarity scoring approach for gene expression profiles and the new
tool ToxDBScan offer a novel and unique similarity scoring method for the two largest
toxicogenomics databases and may contribute to the implementation of new approaches
to the evaluation of the carcinogenic potential of chemicals.
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Chapter 6
Multi-omics approaches for prediction
of nongenotoxic carcinogenicity
The previous chapter presented ToxDBScan, a web tool that can be used to query TG-
GATEs and DrugMatrix for compounds that induce gene expression changes similar to
those observed for new compounds. This could help identify potential side effects and
characterize the modes of action of new drugs. We also demonstrated that ToxDBScan
can be used to predict the carcinogenic potential of new drugs using microarray data and
thus help replace the lifetime rodent cancer bioassay (LRB) with short-term alternatives.
Several other groups have also developed systems or methods for the identification
of nongenotoxic compounds in short-term assays, both in vivo and in vitro. Similar to
ToxDBScan, most of these groups used a combination of mRNA expression profiling
and machine learning algorithms or statistical methods to perform the prediction (see
for example the reviews by Waters et al. (2010) and Afshari et al. (2011)). Auerbach
et al. (2010) proposed the use of these short-term prediction systems to prioritize envi-
ronmental or industrial chemicals for long-term carcinogenicity bioassays. Other studies
showed that toxicologists can gain mechanistic insights from these toxicogenomics stud-
ies, e.g., specific molecular profiles can be associated with toxicological phenotypes and
adverse effects observed in animal studies (Afshari et al., 2011). Among others, Ellinger-
Ziegelbauer et al. (2005) published a signature, i.e., a list of early biomarker genes, for
discriminating GCs and NGCs in Wistar-Hannover rats after short (up to two weeks), re-
peated administration. They report that their signature reflects established GC and NGC
modes of action: for GCs, a strong DNA damage response is observed, whereas an in-
creased cell cycle progression is the dominant feature for NGCs (Ellinger-Ziegelbauer
et al., 2005). In a follow-up study, they collected mRNA expression data for a larger
set of compounds and trained a prediction model using SVMs (Ellinger-Ziegelbauer
et al., 2008). Similarly, Japanese researchers published two signatures for discriminating
NGCs and NCs based on mRNA expression data collected in Sprague-Dawley rats (Ue-
hara et al., 2008, 2011). In their first study, Uehara et al. (2008) used an experimental
setup with a single drug exposure and collected liver samples after 24 hours. In the sec-
ond study, Uehara et al. (2011) used a repeated dosing setup, in which animals received
a daily administration of one compound for 28 days, similar to the study by Ellinger-
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Ziegelbauer et al. (2008). The data used in these studies has been made available in the
TG-GATEs database (Uehara et al., 2010). The results that were observed by Uehara
et al. (2011) and Auerbach et al. (2010) suggest that longer dosing may allow a better
detection of carcinogenic activity, which needs to be weighed against the desired early
detection of NGCs. Two groups also explored the use of different omics layers: Schmitz-
Spanke and Rettenmeier (2011) used a protein expression profiling approach and Yokoi
and Nakajima (2011) explored the use of microRNAs (miRNAs) for toxicogenomics.
The development of short-term assays that can reliably predict NGCs and thus help
prioritize compounds that are most likely NCs for development would reduce the invest-
ment of animals, time, and money in chemical and drug development. Currently, most
groups used mRNA data and only a few groups explored other omics layers, but no group
combined multiple omics layers to build an integrated prediction system. Tong et al.
(2009) proposed the integration of multiple regulatory layers for the analysis of NGC
mechanisms, which was later repeated by Khan et al. (2014). Here, we propose a new,
holistic approach that uses multiple omics layers to predict the hepatocarcinogenicity of
drug candidates or other chemical substances. Building on the previous research with
single omics approaches, we introduce two new concepts: the integration of omics data
for multiple regulatory and functional biological layers (mRNA, miRNA, and protein
expression) and the abstraction from individual signature genes to higher-order levels,
such as pathway enrichments or molecular interactions. We demonstrate the value of
these new concepts with a unique data resource that combines mRNA expression pro-
files with miRNA and protein expression profiles obtained from male Wistar rats for
multiple GCs, NGCs, and NCs after up to 14 days of daily compound administration.
We use CV to show that the predictive power of mRNA signatures can be increased
by adding complementary omics-based features obtained from profiling other molecular
levels. Furthermore, we demonstrate that an additional improvement can be gained by in-
cluding complex, integrative features. The content of this chapter was published in PLoS
ONE under the title “Cross-platform toxicogenomics for the prediction of nongenotoxic
hepatocarcinogenesis in rat” (Römer et al., 2014a).
6.1 New integrative feature representations for
multi-omics data
As pointed out in Chapter 2, gene regulation is a complex process that is a result of
many layers of regulation. These layers of regulation interact not only with the DNA
locus of a gene but also with the intermediate products of transcription and translation.
For example, miRNAs bind to complementary base sequences in mRNAs and thus si-
lence the mRNA by inhibiting the translation of the mRNA to proteins (Bartel, 2009).
For this reason, the abundance of mRNAs that is translated into a certain protein may
not correlate perfectly with the amount of protein that is present in a cell. The direct
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assessment of the protein abundances in a cell provides the only reliable account of the
actual protein abundance. However, this direct assessment is currently not possible on
a proteome-wide scale because quantitative mass spectrometry is not yet mature enough
for reliable, large-scale application and targeted, antibody-based RPPAs capture only a
small, preselected fraction of all proteins in a cell. By taking additional layers of regu-
lation into account, the uncertainty that is associated with traditional mRNA expression
profiling may be reduced, which in turn may provide better predictors for biological
and toxicological questions. To achieve this, we developed two new concepts that are
designed specifically for multi-omics data and provide an integrated view of gene regu-
lation: molecular interaction features, which capture the interaction of molecules from
two omics layers, and pathway enrichment features, which provide an additional level of
abstraction and incorporate information from external pathway databases.
6.1.1 Molecular interaction features
The molecular interaction features integrate the data observed for two interacting mole-
cules, which were measured by two different omics technologies into a single interaction
score (see Fig. 6.1A). To account for the varying dynamic ranges of differential expres-
sion for different omics technologies, we first transform the observed log-ratios, i.e.,
log2(fold changes), to a common scale. This transformation is performed for each tech-
nology and assures that each omics platform contributes equally to the final interaction
score, independent of the dynamic range. All log-ratios are transformed using a simple
linear scaling function s : x→ [−1,1] with
s(x) =
x
max(−min(F),max(F)) . (6.1)
where F ∈ {FmRNA,FmiRNA,Fprotein} is the set of all log-ratios observed for the source
omics platform. The molecular interaction score m(xi,x j) for each potential interaction
between two molecules (e.g., miRNA i and target mRNA j) is calculated by the linear
combination of the observed log-ratios for each molecule, i.e., the product of the scaled
log-ratios:
m(xi,x j) = s(xi) · s(x j) (6.2)
We expect m(xi,x j) to be close to 1 if the expression of the molecules i and j is positively
correlated (e.g., mRNA and protein product) and close to −1 for inhibiting interactions
(e.g., miRNA and target mRNAs).
To identify interacting molecules, we used external databases and biological princi-
ples. We gathered potential interactions between miRNAs and mRNAs from curated
databases of validated miRNA targets (TarBase v5.0c (Papadopoulos et al., 2009), miR-
TarBase v2.4 (Hsu et al., 2011), and miRecords v3 (Xiao et al., 2009)) as well as
miRNA target prediction tools (ElMMo v5 (Gaidatzis et al., 2007), DIANA-microT v4.0
(Maragkakis et al., 2009), and TargetScan v5.2 (Lewis et al., 2003)). An mRNA and a
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protein were considered to interact if the protein is the product of the mRNA’s translation.
We also defined interactions between miRNAs and proteins such that a miRNA is consid-
ered to interact with a protein if the protein is translated from an mRNA that is targeted
by the miRNA. We expect to find mainly negative correlations between miRNAs and
their targeted mRNAs (because miRNAs inhibit translation of target mRNAs), positive
correlations between mRNAs and translated proteins, and negative correlations between
miRNAs and proteins that are translated from the targeted mRNAs.
6.1.2 Pathway enrichment features
The pathway enrichment features integrate data for several data points from multiple
omics platforms into a single pathway score. This is achieved through an abstraction
from genes (or other genetic molecules such as miRNAs or protein) to pathways (see
Fig. 6.1B). This abstraction could provide a more robust representation of a compound’s
toxicological effects in an organism because changes in different genes or other regula-
tory molecules may contribute to an alteration of the same pathway and thus to similar
effects.
To integrate the observed effects across multiple omics platforms, we combine the
lists of molecules that are found to be differentially expressed in each platform into a
common list. For this purpose, all profiled mRNAs and proteins were mapped to their
corresponding genes, which can, in turn, be attributed to canonical pathways. The inte-
gration of miRNAs into this process is more difficult because most canonical pathway
databases do not include miRNAs in their pathways. For this reason, we modeled the
effect of deregulated miRNAs through the targeted mRNAs. Next, we used a hyperge-
ometric test to calculate p-values for pathways, which we had previously obtained from
pathway databases. We do not include topological information from the network of the
pathway. The p-values are calculated with the following formula:
p = P(X ≥ m) =
M
∑
i=m
(M
m
)(N−M
n−m
)(N
n
) (6.3)
where N is the number of all genes that were measured, M is the size of the pathway, n
is the size of the combined list of differentially regulated genes on all omics platforms,
and m is the number of the genes that are also in the pathway. The final pathway enrich-
ment score is calculated as −log10(p). Thus, the higher the enrichment score computed
for a certain pathway, the more significant is the overrepresentation of genes from the
combined list in this pathway. The hypergeometric test is performed for each pathway to
construct the pathway enrichment feature vector for a compound. This feature vector rep-
resents both an abstraction from the level of single genes to pathways and an integration
of multiple omics platforms. We used three canonical pathway databases to calculate
pathway enrichment scores: KEGG (Kanehisa and Goto, 2000), Reactome (Matthews
et al., 2009), and BioCarta (Nishimura, 2001).
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Figure 6.1: Feature representations used for cross-toxicogenomics prediction mod-
els. (A) Molecular interaction features. The processed data from the different platforms,
given in the form of log2-transformed fold changes, were mapped to the same inter-
val (here: [-1, 1]) using a linear function in order to account for the different dynamic
ranges of the platforms. Next, putative interactions between molecules represented on
different platforms were inferred based on negatively or positively correlated expres-
sion profiles. For miRNAs, all possible interactions with experimentally validated and
predicted mRNA targets were considered. Associations between mRNAs and proteins
were made based on common gene loci. The connections between miRNAs and proteins
can be transitively inferred from the corresponding mRNA interactions. In order to ob-
tain a numeric feature representation, a score was computed for each interaction, which
equals the product of the scaled log-ratios calculated for the two interacting molecules.
(B) Pathway enrichment features. First, differentially expressed features were detected
for each platform separately based on appropriate fold change and/or p-value cutoffs.
All transcripts and proteins were mapped to the corresponding genes in order to facili-
tate their association with metabolic and signaling pathways. As miRNAs are typically
not contained in canonical pathways, deregulated miRNAs were represented by the genes
corresponding to their experimentally confirmed target mRNAs in order to model their
impact on pathways. The union of deregulated genes was computed across platforms.
Then a hypergeometric test was applied to determine enriched pathways represented by
these genes. Finally, a feature vector was constructed, representing the log10-transformed
p-values obtained for each pathway from the overrepresentation test. Figure from Römer
et al. (2014a).
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6.2 Model construction workflow with single- and
multi-omics features
The study that we describe in this chapter was designed to explore the potential of in-
tegrated molecular signatures. In total, we collected data from four molecular profiling
techniques: traditional mRNA microarrays, miRNA microarrays, DNA methylation ar-
rays and RPPAs. Some of these techniques are not yet as mature as the established
mRNA microarrays, which leads to higher costs and less reliability. For this reason, the
number of substances was small in comparison with other toxicogenomics studies. We
also had to reject the data collected with DNA methylation arrays to due experimental
problems, which led to a significant bias in the observed methylation patterns. In total,
we have collected data with three omics technologies for 15 compounds, of which 8 are
NGCs, 2 are GCs, and 2 are NCs (see Table A.2). For each compound, three biological
replicates were profiled. We excluded three of the study compounds (CPA, TAA, and
WY) from the model construction process because the classification of these was uncer-
tain. To reach a sample size that allows the application of machine learning, we decided
to use the data from each biological replicate as a sample instead of summarizing the data
of the replicates. This results in a dataset of 36 samples for training and evaluation. Due
to the small number of samples, we chose a nested CV procedure over an external vali-
dation set. The following sections describe the data processing and model construction
in more detail.
6.2.1 Data preprocessing
The tissue samples for this study were collected from the liver of 8 to 10 weeks old,
male Wistar Hanover rats (strain Crl:WI[Gl/BRL/Han]IGS BR), which were assigned to
treatment groups using a weight stratification-based computer program. Each group of
animals received either a daily dose of one substance or solvent control for up to 14 days.
The time points at which the tissues for this study were collected are listed in Table A.2.
The administered doses were selected based on those reported to induce liver tumors in
the LRB (Ellinger-Ziegelbauer et al., 2008). We used time-matched groups that were
treated with the corresponding vehicles (methylcellulose (MC) or corn oil (CO)) to serve
as a reference for the calculation of expression changes for all omics molecules.
Total mRNA expression was profiled with Affymetrix GeneChip RAE230A microar-
rays and data was exported as CEL files. The RAE230A array contains 15,866 probe sets,
which correspond to 5,399 annotated rat genes and 10,467 expressed-sequence tags. We
used the package arrayQualityMetrics (Kauffmann et al., 2009) for R/Bioconductor
(Gentleman et al., 2004) to assess the quality and validate that no experimental problems
were present. Next, we used the package affy (Gautier et al., 2004) to perform back-
ground correction, normalization between arrays, and probe summarization with RMA
normalization.
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The Agilent Rat miRNA Microarray 1.0 (G4473A) was used to profile miRNA ex-
pression. Again, sample quality was assessed with the arrayQualityMetrics package.
We performed the normalization with a variant of the RMA algorithm as proposed by
López-Romero (2011). To identify the putative molecular interactions between miRNAs
and mRNAs, we collected experimentally confirmed and predicted target mRNAs for
all miRNAs. We obtained information for validated mRNA-miRNA interactions from
TarBase v5.0c (Papadopoulos et al., 2009), miRTarBase v2.4 (Hsu et al., 2011), and
miRecords v3 (Xiao et al., 2009) and predicted interactions with the miRNA target pre-
diction tools ElMMo v5 (Gaidatzis et al., 2007), DIANA-microT v4.0 (Maragkakis et al.,
2009), and TargetScan v5.2 (Lewis et al., 2003).
Protein expression was profiled with ZeptoMARK RPPAs as described by (Pirnia
et al., 2009). In short, specific primary antibodies were used to perform a two-step im-
munoassay and detect proteins and protein modifications. The measured signal intensity
was background corrected and quantile normalized within each array. Missing values,
which accounted for approx. 1% of the data, were estimated using k-Nearest-Neighbor
imputation.
For all omics platforms, we calculated sample-wise intensity ratios by dividing the
observed signal intensity for a molecule by the mean intensity that was observed for
the time-matched vehicle control. Finally, the intensity ratios were log2-transformed to
obtain the sample-wise, log2 fold changes, which we used as features for single-omics
models and to calculate the integrative multi-omics features.
6.2.2 Inference of predictive molecular signatures
A predictive molecular signature is a list of biomarkers, e.g., mRNAs or proteins, which
can be used to predict the toxicological properties of a compound. To filter predictive
biomarkers from the thousands of measured biomolecules, we used recursive feature
selection (RFE) with SVMs, which is called SVM-RFE. This method is well estab-
lished and has been used by other toxicogenomics researchers before, e.g., by Ellinger-
Ziegelbauer et al. (2008). The SVM-RFE method trains an SVM with a given set of
features and uses the weight vector, which was optimized during SVM training, to rank
the features by their relevance for the classification (Guyon et al., 2002). This procedure
is repeated on a reduced feature set in the next iteration after elimination of the least
informative features. For example, the 10% least informative features are removed in
each iteration, and this process is repeated until the desired signature size is reached or
all features have been eliminated.
Then, we selected the best signature based on the predictive power of signatures of
different sizes. We assessed the predictive power as the mean prediction accuracy in a
nested CV with five different machine learning methods. More specifically, we assessed
signatures containing 5, 10, 15, 20, and 25 features for their predictive power. Based
on the mean accuracy that was observed for each of the signature sizes, we used spline
interpolation to approximate the optimal signature size numerically.
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To build a common signature across multiple repetitions of the CV evaluations, we
merged the signatures which were obtained for each repetition into a rank-based consen-
sus signature. For each signature, the rank of all features is determined by the SVM-RFE
weights and each feature is ranked in the final signature by the average observed rank in
the individual signatures. The consensus signature was then constructed by selecting the
best features until the approximated optimal signature size was reached.
6.2.3 Validation of prediction models
Due to the small number of compounds in this exploratory study, we used 2×2-fold
nested CV to evaluate the model performance (see Fig. 6.2). The nested CV scheme en-
sures that we perform an unbiased evaluation, as the parameter tuning is performed in the
inner CV. The performance of each model is thus evaluated with independent samples,
which were not seen during the model construction and tuning process. To minimize se-
lection bias, which could lead to overestimation of the model performance, we repeated
the CV 10 times with different random splits of training and validation data. Further-
more, to obtain an unbiased estimate of the prediction accuracy that can be achieved with
the various single- and multi-omics features, we used five different classification meth-
ods to evaluate the predictive molecular signatures. These five classification methods are
linear SVMs, random forests (RFs), Neural Networks (NN), Bayesian Generalized Lin-
ear Models (BGLM), and Principal Component Regression (PCR). RF, NN, BGLM, and
PCR are implemented in the caret pacakge for R (Kuhn, 2008). The SVM was used
via the R interface provided by the SHOGUN machine learning toolbox (Sonnenburg
et al., 2010). We used the AUC as the primary performance indicator and averaged the
AUC obtained with the five classifiers to assess the predictive power of each single- or
multi-omics signature.
6.3 Results of the model evaluation
As described above, we evaluated the performance of all models with a 2×2, nested
CV, which we repeated 10 times to eliminate a potential selection bias. In the following
section, we will report the results that we observed, as well as analyze the consensus
signatures for the single- and multi-omics features and the classification of the three
compounds that are not clearly assigned to a carcinogenicity class.
6.3.1 Classification performance of omics signatures
The primary goal of the application of toxicogenomics to compound carcinogenicity is
the identification of lists of biomarkers, also called molecular signatures, which allow
the prediction of tumor development before any histopathological changes can be ob-
served. To this end, we inferred molecular signatures from features that were obtained
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Figure 6.2: Workflow used for signature extraction and evaluation of classification
performance. For the multi-level omics data available in this study, which includes
mRNA, miRNA, and protein expression profiles of diverse compounds, fold changes
were calculated for each gene and sample that could be confidently assigned to a cer-
tain compound class (C: carcinogens, GC: genotoxic carcinogens, NGC: nongenotoxic
carcinogens, NC: noncarcinogens). Single-platform features simply correspond to fold
changes observed on each specific biological level. In contrast, cross-platform features
capture molecular interactions and pathway alterations, which can be inferred by in-
tegrating omics data across multiple layers. For each class contrast (e.g., C vs. NC) of
interest, the dataset was split into a training set and a validation set. Using the SVM-RFE
feature selection technique, a predictive signature for class discrimination was extracted,
which was then used to predict the carcinogenic class of the samples in the validation set.
By embedding this process into a 2-fold CV which was repeated 10 times with different
random splits of the data, the classification performance can be robustly estimated based
on the mean AUC. Figure from Römer et al. (2014a).
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from three different omics platforms and from complex features that integrate the features
from multiple omics platforms. We developed two types of complex features: molecular
interaction (MI) features, which score putative molecular interactions based on miRNA-
mRNA target and mRNA-protein relationships and pathway enrichment (PE) features,
which encompass pathway level perturbations in the hepatic cells (Fig. 6.1). To assess
if different omics platforms yield a different predictive power, we evaluated the signa-
tures from each omics platform separately. We also build a combined signature, which
was generated by merging the single-platform signatures, to determine if the profiling of
multiple layers of gene expression improves the predictive power. This combined sig-
nature was further expanded into a hybrid signature by adding the signatures that were
inferred with the MI and PE features to evaluate if the complex features improve the pre-
dictive power. To identify the contribution of each complex feature type, we evaluated
the combination of the multi-omics signature with each complex feature type individually
and with both complex feature types, which results in three different hybrid signatures:
multi-omics and MI features, multi-omics and PE features, and multi-omics and both
MI and PE features. This signature extraction process was performed for three different
class contrasts (C:NGC+GC vs. NC, NGC vs. GC, NGC vs. NC) and evaluated with
five supervised classification methods (Fig. 6.2). We determined the predictive power
by calculating the average AUCs observed across the 10 repetitions for each contrast,
classifier, and signature type (single-platform, combined, hybrid).
The results of the signature evaluation are shown in Fig. 6.3. In all three contrasts, we
observed a higher mean AUC for the combined, multi-omics signature compared with
the single-platform signatures. The only exception is the single-platform, protein signa-
ture in the NGC vs. GC contrast, which performed better than the combined signature
(Fig. 6.3B). This indicates that the combination of biomarkers from multiple regulatory
layers can increase the predictive performance, at least in this exploratory study with a
small number of compounds. Moreover, we observed a better performance of the com-
bined signature compared to the mRNA signatures, which are the current standard in
most toxicogenomics studies. The miRNA signature performs worse than all other sig-
natures in all cases, which indicates that miRNAs alone are not sufficient to reliably
detect tumorigenic effects.
We also observed an increased AUC when adding the complex, integrative feature
types to the combined signature. In two contrasts, C vs. NC and NGC vs. GC, the hybrid
signatures performed consistently better than the multi-omics signature alone (Fig. 6.3A
and C) and achieved higher mean AUCs. In the NGC vs. NC contrast, we observed
only slight changes in the mean AUCs which does not allow a clear decision on an im-
provement. However, the performance of the hybrid signatures, particularly of the hybrid
signature that encompasses both MI and PE features, was always at least as good or bet-
ter than the combined signature and achieved the best AUCs in two of the three contrasts
and the second best in the C vs. NC contrast. This indicates that the complex features
can capture meaningful signals and thus add to the predictive power of the classifier.
Furthermore, we observed a large variance in the AUCs of the single-platform signatures
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Figure 6.3: Classification performance for different class contrasts depending on sig-
nature types. The bar plots correspond to the average AUC obtained from five widely
used supervised classification methods (SVM, RF, NN, PCR, and BGLM). Before aver-
aging across classifiers, the prediction scores were integrated across repetitions and CV
folds. Each column corresponds to a certain signature type, which may be composed
of different modules. The combined signature contains all predictive features from the
mRNA, miRNA, and protein signatures. MI and PE indicate the additional use of molec-
ular interaction and pathway enrichment features, respectively. Bar plots were generated
for (A) C vs. NC classification, (B) NGC vs. GC classification, and (C) NGC vs. NC
classification. Figure from Römer et al. (2014a).
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across all three contrasts, which we did not observe after the combination of the multiple
platform features and the integration of MI and PE features. For example, the mRNA
and miRNA signatures performed much worse in the NGC vs. GC contrast than in the
other two contrasts, whereas the protein signature failed to achieve a high AUC in the
C vs. NC contrast. This indicates that the classification robustness can be increased by
the integration of multiple molecular levels of gene regulation and an abstraction from
molecular level to systemic, pathway level by calculating integrative features. Overall,
we observed high (AUC > 0.95) and robust AUCs for the combined signature and the
hybrid signatures complemented by the MI and PE features independent of the evaluated
class contrast, whereas the single-platform features showed a strong dependence on the
class contrast.
6.3.2 Predictive features for toxicogenomics models
To further analyze the performance and interpretability of the molecular signatures, we
build consensus signatures by merging the feature rankings that we had obtained in each
of the 10 repetitions. To this end, features were ranked by their average rank in the
10 repetitions. The optimal signature size was estimated as described above and for
each classifier the consensus signature was created by selecting the top features from the
feature ranking until the optimal size was reached. As an example, heat maps which
illustrate the expression changes for the most informative genes or probes (for mRNA
features), miRNAs, and proteins for distinguishing Cs from NCs are shown in Fig. 6.4.
We observed a good correlation (Spearman’s ρ > 0.5) between the change in gene ex-
pression and carcinogenicity classification for the mRNA features. For miRNAs and
proteins, only a few molecules show a clear, carcinogen-specific expression. Particu-
larly, PB and PBO show distinct expression patterns for some of the top-ranked miRNA
and protein features (e.g., rno-miR-34a and CYP2C8, see Fig. 6.4B,C) This is consistent
with the observed lower classification performance for miRNA and protein signatures in
the C vs. NC contrast (see also Fig. 6.3).
We performed a literature search for the identified biomarkers to see if the signatures
include genes, miRNAs, or proteins which have been linked to carcinogen exposure by
other groups. In the mRNA signature for C vs. NC discrimination, we found many
genes that are related to carcinogenic exposure, e.g., Gsta5 (Hayes et al., 1998), Aldh1a1
(McMillian et al., 2004), Ephx1 (Yates et al., 2006), and Akr7a3 (Dewa et al., 2009).
These genes are mostly related to detoxification in the context of oxidative stress. Several
probe sets that were not annotated with a rat gene are also included in the top features, but
could not be verified against the literature. Two of the top miRNA markers for detection
of carcinogen exposure, miR-34a (Dutta et al., 2007) and rno-miR-200b (Tryndyak et al.,
2009), are associated with cancer formation. Several of the informative proteins for the
C vs. NC contrast have also been linked to carcinogenesis, e.g., JUN (Sakai et al., 1989),
GLUL (DeBerardinis and Cheng, 2010), and CDKN1B (Nishimura et al., 2008).
We also generated consensus signatures for the MI and PE features in the same man-
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Figure 6.4: Heat map plots of single-platform signatures for C vs. NC classification.
These heat maps depict characteristic expression patterns observed in livers of rats after
exposure to several rodent liver carcinogens and noncarcinogens. A selection of signa-
ture molecules is shown for each profiled molecular level: (A) mRNA expression, (B)
miRNA expression, and (C) protein expression. In each heat map, rows correspond to
signature molecules and columns correspond to liver samples from differentially treated
rats. The bold vertical lines separate the carcinogens from the noncarcinogens. Plot-
ted are the log2(fold changes), where red indicates up-regulation and green indicates
down-regulation (see color keys). The color bar on top refers to the compound class (see
legend). Figure from Römer et al. (2014a).
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ner as for the single-platform features. The most informative pathways for the C vs. NC
and NGC vs. GC contrasts are shown in the heat maps in Fig. 6.5. The top pathways
selected by SVM-RFE are highly specific for carcinogen exposure. Whereas no pathway
is significantly enriched in all samples, none of the top pathways shows any enrichment
in the NCs, which provides a clear, visual separation of the classes (Fig. 6.5A). In the
NGC vs. GC contrast, the top features for discrimination of the classes also show very
specific patterns, in particular for the genotoxic response to GC exposure (Fig. 6.5B).
While few pathways are specifically enriched in NGCs, other pathways are enriched
only in GCs, e.g., p53 related pathways. Only one of the three samples of the genotoxic
substance DMN shows an uncharacteristic enrichment pattern. The enrichment of vari-
ous pathways that are related to p53, which is a key gene in the cellular DNA damage
response, is consistent with the expected DNA damage response after administration of
genotoxic substances (Lopes et al., 1997). Among the NGC-specific pathways are cy-
tokine and interferon signaling pathways, which have been associated with nongenotoxic
carcinogenesis before (Roberts and Kimber, 1999).
Figure 6.6 shows the interacting molecules of the MI feature signature for C vs. NC
classification for selected compounds. In these volcano plots, we highlighted interactions
where we observed a 1.5 fold up- or downregulation of both interacting partners, e.g.,
a miRNA and its mRNA target. Due to the biological interactions of the biomolecules,
we expected that the expression of miRNAs and their target mRNAs are negatively cor-
related, whereas a positive correlation should be present for the expression of mRNAs
and translated proteins. Several of the interactions in the MI signature involve genes
that have been linked to carcinogenesis in the rat such as Glul (DeBerardinis and Cheng,
2010), Dusp1 (Feo et al., 2009), Jun (Sakai et al., 1989), Sgk1 (Won et al., 2009), and
Mgat4b (Liu et al., 2010). Some of these genes have also been encompassed by the
single-platform signatures that we discussed above. For the mRNAs of the genes Glul
and Jun and their corresponding proteins, we found matching changes at transcriptional
and translational levels after treatment with liver carcinogens (see Fig. 6.6). For NGCs,
we observed a highly specific putative interaction between the miRNA rno-miR-29b and
its potential target mRNAs Sgk1 and Mgat4. In contrast, we observed no putative inter-
actions that were affected on multiple layers for NCs.
6.3.3 Toxicogenomics-based classification of undefined compounds
Of the 15 compounds that were selected for this exploratory study, the three compounds
CPA, TAA, and WY are generally considered to be nongenotoxic carcinogens in the lit-
erature (for example in Ellinger-Ziegelbauer et al. (2008)). However, due to ongoing
discussions on a possible genotoxic component to their carcinogenic potential, we de-
cided to remove them from the training set to prevent confounding effects. For CPA,
Lang and Redmann (1979) reported negative results in the Ames test, which indicates
the absence of genotoxic activity, but later Martelli et al. (1996) reported positive results
in a micronucleus test in female rats, such that the genotoxicity of CPA is still subject
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Figure 6.5: Heat map plots of pathway enrichment signatures. These heat maps depict
overrepresentation of genes involved in relevant pathways among the genes deregulated
in liver upon treatment of rats with a certain compound. Pathways relevant for compound
classification were selected by SVM-RFE for different class contrasts: (A) C vs. NC
and (B) NGC vs. GC. The rows correspond to canonical pathways from the databases
Reactome (R), KEGG (K), or BioCarta (B) and the columns correspond to samples. The
bold vertical lines separate carcinogens and NCs. The color of each cell refers to the
− log10(p-value) obtained from a hypergeometric overrepresentation test and indicates
the significance of a certain pathway enrichment (see color key). The color bar on top
of each heat map denotes the carcinogenic class (see legend). Figure from Römer et al.
(2014a).
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Figure 6.6: Volcano plots of molecular interaction signatures. Shown are volcano
plots for two representative compound profiles of each of the three compound classes
(i.e., NGC, GC, and NC). The plots represent putative molecular interactions between
different molecular layers, which were found to be predictive for C vs. NC classifica-
tion. For each interacting molecule (i.e., mRNA, miRNA, or protein) the strength of its
differential expression was assessed in terms of the log2(fold change) and plotted against
its significance, which is given by the FDR-corrected log10(p-value) obtained from a
moderated t-test. Different shapes and colors denote different types of molecules (see
legend). Colored edges were used to highlight molecular interactions for which a pos-
itive or negative correlation was observed between two molecule types. We considered
correlations in the expression profiles of miRNAs and their experimentally confirmed
or predicted mRNA targets, as well as between mRNAs and proteins sharing the same
genomic locus. As a formal criterion for a putative molecular interaction, we required a
1.5-fold up- or downregulation for both interaction partners. Figure from Römer et al.
(2014a).
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of discussion. Similarly, we found negative Ames test results (Chieli et al., 1987) and
positive micronucleus tests (Mirkova, 1994) for TAA in the literature. WY is gener-
ally classified as a peroxisome proliferator, which is a subclass of nongenotoxic rodent
hepatocarcinogens (Cattley and Popp, 1989), but Deutsch et al. (2001) reported positive
results for a Comet assay with WY and Lefevre et al. (1994) observed clastogenicity
in two cell types. These conflicting results led us to consider these compounds as not
reliably labeled and we excluded them for all training and validation purposes.
To provide a mechanistic classification of these compounds and their putative mode of
action for carcinogenicity, we used the signatures that were extracted from the remain-
ing, well-annotated compounds for a predictive analysis with the same five classification
methods that we used in the performance evaluation above. We also performed PCA to
visualize the complex, high-dimensional expression patterns for all samples. The vector
of signature features for each compound was transformed into a two-dimensional space
spanned by the two principal components explaining most of the variance in the data
and the resulting plots were generated for two different signatures for NGC vs. GC dis-
crimination. The PCA plots for the mRNA signature and the hybrid signature, which
encompasses all omics platforms and the MI and PE features, are shown in Fig. 6.7A
and B. Most previous toxicogenomics studies used mRNA data and published mRNA
signatures, which is why we compare the hybrid signature to the mRNA signature. Fig-
ure 6.7A shows a separation of the three classes based solely on mRNA expression
changes. However, the two carcinogenic classes (GC and NGC) are rather close to each
other and some samples treated with WY are placed outside of the space spanned by the
NGC class. In contrast, the PCA plot for the hybrid signature with all omics signatures
and the integrative MI and PE features in figure Fig. 6.7B shows a better separation of the
three classes and all of the unclassified samples are encompassed by the area spanned by
the NGC samples. This provides a clear indication for the classification of the undefined
samples and compounds. Figure 6.7C-D shows a heat map of the classification confi-
dence with the five classification methods that we used in the validation process. With
the mRNA data, we observed that the unclassified samples are consistently classified as
NGCs for most classification methods, indicating that the compounds CPA, TAA, and
WY are indeed NGCs. When we used only the protein or miRNA signatures for the
classification, we observed inconsistent classification and a low mean confidence for all
samples. Using the hybrid signature with all available feature signatures, we observed
high confidence scores and a robust classification across all employed learning algo-
rithms, which further supports our claim that the integration of multiple omics features
and complex, integrative features enhances the classification performance. All undefined
compounds were classified as NGCs based on their molecular profiles. Our results thus
support the outcomes of the carcinogenicity assays that were performed for WY, TAA,
and CPA (Lang and Redmann, 1979; Chieli et al., 1987; Cattley and Popp, 1989).
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Figure 6.7: Classification of undefined compounds. (A) Samples are represented based
on the mRNA signature for NGC vs. GC discrimination. The corresponding fold changes
were PCA-transformed and plotted in a lower-dimensional space spanned by the first two
principal components. The color of the spheres corresponds to the class of the admin-
istered compounds with respect to their hepatocarcinogenic properties in rats. Clusters
of rat liver samples after treatment of rats with compounds of the same class are high-
lighted by means of transparent polygons. (B) Same as (A), but instead of using the
mRNA signature for sample representation, all single-platform (mRNA, miRNA, pro-
tein) and cross-platform signatures (PE, MI) were combined. (C) The heat map displays
the confidence scores obtained from five different machine learning methods that were
used to classify the undefined compounds CPA, TAA, and WY as either NGC or GC. The
confidence scores are [0, 1]-scaled and correspond to the probability that a certain sam-
ple was treated with an NGC (see color key). (D) Similar illustration as in (C) obtained
with classifiers trained on all signatures combined. Figure from Römer et al. (2014a).
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In this chapter, we proposed a method for the prediction of carcinogenic effects of chem-
icals in the liver of rats in the LRB. The proposed method is based on expression data,
which was obtained by profiling changes in the expression of mRNAs, miRNAs, and
proteins using multiple omics technologies after rats received a daily oral administration
of a set of prototypic Cs and NCs for up to 14 days. The development of short-term (two
to four weeks) assays that reliably detect putative carcinogens can facilitate and accel-
erate the development of drugs and industrial chemicals. New short-term assays could
be used to perform a prescreening of candidate chemicals to prioritize those chemicals
that are less likely to induce tumors for LRBs or even replace the LRB. Toxicogenomics
is currently one of the most promising approaches for the development of such short-
term assays. Most of the toxicogenomics studies that have been performed previously
profiled the mRNA expression changes and employed machine learning to infer signa-
tures and build predictive models (Ellinger-Ziegelbauer et al., 2008; Uehara et al., 2011;
Auerbach et al., 2010). Some groups have also tried to use other, more recent omics
technologies such as miRNA or protein expression changes to build predictive models
(Schmitz-Spanke and Rettenmeier, 2011; Yokoi and Nakajima, 2011). Here, we used not
only the data from one omics layer but included and integrated multiple layers of omics
data to increase the predictive power of the prediction models. In addition to the profiled
expression changes, we further introduced two integrative feature types (molecular inter-
actions and the pathway enrichment), which use prior knowledge from interaction and
pathway databases to calculate new features for model building.
We used a repeated nested-CV workflow to evaluate the predictive power of signatures
that were inferred using either only the single omics platforms, the combination of all
omics platforms, or the integrative features. For this evaluation, a unique dataset was
generated, in which mRNA microarrays, miRNA microarrays, and RPPAs were used
to profile expression changes on three omics levels for 15 prototypic compounds. The
dataset was deposited in GEO and is available under the accession number GSE53085
(Edgar et al., 2002; Barrett et al., 2013). We used 12 well-annotated compounds to
construct models with an unbiased 2×2 nested CV with 10 randomly created splits into
training and validation set. The three remaining compounds had conflicting genotoxicity
information and were therefore excluded from the training and validation sets.
We observed that the predictive power of classification models was higher when we
used the combination of all three omics levels compared to models built based on a
single omics platform. This observation was consistent across the three different class
contrasts for which we built models (C vs. NC, NGC vs. GC, and NGC vs. NC). The
predictive power could be increased further by the inclusion of the integrative MI and
PE features. These features provide an abstraction of the molecular expression changes
to molecular interactions and biochemical pathways. We observed a consistent increase
in the average AUC that was obtained for each signature with five different classification
methods, with the exception of the NGC vs. GC contrast, where the protein signature
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performed slightly better. The inclusion of the integrative features also improved the ro-
bustness by reducing the variance in classification AUC in the random resamplings. We
also observed a better separation of the three classes in a PCA plot when using the hybrid
signature compared to single-platform signatures. In summary, the combination of mul-
tiple omics layers yielded a high prediction accuracy (AUCs > 0.9) in all class contrasts
and outperformed the single-platform signatures in terms of power and robustness. The
best classification (AUCs > 0.95) was achieved by including the pathway enrichment
and molecular interaction features.
We used the single-platform, combined multi-platform, and hybrid signatures to re-
classify the three compounds CPA, TAA, and WY for which conflicting genotoxicity
information was found in the literature. These three compounds are known to be car-
cinogenic in rats and have been negative in Ames tests, but have shown some positive
results in micronucleus or Comet assays (e.g., Lang and Redmann, 1979; Martelli et al.,
1996; Chieli et al., 1987; Mirkova, 1994). Our prediction models have consistently pre-
dicted all three substances to be nongenotoxic carcinogens, which is consistent with
their classification by other experts (e.g., Ellinger-Ziegelbauer et al., 2008; Uehara et al.,
2011). In line with the results of the model performance evaluation, we observed a much
higher prediction confidence for the hybrid signatures compared with the single-platform
signatures.
In conclusion, this exploratory study demonstrated that the combination and integra-
tion of data from multiple layers of gene regulation improves the power of prediction
models in toxicogenomics. Studies with more compounds and global profiling technolo-
gies, e.g., for protein expression and DNA methylation, are necessary to fully assess the
impact of multi-omics data in the context of toxicological risk assessment. We believe
that future toxicogenomics studies can benefit from profiling additional omics layers,
e.g., metabolomics, DNA mutations, or genome-wide promoter methylation. We hope
that our work encourages the maintainers of the currently available, large databases in
toxicogenomics (e.g., TG-GATEs and DrugMatrix) to generate additional data to com-
plement the existing mRNA data.
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The detection of tumors during preclinical toxicology studies in drug development can
result in the delay of drug candidates reaching the market depending on the MOA, hu-
man relevance, and the intended therapeutic indication. Drug candidates associated with
direct genotoxicity leading to DNA mutations are efficiently eliminated early during de-
velopment with established short-term assays. However, NGCs form a significant pro-
portion of carcinogenic drug candidates and induce tumors through mechanisms other
than DNA mutations. To identify such compounds, time-consuming in vivo LRBs are
required. These LRBs require a large number of animals, take at least three years to be
completed, and cost up to 2 million US dollars (Johnson, 2012). The earlier detection of
cancer development upon compound treatment could lead to significant savings in time,
cost, and animal numbers, and could benefit patients regarding drug safety.
In this context, the MARCAR project (MARCAR Consortium, 2010) generated a
wealth of data to increase insights into mechanisms of NGC action to detect carcino-
genic effects of drug candidates earlier (e.g., Lempiainen et al., 2013; Unterberger et al.,
2014; Thomson et al., 2014; Römer et al., 2014a). The MARCAR project explored
primarily the liver, which is the major target organ of NGC induced tumors in rodents
(Knight et al., 2006a). A particular goal was the identification of early biomarkers of
NGC effects to provide the basis for designing new short-term assays for earlier detec-
tion of potential NGCs. GCs and NCs were used as control substances to ensure that
identified biomarkers are specific for NGCs.
A fundamental concept of the MARCAR project was the integration of data collected
at multiple levels of gene expression regulation. In addition to traditional profiling of
mRNA abundance with microarrays, non-coding mRNAs were measured by array tech-
nology, protein abundance and modifications were assessed by RPPAs, and DNA methy-
lation patterns were identified with methylation arrays (Unterberger et al., 2014; Römer
et al., 2014a; Thomson et al., 2012). Potential biomarkers identified include, e.g., the
Dlk1-Dio3 imprinted gene cluster of noncoding RNAs (Lempiainen et al., 2013), epi-
genetic changes in the 5-hydroxymethylome (Thomson et al., 2012), and effects on the
hepatic mesenchyme (Riegler et al., 2015). To effectively explore the interaction of mul-
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tiple layers of gene regulation, the InCroMAP software was developed, which provides
KEGG pathway maps with overlaid information on, e.g., mRNA expression, miRNA-
gene interactions, and methylation changes (Wrzodek et al., 2013). Toxicogenomics
approaches were applied to extract signatures (i.e., lists of biomarkers) to identify NGC
action in both rats and mice (Kossler et al., 2015; Eichner et al., 2013b). In total, the
MARCAR project has generated 27 datasets across three species (Homo sapiens, Rattus
norvegicus, Mus musculus) and four regulation levels (mRNAs, miRNAs, proteins, and
DNA methylation), which are available from GEO under accession number GSE68387.
The majority of MARCAR datasets were generated with traditional mRNA microarray
profiling techniques. These arrays measure the expression of almost all known genes in
the genome of a certain species at once. This provides an enormous amount of raw data
that requires preprocessing, normalization, and statistical or computational approaches
to effectively identify patterns and specific biomarkers. Traditionally, bioinformaticians
would process the data and provide tables and static visualizations to biologists, who
would then try to interpret the data. To facilitate the process of generating insights
from the wealth of data, we created MARCARviz, a set of software tools that allows
an interactive visual analysis to quickly identify relevant patterns in large amounts of
microarray data by non-bioinformaticians. MARCARviz can be used to quickly answer
common questions associated with the experiments, e.g., which genes are affected by the
treatment with a specific compound, generate a mechanistic hypothesis, for example by
finding enriched pathways and Gene Ontology (GO) terms, or compare the effects of sev-
eral compounds. MARCARviz also provides cross-platform and cross-species analysis,
which usually require the mapping of several types of identifiers (e.g., Affymetrix probe
IDs to gene names) or identification of orthologous genes. The most relevant visualiza-
tions for microarray data (e.g., heat maps, Venn diagrams, volcano plots) are provided
and extended with interactive functionality for pattern identification.
MARCARviz is available as a web platform, which requires no additional plugins and
few computational resources on the user’s side. All analyses are performed on a compu-
tation cluster to provide results as fast as possible. The major advantage of MARCARviz
is that it allows biologists without advanced bioinformatics knowledge to quickly answer
the most common questions that might be asked of the MARCAR mRNA expression
data, extract data and figures that support their hypothesis, and generate new insights and
hypotheses about NGC mechanisms and biomarkers. This chapter was presented at the
German Conference for Bioinformatics 2016 and is available as a preprint from PeerJ
Preprints (Römer et al., 2016a).
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7.1.1 Datasets and data analysis
All animal experiments have been approved by the respective ethics committees and
were performed according to established experimental guidelines. Study design and raw
data generation have been described in previous publications (Unterberger et al., 2014;
Riegler et al., 2015; Braeuning et al., 2010; Luisier et al., 2014; Eichner et al., 2014a;
Lempiäinen et al., 2011; Ellinger-Ziegelbauer et al., 2008; Braeuning et al., 2016). The
datasets cover three species: mouse (Mus musculus), rat (Rattus norvegicus), and hu-
mans (Homo sapiens). The MARCAR studies can be grouped into two broad categories:
(i) short-term effects of NGCs and (ii) mechanistic analysis of a model NGC (pheno-
barbital). To study the common characteristics of NGCs, rats and mice were adminis-
tered daily doses of several NGCs for up to four weeks. For comparison, GCs and NCs
have been included to identify effects that are specific for NGCs (see Table A.3). For
the mechanistic investigation of the model substance phenobarbital, several knockout
studies have been performed in mice, along with transcriptomic profiling of tumor and
normal tissue. In total, 16 microarray datasets have been generated and processed for
inclusion in MARCARviz. All raw data was submitted to GEO and is available under
the accession number GSE68387 (see Table A.4).
Microarray quality control was done with the R package arrayQualityMetrics to
remove outliers and low-quality samples (Kauffmann et al., 2009). Raw data process-
ing was performed with the R packages affy and limma (Gautier et al., 2004; Smyth,
2005). In short, Affymetrix 3’ IVT expression array data was normalized with RMA and
summarized to Entrez Gene IDs using custom Brainarray CDF files (Dai et al., 2005).
Agilent microarray data was within-array background corrected, quantile normalized be-
tween arrays, and summarized to Entrez Gene IDs. For each dataset, we normalized all
samples together. To eliminate batch effects, all studies use designs that ensure that
treated and control samples are run in a single batch. A moderated t-value implemented
in limma was used to compute p-values for significant deregulation of genes. We used the
Benjamini-Hochberg method to correct for multiple hypothesis testing. Logarithmized
(base 2) fold changes were calculated as the log2 of the observed mean intensity ratio be-
tween treated and control animals for each gene. The biomaRt package for R was used
to identify orthologous genes for cross-species data comparison (Durinck et al., 2009).
Gene to gene set mapping files were obtained from the Molecular Signature Database
(MSigDB, Liberzon et al. (2011)) for the KEGG, BioCarta, Reactome, and Gene Ontol-
ogy databases (Ashburner et al., 2000; Nishimura, 2001; Matthews et al., 2009; Kanehisa
et al., 2012). For the enrichment analysis, all gene identifiers are mapped to orthologous
HGNC gene symbols based on information available from the Entrez Gene database
(Maglott, 2004). A hypergeometric test was used to calculate enrichment p-values. All
calculated p-values were corrected for multiple hypothesis testing with the method de-
veloped by Benjamini-Hochberg.
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7.1.2 Database construction
We used a combination of spreadsheets, R scripts, and a schema-free NoSQL database to
edit, process, and store all data and metadata. The biggest metadata unit is called Study,
which is conceptually similar to a GEO entry. A Study usually encompasses several
different conditions (called Treatment) that are compared to identify biological effects.
A Treatment constitutes a specific set of conditions that is of interest. For example,
toxicogenomics studies often involve multiple drugs that are administered to animals of
the same species for a specific time period. In this example, each drug constitutes a
Treatment. If multiple parameters are varied in a study, e.g., multiple drugs are mea-
sured at several different time points, each Treatment corresponds to a unique combi-
nation of parameters. All MARCAR studies used a case-control design, i.e., for each
Treatment a corresponding control is available, which establishes the baseline for com-
parison. Most MARCAR studies also used biological replicates to allow a statistical
analysis of the observed biological effects. Thus, each Treatment encompasses several
units called Samples, each of which is labeled as either treated or control Sample.
A Sample is the smallest unit of metadata and represents a single microarray exper-
iment (e.g., a CEL file for Affymetrix microarrays). For each Study, this metadata
scheme was represented by an XLS file with three tables: one table for the Study in-
formation, one table for the metadata of each Treatment, and one table for the Sample
metadata that also contains the raw data file paths. We decided to use XLS spreadsheets
because they facilitate the editing of the metadata, allow the storage of all three metadata
levels in one file, and can easily be parsed with R.
We processed the raw microarray data as described above with a standardized R
script. The R script read the metadata spreadsheet to determine the microarray platform,
the experimental design, and the assignment of raw data files (i.e., Samples) to each
Treatment for statistical analysis. The processed data was stored as an R workspace
in binary format for faster reading. Also, the metadata tables were included in the R
workspace to provide a single file that contains all relevant data and metadata. An R
script pushed all metadata and data into the NoSQL database.
To store the processed microarray data, we used one table for each Study that was
named expr_[Study]. With the NoSQL-based MongoDB database system1, this al-
lowed for an easy retrieval of expression data for individual genes or Treatments as
well as for the whole expression table. The expression table was exported from R as a
CSV file that is subsequently imported into the MongoDB. Each expression data table
encompassed all three types of stored data: the normalized signal intensities for each
probe, the fold change, and the p-value for differential expression. We created indices
automatically to ensure a fast retrieval of expression data for the expected query struc-
tures.
1https://www.mongodb.com/, accessed 15 September, 2016
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Seperate tables were created to store the metadata data for Studies and Treatments.
Because sample metadata was only required for the data processing, the Samples are
only included in the Treatment table. Due to the use of a schema-free database sys-
tem, we could adapt the metadata tables to allow for additional fields in the XLS files.
Through these additional fields, other users of the MARCARviz framework can include
additional metadata fields without having to modify the database schema. For example,
the Study table includes a field details, which includes all fields from the study table
in the XLS file that are not required. This details field can be used to provide users
with information on particular study designs, e.g., on the summary web page for a Study.
We also created several database tables that were necessary for managing jobs and users.
Although we used the schema-free MongoDB database system, we applied concepts of
relational databases where applicable.
Figure 7.1 shows an approximate database schema of the final database.
Study
name: String, unique
species: String
platform: String
GEO: String
shortname: String
details: Mixed
Treatment
name: String
study: String
description: String
conditions: Mixed
samples: [String]
controls: [String]
1             n
expr_[Study]
probe: String, unique
species: String
symbol: String
source: String
description: String
[Treatment]: Number
1
1
TreatmentList
name: String
owner: Account
treatments: [Treatment]
Job
name: String, unique
owner: Account
tool: String
param: Mixed
state: Number
Account
name: String, unique
password: String
n
1
n
n m
1
1
n
Figure 7.1: Schema of the MARCARviz database. Each MARCAR dataset is repre-
sented as a Study, which is identified by a unique internal identifier (name). A Study
consists of several Treatments, each of which corresponds to a group of biological
replicates (samples and controls). The fields details (Study) and conditions
(Treatment) enable the storage of additional metadata in a schema-free manner. Ex-
pression data is stored in an individual table for each study to allow fast retrieval through
MongoDB’s document storage and querying concept. Indeces were created to allow a
fast retrieval of data with common queries.
103
Chapter 7 Web-based interactive visualization of gene regulation data
7.1.3 Architecture of the interactive web platform
The MARCARviz front end is written entirely in the current web standards HTML5,
JavaScript, and CSS. In consequence, MARCARviz requires no Flash or Java applets to
achieve its interactive functionality. We use several existing JavaScript libraries to gen-
erate the interactive visualizations directly in the browser. For scatter, volcano, bar, and
box plots, we use Highcharts JS2, a JavaScript library that provides interactive, highly-
customizable charts. We use Highcharts box plots to visualize the distribution of expres-
sion values and bar plots to show the signal intensity across multiple replicates. Both
volcano and scatter plots are a customized variant of Highcharts’ x-y-plots. To create
interactive heat maps, we used a modified version of InCHlib.js (Škuta et al., 2014),
an open-source JavaScript library for interactive heat maps based on KineticJS. We ex-
tended InCHlib.js with legends, which provide additional metadata for samples and are
visible when exporting static images of the interactive heat map, e.g., for presentations
or publications. Venn diagrams were created with jvenn.js (Bardou et al., 2014), which
is a plug-in for the popular jQuery JavaScript library. Interactive and responsive tables
were created with the DataTables3 plug-in for jQuery. The DataTables library extends
standard HTML tables with functionality such as sorting, pagination, and searching. We
used the Bootstrap4 framework to customize the style of our web platform through CSS
and JavaScript. Bootstrap is an open-source framework that is well integrated with many
other libraries that we used.
As middleware, MARCARviz uses a Node.js5 web server to handle communication
between server and client. Node.js is a runtime environment for server-side web ap-
plications, which uses JavaScript for development. In particular, Node.js uses an asyn-
chronous approach for processing input and outputs in an event-driven architecture to
optimize performance and scalability. Thus, the Node.js server can handle simultane-
ous requests from multiple clients to provide real-time data responses to provide the
data for the interactive visualizations. We used the Express framework6 to implement
the server-side application of our web platform. Express provides utility methods for
HTTP request handling, e.g., parsing and session management, along with an API for
other middlewares that facilitate client-server communication. All client-server traffic is
encrypted according to the HTTPs standard with Express.
The Node.js server distributs requests to a backend that handles data retrieval from
the MongoDB database and processes the data for the visualizations. The R backend
preprocesses the expression data and exports JavaScript Object Notation (JSON) files,
which are passed back to the client’s browser and can easily be parsed and visualized
with JavaScript. A schematic overview of the architecture is shown in Fig. 7.2.
2http://www.highcharts.com/, accessed 21 June, 2016
3https://datatables.net/, accessed 21 June, 2016
4http://getbootstrap.com/, accessed 21 June, 2016
5https://nodejs.org/, accessed 21 June, 2016
6http://expressjs.com/, accessed 21 June, 2016
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Figure 7.2: Architecture of the MARCARviz web platform. This is a simplified
scheme of the MARCARviz platform architecture that demonstrates the interaction of
the general components. Researchers access MARCARviz through the internet with the
supported major browsers and use the web interface to request analyses or visualizations.
A node.js server handles the communication, serves static content, and manages the dis-
tribution of the requested analyses to the computation cluster. Database queries, data
preprocessing and integration (e.g., for data from multiple studies) are performed on the
computation cluster. The results of the requested analyses are then returned to the user
and rendered by the browser with Javascript, HTML5, and CSS.
7.2 Interactive visualizations of microarry data
The MARCARviz web platform is navigated through a menu available on all pages. We
made a major distinction between “Analysis” and “Visualization” tools. Typically, an
analysis will give a report in the form of a table, e.g., of differentially expressed genes
or enriched pathways. A visualization will produce an interactive plot that can be used
for visual exploration of the data or as a figure supporting a hypothesis in a manuscript
or presentation. Currently, MARCARviz supports two analyses and five visualizations,
which are described in the following sections along with possible use cases. An example
of the user interface is shown in Fig. 7.3.
Differential expression tables
The differential expression analysis allows the identification of genes that are affected by
a specific condition, e.g., after treatment of rodents with an NGC. Differential expression
is established by comparing the gene expression in treated animals or tumor tissue with
expression in untreated control animals or normal, non-tumor tissue. The strength of
differential expression is measured as a fold change, i.e., the ratio of expression between
treated and control animals. The significance of deregulation is given as the p-value of a
moderated t-test. Users can define custom fold change and p-value thresholds to identify
differentially expressed genes. The deregulated genes are shown in a table that also
gives a summary for each gene and provides links to external databases with additional
information on the gene. The user can also inspect the observed expression in individual
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Figure 7.3: User interface of an interactive table of differential expression. This
screenshot shows the result page of the differential expression tool. The differentially
regulated genes that pass the inclusion criteria defined by the user are shown in a table.
The table provides supplementary information, e.g., the official gene symbol and a short
gene summary. By clicking on the table row, the expression data for the selected gene is
shown in more detail. The table can be exported in common file formats (CSV, XLS, and
PDF) or saved as a gene list for further analysis. Links to a gene set enrichment analysis
and a volcano plot visualization of the data are also provided.
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samples to confirm the observed deregulation. The list of genes identified by this tool
can be saved to be used as input for other tools, e.g., for a gene set enrichment analysis,
or exported as a CSV, PDF, or XLS file. Figure 7.4(a) shows a differential expression
table created with MARCARviz.
Gene set enrichment analysis
Gene set enrichment analyses identify gene sets, e.g., biochemical pathways or GO cat-
egories, for which a higher-than-expected number of genes is up- or downregulated in
a condition. The test for enrichment is performed with a hypergeometric test and and
the result is reported as an enrichment q-value, i.e., the Benjamini-Hochberg multiple-
testing corrected p-value. The user can define the thresholds applied to filter differen-
tially expressed genes and select the gene sets for which enrichment is tested. Currently,
MARCARviz supports enrichment tests for GO categories and three pathway databases:
KEGG, BioCarta, and Reactome. The results of the gene set enrichment analysis are
shown in a table that reports the significance for each gene set along with the deregulated
genes, the gene set statistics, and links to external databases with additional information
on the gene sets. The table can be exported as a CSV, PDF, or XLS file
Volcano plots
Volcano plots are a visual representation of the strength and significance of differential
gene expression in a single condition. Fold change and p-value are used to represent
the condition-dependent gene regulation. The interactive volcano plot shows the effect
strength, i.e., the fold change, on the x-axis and the significance, i.e., the p-value, on the
y-axis. Each point in the plot corresponds to a single gene. The gene symbol and the
observed expression in samples and controls can be displayed by hovering and clicking
on a point. Again, users can set individual thresholds for fold change and p-value and
save the list of deregulated genes for further analyses. The volcano plot can be exported
as PNG or PDF. Figure 7.4(b) shows a volcano plot created with MARCARviz.
Scatter plots
Scatter plots show the general effects on gene expression in two conditions. For each
gene, the fold change in the first condition is plotted on the x-axis and the fold change in
the second condition on the y-axis. In addition, a linear regression analysis is performed
to provide statistical measures (for example the R2 value) of the concordance between
the conditions. This tool supports cross-platform and cross-species comparisons, e.g., to
compare the effects of the administration of a carcinogenic substance in rats and mice.
Users can set a fold change threshold to exclude non-affected genes from the comparison
and export the resulting plot as PNG or PDF.
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(b) Volcano plot
Figure 7.4: Microarray data visualizations provided by MARCARviz.
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(c) Venn diagram
(d) Heat map
Figure 7.4: Microarray data visualizations provided by MARCARviz (continued).
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Venn diagrams
Venn diagrams show the overlap of lists of deregulated genes for up to six different condi-
tions, which enables the identification of genes that are deregulated in several conditions.
They can be used to find genes that are affected by several nongenotoxic substances or
by one substance at multiple time points. As with the other tools, the user can set the
fold change and p-value thresholds used to identify deregulated genes or choose to in-
clude only up- or downregulated genes. The MARCARviz Venn diagrams also support
cross-platform and cross-species comparisons by mapping genes to orthologous genes
across species. The lists of shared deregulated genes can be saved for other analyses
or downloaded as standard text files. Figure 7.4(c) shows a Venn diagram created with
MARCARviz.
Heat maps
The most powerful tool for visual data exploration in MARCARviz are heat maps, i.e.,
color-coded matrix representations of the strength of gene deregulation in multiple con-
ditions. This enables an easy, visual identification of common expression patterns that
are shared across several conditions. Control conditions, e.g., NCs or GCs, can be in-
cluded to visually identify genes that are deregulated specifically in the conditions of
interest.
The visual exploration is further facilitated by the interactivity of the heat map: the
user can zoom in on genes or gene clusters that are interesting, search for specific genes,
or hide conditions that are not of interest. Genes are clustered hierarchically by their
expression pattern in the selected conditions to group co-expressed genes. Again, users
can set individual thresholds for fold changes and p-values to exclude genes that are not
deregulated in any selected condition. They can also provide a list of genes that should
be shown in the heat map, e.g., from a previous analysis of deregulated genes in a specific
condition. The heat map can be downloaded as a PNG file for inclusion in manuscripts
or presentations. The genes that the user identified can be saved as a gene list for further
analysis. Figure 7.4(d) shows a heat map created with MARCARviz.
A modified variant, gene set enrichment heat maps, allows the visual exploration for
gene set enrichments. Here, the significance of the hypergeometric test for gene set
enrichment is color coded in the heat map. This exploratory analysis can help with the
generation of new hypotheses on the mechanisms of NGCs, both on the level of single
genes and gene sets.
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7.3 Use case: Identification of phenobarbital target genes
and pathways
Phenobarbital is an anticonvulsant drug that is used to treat many types of seizures in
patients and has been in use for over a century. It is included in the WHO Model List of
Essential Medicines. However, it has repeatedly been shown that phenobarbital acts as a
nongenotoxic hepatocarcinogen in male and female mice (see, e.g., in the Carcinogenic
Potency Database by Fitzpatrick, 2008) and is listed as a group 2B carcinogen by the
IARC. Therefore, phenobarbital has been extensively studied as a model substance for
NGCs.
Here, we used MARCARviz and a MARCAR dataset to identify potential target genes
of phenobarbital, pathways that were affected by treatment with phenobarbital, and in-
vestigated the dependence of these effects on the constitutive androstane receptor (CAR)
and the pregnane X receptor (PXR). The dataset is available from the Gene Expression
Omnibus under the accession number GSE60684. An extensive analysis of this dataset
was previously published by Luisier et al. (2014). This use case is also available as an
interactive example online at the MARCARviz web platform.
The dataset was generated with Affymetrix microarrays. We assessed the array and
sample quality, normalized the raw data with the RMA method, and calculated fold
changes and Benjamini-Hochberg multiple-testing corrected p-values as described in
Section 7.1.
As the first step in our analysis, we used a differential expression analysis to identify
potential target genes. We selected genes that were at least two-fold up- or downregulated
and showed significant differences between treated and control animals (corrected p-
value ≤ 0.05) for wild-type mice receiving phenobarbital each day for up to 13 weeks.
Gene expression has been profiled with microarrays at five time points, after 1, 7, 14,
28, and 91 days. At all five time points, Cyp2b10 and Cyp2c55 were among the top
deregulated genes.
With a Venn diagram, we identified 11 genes that were significantly up- or downregu-
lated at all five time points, among them four Cyp genes (Cyp2b10, Cyp2c55, Cyp2c37,
and Cyp2c54), the Wnt signaling inhibitor Wisp1, and other genes that have previously
been linked with phenobarbital treatment, e.g., Gstm3 (Lempiäinen et al., 2011; Lem-
piainen et al., 2013). Similar observations were made in mice in which CAR and PXR
have been replaced with humanized CAR and PXR. Again, Cyp2b10 and Cyp2c55 were
among the top deregulated genes at all five time points, and five other genes were dereg-
ulated at all five time points: Abcc4, Akr1b7, Cbr3, Gstm3, and Por. In contrast, in mice
with CAR and PXR knock outs, differential regulation was almost entirely eliminated at
all time points.
We also performed gene set enrichment to find pathways that were deregulated after
treatment with phenobarbital. For wild-type mice, the most affected KEGG pathways
were the drug metabolism by cytochrome P450, glutathione metabolism, and retinol me-
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Figure 7.5: Heat map of deregulated genes after treatment with phenobarbital of
wild-type mice, mice with humanized CAR/PXR and CAR/PXR knockout mice.
Genes have been filtered for three-fold up- or downregulation and significant deregula-
tion (corrected limma p-value≤ 0.01) in at least one condition. Each row corresponds to
a gene, each column to a condition (i.e., a combination of time point and mouse strain),
each cell shows the log2 fold change between treated and vehicle control samples. The
annotation bar above the heat map shows the time point and strain for each condition.
The hierarchical clustering demonstrates the similarities of phenobarbital-mediated ef-
fects in the wild-type and humanized CAR/PXR mice. In contrast, gene deregulation is
almost completely eliminated in CAR/PXR knockout mice. After recovery (conditions
after 119 days), gene expression in wild-type and humanized CAR/PXR mice is similar
to the knockout mice.
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tabolism. These were consistently deregulated (q-value < 0.001) at all five time points.
Again, we found very similar results for the mice with humanized CAR and PXR. For the
CAR and PXR knockout mice, no pathway deregulation was observed as expected due to
the lack of deregulation of individual genes. These results obtained with MARCARviz
are in concordance with the results of the analysis performed by Luisier et al. (2014).
To visualize the major effects of phenobarbital on gene expression in wild type, hu-
manized CAR/PXR, and CAR/PXR knockout mice, we created a heat map using the
same filter criteria (two-fold deregulation and corrected p-value ≤ 0.05) with clustering
of both genes and conditions, which is shown in Fig. 7.5. The clustering of the con-
ditions shows a large difference in gene expression between wild-type and humanized
CAR/PXR mice on one hand and the CAR/PXR knockout mice on the other, which
confirms the analysis reported by Luisier et al. (2014).
7.4 Summary and conclusions
The MARCARviz web platform allows researchers to perform the most commonly used
analyses and visualizations for microarray data. Summaries for genes and pathways
are provided together with links to databases that contain additional information. This
allows researchers to address a wide range of questions using the MARCAR data. In
general, these can be classified into three overall tasks: identifying differentially regu-
lated genes in a condition, mechanistic analysis of these genes, and comparison of the
observed effects in two or more conditions. By facilitating these analyses, MARCARviz
provides toxicological researchers with the opportunity to generate and confirm mecha-
nistic hypotheses supported by the MARCAR data, which is one of the largest resources
for molecular effects of short-term exposures of rodents to NGCs.
The interactive results can easily be shared with collaborators by sending links to the
result web page. Alternatively, all tables and figures can be exported to standard table
and image formats. The MARCAR data is additionally provided through GEO, such that
bioinformatics analyses could also be performed starting with these raw data. However,
MARCARviz provides preprocessed, ready-for-analysis data along with a user interface
and no necessity to install any additional software. Only a browser with HTML and
JavaScript support is required and all major browsers are supported.
The cross-species and cross-platform comparison of multiple datasets that is offered
by MARCARviz is a particular advantage that would otherwise require mapping of the
different manufacturer identifiers and identifying orthologous genes across species. We
also provide all preprocessed data for download to allow researchers the use of their
preferred tools to perform analyses that are not already offered by MARCARviz.
In conclusion, MARCARviz is a web platform for interactive visual exploration of the
effects of NGCs on transcriptional regulation. We collected data from 16 datasets com-
prising 274 different conditions that were generated and analyzed over the course of the
MARCAR project. The data included in MARCARviz cover the two most used rodent
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species in preclinical risk assessment: mouse (Mus musculus) and rat (Rattus norvegi-
cus), as well as human in vitro data. We provide the most commonly used analyses and
visualizations for microarray data in an interactive fashion that allows visual exploration
to aid the generation and validation of new hypotheses about the mechanism of NGCs.
This will facilitate the discovery of biomarkers for NGC exposure and the development
of new methods for early detection of carcinogenic effects in preclinical risk assessment.
MARCARviz is available from https://tea.cs.uni-tuebingen.de/. In addition,
we provide the framework under MIT License on GitHub 7. The framework can be used
by other groups that use high-dimensional expression data to set up their custom web
platforms for expression data analysis. There are no restrictions on its use by academic
users.
7https://github.com/mroemer/marcarviz
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Summary and general conclusions
During its 5-year duration, the MARCAR project has generated a rich set of toxicoge-
nomics data to study the effects of NGCs. Ultimately, the goal of the MARCAR project
was to provide a proof of concept that early molecular biomarkers can be used to predict
later cancer development. To investigate the effects of NGCs on the molecular level,
the MARCAR consortium used several high-throughput technologies that interrogate
the transcriptome, proteome, and methylome. The volume of the generated data requires
bioinformatics methods for efficient processing, exploration, and visualization. To facili-
tate the access to bioinformatics software for life science researchers, this thesis provided
the ZBIT Bioinformatics Toolbox, a set of bioinformatics tools for the analysis of biolog-
ical data that can be applied in several biological fields (Chapter 4). We also developed a
new similarity scoring approach for gene expression profiles that can be used to identify
substances that have similar effects on the gene regulation in rodents (Chapter 5). As a
proof of concept that the integration of early biomarkers from multiple omics platforms
enables the reliable identification of nongenotoxic carcinogens (NGCs), we performed
a series of experiments with a multi-omics dataset generated in the MARCAR project
(Chapter 6). Finally, we designed and implemented a web platform that allows other
researchers to inspect the MARCAR gene expression datasets interactively and visually
(Chapter 7). This chapter summarizes the four individual contributions and provides a
general conclusion of this thesis.
The ZBIT Bioinformatics Toolbox
Chapter 4 describes the ZBIT Bioinformatics Toolbox (Römer et al., 2016b), which is a
web platform that provides bioinformatics tools for life science researchers. The rise of
high-throughput technologies and the increase in computational resources enabled many
new insights and gave birth to bioinformatics, which encompasses disciplines on the
border of biology and computer science, such as systems biology, genomics, transcrip-
tomics, and a whole range of other omics disciplines. However, life science researchers
often struggle with the required technical knowledge that is needed to operate bioinfor-
matics software. Currently, bioinformatics software often depends on specific operating
systems, third-party libraries, or command-line interface skills. To facilitate the access
to a range of bioinformatics tools that were developed by our bioinformatics team, we
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implemented a web platform that enables life science researchers to use our tools without
the problems mentioned above. Users can execute all tools from any web browser with-
out installing software on their local machine and independent of their operating system
or hardware configuration because all analyses are run on our computation cluster.
The ZBIT Bioinformatics Toolbox encompasses eight tools from three important fields
of bioinformatics: systems biology, transcription factor analysis, and expression data
analysis. In systems biology, we provide tools for processing and annotating models in
the systems biology community standards BioPAX and SBML. BioPAX2SBML trans-
lates models from BioPAX into SBML and maintains qualitative information. SBML-
squeezer adds kinetic rate law equations to qualitative SBML models to enable model
simulation. SBML2LATEX generates human-readable reports for model checking and
exchange. ModelPolisher enriches SBML models with information from the BiGG
database. In transcription factor annotation, we provide the tools TFpredict and SABINE,
which can be used to identify and annotate transcription factors from the protein se-
quence and predict the DNA motif that is bound by the transcription factor. For expres-
sion data analysis, we provide RPPApipe for the processing, analysis, and visualization
of RPPA data and ToxDBScan to identify chemicals that induce similar gene expression
changes in rodents after subchronic treatment.
The ZBIT Bioinformatics Toolbox uses the Galaxy framework, which is well estab-
lished in the life science community and offers a familiar interface for researchers. Also,
by using the Galaxy framework, the ZBIT Bioinformatics Toolbox provides job histo-
ries, data management, and workflow editors which adhere to scientific standards for
reproducibility and the storage of results. We have compared the ZBIT Bioinformatics
Toolbox with competing software and web platforms in the target bioinformatics areas
and demonstrated that our tools and the ZBIT Bioinformatics Toolbox provide signif-
icant advantages over existing software. Furthermore, we recorded usage statistics to
evaluate if and how our web platform is frequented by users. In the one-year period
from May 2015 to June 2016, we recorded 4,403 individual jobs that were submitted by
16 registered users and an unknown number of anonymous users. The most used tool
was RPPApipe, with over 2,000 individual tool executions. In one case that we know of,
the ZBIT Bioinformatics Toolbox inspired the integration of RPPApipe into the standard
workflow of a research group.
In summary, the ZBIT Bioinformatics Toolbox provides life science researchers with
an easier method of using bioinformatics software. Because no software must be in-
stalled locally and jobs are executed on our computation cluster, researchers can use
bioinformatics on any device, e.g., low-end desktop computers or mobile devices in the
lab. Also, the ZBIT Bioinformatics Toolbox offers an opportunity to evaluate tools be-
fore installing them locally for integration with other tools. Based on user feedback and
usage statistics, we have improved and extended the ZBIT Bioinformatics Toolbox and
will continue to include new tools as they are developed, as demonstrated by the addition
of ModelPolisher earlier this year.
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Chapter 5 introduces a novel similarity scoring method for gene expression profiles
(Römer et al., 2014b). Microarrays and more recently RNAseq allow the large-scale
profiling of gene expression, which has become a standard method in many areas of bi-
ology, including toxicogenomics. However, the comparison of gene expression profiles
from experiments run at different times or in different labs remains challenging due to
systematic biases that introduce batch effects and affect the dynamic range of the mea-
sured expression. Most existing similarity measures for gene expression profiles (e.g.,
Pearson correlation or Euclidean distance) depend on the strength of the observed effects,
which can confound analyses when the dynamic range differs between experiments.
We developed a new similarity measure that is based on chemoinformatics concepts
and set theory and uses only information on up- and downregulation of genes without
considering the strength of the regulation. The sets of up- and downregulated genes
define the gene expression fingerprint of an experiment, for which the similarity with
fingerprints of other experiments can be calculated. To this end, we developed a modi-
fied Jaccard index based on the idea of the Tanimoto index. In short, the genes that are
deregulated in the same direction (up or down) in both experiments are compared to the
total number of observed genes to determine the similarity. Furthermore, we introduced
a weighting of each gene according to the information content concept from informa-
tion theory. A gene is considered to have higher information content, and thus a higher
weight if it is regulated in few experiments, whereas genes that are deregulated in many
experiments have a lower information content and thus lower weight.
To evaluate our new similarity scoring method, we performed a series of experiments
with toxicogenomics datasets. First, we obtained two large toxicogenomics datasets (TG-
GATEs and DrugMatrix) to construct a reference database of gene expression finger-
prints and calculated the information content of the genes for which gene expression was
measured. Next, we calculated gene expression fingerprints of an independent dataset
from the MARCAR project that used a similar experimental setting but other dosages
and time points than TG-GATEs and DrugMatrix. Using the fingerprints of several com-
pounds used in the MARCAR experiment, we assessed whether the ten compounds that
were present in the reference database and the MARCAR experiment could be recalled
from the reference database with the MARCAR fingerprints. All ten substances were
successfully recalled as either the most or the second-most similar compound from the
over 200 compounds in the reference database. For these ten substances and the five
substances only present in the MARCAR experiment, we also observed that compounds
with a similar biological MOA were enriched in fingerprints with high relative similarity
(≥ 0.8). These results with independent data indicate that our similarity measure can
successfully detect similarities in gene expression experiments.
Next, we evaluated if our similarity scoring method can be used to identify NGCs.
We used publicly available carcinogenicity annotations for the compounds in the three
datasets. The MARCAR dataset was used as the evaluation dataset and TG-GATEs and
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DrugMatrix to construct the reference database. All 15 substances in the MARCAR
dataset were correctly classified as either NGC, GC, or NC.
To make our reference database and the similarity scoring available to the public, we
developed ToxDBScan. After performing gene expression profiling, toxicologists can
use ToxDBScan to identify substances that induce similar gene expression profiles. This
can provide leads for the mechanistic analysis, e.g., to determine the MOA if tumor
growth is observed in an experiment. ToxDBScan also offers visualizations and pathway
enrichment analysis to facilitate the interpretation of gene expression profiles further.
The major advantage of both ToxDBScan and the underlying similarity scoring approach
is the platform independence, i.e., users can upload gene expression fingerprints that
have been obtained with any expression profiling technology. ToxDBScan is available as
a web tool from the ZBIT Bioinformatics Toolbox.
Multi-omics prediction of nongenotoxic carcinogenicity
Chapter 6 demonstrates that the integration of data from multiple omics platforms im-
proves the identification of NGCs (Römer et al., 2014a). Predictive toxicogenomics
studies have shown that gene expression profiling can be used to find early biomarkers
that can identify nongenotoxic substances significantly earlier than the traditional LRB.
However, regulatory agencies have not yet implemented omics-based short-term assays
for NGCs into the preclinical development of new drugs due to the lack of mechanistic
understanding and low overlap in the biomarkers identified in different studies. Cur-
rently, most toxicogenomics studies use only mRNA microarrays to search for biomark-
ers. Only very few have explored other platforms, such as miRNA microarrays or protein
arrays, but did not attempt to integrate these with gene expression data.
We explored the use of multiple omics platforms to identify changes that are con-
served across several layers of gene regulation. Furthermore, we developed two new fea-
ture representations for multi-omics data which integrate the expression observed across
several platforms into a single value. The pathway enrichment features use informa-
tion from pathway databases to perform an integrated pathway enrichment that assesses
the multi-layer deregulation of biological pathways. The molecular interaction features
use databases of gene-regulatory interactions to identify changes in multiple, connected
levels of regulation.
To evaluate the multi-platform approach and our new features, we collected a new
short-term toxicogenomics dataset that encompasses mRNA, miRNA, and protein ex-
pression data for a set of NCs, NGCs, and GCs. Using the new dataset, we trained
predictive models on individual platform data, multi-platform data, and multi-platform
data enriched with integrative features. The model training and evaluation was performed
in a 2× 2-nested CV (with parameter optimization) that was replicated ten times to get
an unbiased estimate of the classification performance. We performed the evaluation for
three different contrasts: C vs. NC, GC vs. NGC, and NGC vs. NC. Across all three
contrasts we observed an increase in performance when we used the combined multi-
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platform features compared to each individual platform. The multi-platform prediction
achieved AUCs > 0.9 in all three contrasts and > 0.97 for C vs. NC and NGC vs. NC.
Except for the protein signature in the NGC vs. GC contrast, the multi-platform signature
performed better than the individual signatures in all settings. By additionally using the
new pathway enrichment and molecular interaction features, the prediction performance
was further increased. This demonstrates that our integrative approach can improve the
identification of (nongenotoxic) carcinogens in short-term toxicogenomics studies.
The integrative pathway enrichment and molecular interaction features offer an ab-
straction of molecular changes to molecular interactions and biological pathways. This
abstraction can help researchers identify relevant systemic changes that may not be ap-
parent from the individual expression profiles, e.g., if compounds act by altering the same
downstream pathway by perturbing the regulation of different genes or miRNAs. Also,
we expect that changes that are conserved across multiple layers of gene regulation will
provide more robust biomarkers. Our abstract feature representations incorporate this
multi-layer aspect directly into the model training.
In summary, we investigated the use of multiple omics platforms for biomarker dis-
covery in toxicogenomics. We showed that the classification accuracy of models trained
with data from multiple omics platforms is higher than for models trained on data from
the individual platforms. Also, we developed two integrative feature representations
for multi-omics data that further increase the performance in combination with multi-
platform data. Although the number of compounds in our study was very small, we
demonstrated that toxicogenomics can benefit from the integration of data from multiple
omics platforms.
MARCARviz
Chapter 7 describes MARCARviz, a web platform that provides tools for the interactive
analysis and visualization of the MARCAR transcriptomics data. As discussed in Chap-
ter 6, high-throughput mRNA expression profiling is the de facto standard in toxicoge-
nomics studies for biomarker discovery. However, toxicologists often require the help
of bioinformaticians to analyze and visualize the high-dimensional expression data that
is produced by modern mRNA profiling techniques. While raw and normalized expres-
sion data is often made available to the public through platforms such as ArrayExpress
or the Gene Expression Omnibus, researchers often lack the resources or the bioinfor-
matics support to analyze public data. Using modern web technologies, we simplified
the analysis and visualization of the MARCAR expression data for researchers without
a technical background. To this end, we implemented MARCARviz, a web platform
that is accessible through the web browser and offers the most used analyses and visual-
izations for mRNA expression data, e.g., heat maps, differential expression analysis, and
pathway enrichment. MARCARviz provides the preprocessed mRNA expression data of
all MARCAR studies together with meta-information on the conditions that were used
in each study, quality control results, and additional information on genes and pathways
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from external databases.
The architecture of the MARCARviz web platform consists of three layers: the front-
end that is visible to the user, the back-end that stores and analyzes the expression data,
and the middleware, which handles the communication between front-end and back-end.
The MARCARviz front-end uses JavaScript visualization libraries and jQuery plugins
to render expression tables and plots directly in the user’s web browser. Therefore, users
require only a web browser to analyze MARCAR data and need not install any additional
software or download large amounts of raw expression data. As middleware, we use a
Node.js server that receives the analysis requests that are submitted by users through
the front-end. These requests are delegated to a dedicated, internal server that hosts the
back-end. The back-end uses a collection of R scripts to process the data, format the
results according to the requirements of the front-end JavaScript libraries, and retrieves
the expression data from a MongoDB database. When the analysis is finished, the results
are passed back by the Node.js server and rendered for the user by the front-end.
MARCARviz improves the visibility of the MARCAR expression data by providing
interactive analysis and visualization tools for researchers without strong technical back-
ground. The framework that was used to set up MARCARviz is provided as a proof-of-
concept for interactive data analysis of expression data in the web browser. Thus, other
groups can use the framework to provide custom web platforms for their expression data
collections. We hope that this improves the efficiency of the current data sharing, which
is hindered by the need for technical and bioinformatics support to analyze external data.
We think that this can lead to a better leveraging of the existing large amounts of ex-
pression data that are available as raw data from ArrayExpress or the Gene Expression
Omnibus, which, in turn, will provide more biological insights and reduce the number of
further animal experiments.
General conclusions and outlook
In the framework of the MARCAR project, this thesis explored novel approaches and
developed new tools for the detection and characterization of NGCs during preclinical
risk assessment. The focus of this thesis was on machine learning techniques for cancer
risk prediction and the visualization of toxicogenomics data. We described four individ-
ual contributions, which provide bioinformaticians and toxicologists with new tools for
the analysis of toxicogenomics data. The developed tools are web-based in order to be
accessible and easily usable for users. We also looked into the integration of gene ex-
pression data (transcriptomics) with other omics data, e.g., from proteomics. We expect
that future studies can build on the developed tools and methods to confirm and extend
upon the results described in this thesis.
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Supplementary Tables
Table A.1: Predefined workflows in the ZBIT Bioinformatics Toolbox.
Workflow name Description Steps
BioPAX2SBML and
Squeeze2LaTeX
Converts BioPAX files to full SBML models and
human-readable reports.
3
TFpredict & SABINE Uses TFpredict and SABINE to annotate transcrip-
tion factors.
2
RPPApipe two-class Processes datasets with paired samples obtained
from RPPAs.
12
RPPApipe time-series Processes replicated time-series datasets obtained
from RPPAs.
12
RPPApipe multi-class Processes datasets with multiple sample classes ob-
tained from RPPAs.
12
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Table A.2: Chemicals used for evaluation of the similarity scoring index. Male Wistar rats were treated with the chemicals
each day for up to 14 days. For each chemical, the Chemical Abstracts Service (CAS) registry number, dosing time and dose
is listed, as well as the short name that is used in the tables and figures. The last column lists the databases that contain the test
compound (DM = DrugMatrix, TGG = TG-GATEs). Table adapted from Römer et al. (Römer et al., 2014a).
Compound Short Name CAS Number Dosing Time (day) Dose (mg/kg/day) Contained in
Genotoxic carcinogens (GCs)
Direct Black 38 CIDB 1937-37-7 7 146 -
Nitrosodimethylamine DMN 62-75-9 7 4 DM
Nongenotoxic carcinogens (NGCs)
Piperonyl butoxide PBO 51-03-6 3 1200 -
Methyl carbamate MCA 598-55-0 14 400 -
Dehydroepiandrosterone DHEA 53-43-0 14 600 -
Methapyrilene MP 135-23-9 14 60 TGG, DM
Thioacetamide TAA 62-55-5 7 19.2 TGG, DM
Diethylstilbestrol DES 56-53-1 3 10 DM
Wy-14643 WY 50892-23-4 3 60 TGG, DM
Acetamide AAA 60-35-5 14 3000 TGG
Ethionine ET 67-21-0 14 200 TGG
Cyproterone acetate CPR 427-51-0 14 100 DM
Phenobarbital PB 50-06-6 14 80 TGG, DM
Non-hepatocarcinogens (NCs)
Cefuroxime CFX 55268-75-2 14 250
Nifedipine NIF 21829-25-4 14 3 TGG
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Table A.3: Compounds used in subacute studies that were performed during the
MARCAR project. The compounds were manually selected and classified by the
MARCAR consortium according to their carcinogenic effects in the liver of rats and
mice.
Classification Abbreviation Compound CAS
Genotoxic 2-AAF 2-Acetylaminofluorene 53-96-3
carcinogen 2-NF 2-Nitrofluorene 607-57-8
AB1 Aflatoxin B1 1162-65-8
CIDB C.I Direct Black 1937-37-7
DMN Dimethylnitrosamine 56-23-5
MDA Methylendianiline 101-77-9
NNK 4-(methylnitrosamino)-1- 64091-91-4
(3-pyridyl)-1-butanone
NNM N-Nitrososmorpholine 59-89-2
NPip N-Nitrosopiperidine 100-75-4
Nongenotoxic AA Acetamide 60-35-5
carcinogen Aap Acetaminophen 103-90-2
CITCO CITCO 338404-52-7
CPA Cyproterone acetate 427-51-0
DES Diethyl-stilbestrol 56-53-1
DHEA Dehydroepiandrosterone 53-43-0
ETH Ethionine 67-21-0
Mcarb Methylcarbamate 589-55-0
MPy Methapyrilene HCl 135-23-9
PB Phenobarbital 50-06-6
PBO Piperonyl-butoxide 51-03-6
TAA Thioacetamid 62-55-5
Wy Wy-14643 50892-23-4
Noncarcinogen 3-MC 3-Methylcholanthrene 56-49-5
AlAl Allyl alcohol 107-18-6
CFX Cefuroxime 55268-75-2
Clon Clonidine 4205-90-7
DCB 1,4-Dichlorobenzene 106-46-7
Ibup Ibuprofen 15687-27-1
Nif Nifedipine 21829-25-4
Pio Pioglitazone 111025-46-8
Praz Prazosin 19216-56-9
Prop Propranolol 525-66-6
Rosi Rosiglitazone 122320-73-4
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Table A.4: Datasets generated in the MARCAR project and available in MARCARviz. All datasets listed in this table are
part of the MARCAR Gene Expression Omnibus SuperSeries “IMI MARCAR Project: towards novel biomarkers for cancer
risk assessment”, which is available from Gene Expression Omnibus under the accession number GSE68387.
GEO Summary Species Microarray
GSE68969 Effect of PB in APC-KO mice Mouse Mouse Genome 430 2.0
GSE68779 Effects of PB in Ctnnb1-KO mice Mouse Mouse Genome 430 2.0
GSE68592 Effects of Pio and Rosi in rat bladder Rat Rat Gene Expression 8x60K G4853A
GSE68365 CAR and PXR dependent PB effects in C57BL mice Mouse Mouse Genome 430 2.0
GSE68364 Effects of NGC in C57BL mice after 4 weeks Mouse Mouse Genome 430 2.0
GSE68361 Effects of PB in CD1 mice after 4 and 13 weeks Mouse Mouse Genome 430 2.0
GSE68128 Effects of NGCs in Wistar rats after 4 and 13 weeks Rat Rat Gene ST 2.0
GSE68121 Effects of PB on tumorigenesis in rats Rat Rat Genome 230 2.0
GSE68120 Effects of PB and CPA in HCs and MCs of rats Rat Rat Genome 230 2.0
GSE68111 Effects of PB in HCs and MCs in mice Mouse Mouse Genome 430A 2.0
GSE68110 Effects of NGCs in Wistar rats after 2 weeks Rat Rat Expression Array 230A
GSE60684 CAR- and PXR dependent effects of PB in mice Mouse Mouse Genome 430 2.0
GSE51355 Ha-ras and beta-catenin mut. mice tumors Mouse Mouse Genome 430 2.0
GSE44783 Effects of NGCs in CD1 mice Mouse Mouse Genome 430 2.0
GSE34423 Effects of PB in B6C3F1 mice Mouse Mouse Genome 430 2.0
GSE68493 CAR/PXR dependent effects of PB in human hepatocytes Human Human Genome U133 Plus 2.0
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Abbreviations
3’-UTR 3’ untranslated region
ACC accuracy
AUC area under the ROC curve
BGLM Bayesian Generalized Linear Models
BioPAX Biological Pathway Exchange
C carcinogen
CAS Chemical Abstracts Service
CPDB Carcinogenic Potency Database
CV cross-validation
DBD DNA-binding domain
DEG differentially expressed gene
DNA deoxyribonucleic acid
GC genotoxic carcinogen
GEO Gene Expression Omnibus
LOO leave-one-out validation
LRB lifetime rodent cancer bioassay
miRNA microRNA
MLP multi-layer perceptron
MM probe mismatch probe
MOA mode of action
mRNA messenger RNA
NC non-hepatocarcinogen
NGC nongenotoxic carcinogen
NN Neural Network
nt nucleotide
PCA principal components analysis
PCR Principal Component Regression
PFM position frequency matrix
PID Pathway Interaction Database
PM probe perfect match probe
PTM post-translational modification
RF Random Forest
RNA ribonucleic acid
RMA Robust multi-array average
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Abbreviations
RPPA reverse phase protein array
SABINE Stand-alone binding specificity estimator
SBGN Systems Biology Graphical Notation
SBML Systems Biology Markup Language
SBO Systems Biology Ontology
SVM Support Vector Machine
TF transcription factor
TG-GATEs Toxicogenomics Project-Genome Assisted Toxicity Evalua-
tion System
XML Extensible Markup Language
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